Annual Meeting of the International Academy of Cardiovascular Sciences: North American Section

3rd Cardiovascular Forum for Promoting Young Investigators and Centers of Excellence in Cardiovascular Research

September 10 to 12, 2015  •  Omaha, Nebraska, USA

Keynote Address

001
MOLECULAR BASIS FOR THE BENEFICIAL EFFECTS OF CO2 – WATER BATH THERAPY IN PERIPHERAL ARTERY DISEASE
NS Dhalla
Institute of Cardiovascular Sciences, St Boniface Hospital Research, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba

A wide variety of factors are considered to participate in the pathogenesis of peripheral artery disease (PAD) and different agents are being used for the treatment of this major health problem. Although reduction in blood flow due to narrowing of arteries in the ischemic limb is the major cause of PAD, none of the therapeutic interventions are satisfactory. We investigated the effects of CO2-water bath (CWB) therapy on blood flow in the ischemic hind limb. The femoral artery was occluded in rats to induce PAD and the animals were treated with or without CWB at 37°C for 4 weeks (20 min/day; 5 days/week) starting one week after artery occlusion. Peaks, mean and minimal blood flows were not detected in the untreated ischemic hind limb. The femoral artery was occluded in rats to induce PAD and the animals were treated with or without CWB at 37°C for 4 weeks (20 min/day; 5 days/week) starting one week after artery occlusion. Peaks, mean and minimal blood flows were not detected in the untreated ischemic hind limb. However, blood flow values were about 50% of the control upon treatment with CWB; 67% of the ligated animals showed positive blood flow by CO2 treatment. Morphological examination of the treated ischemic skeletal muscle revealed a 3-fold increase in small artery numbers indicating the formation of new blood vessels. Extensive studies have revealed that CO2 at low concentrations serves as a redox sensitive signal transduction molecule for the genesis of angiogenesis. It is suggested that beneficial action of CO2 therapy on blood flow to hind limb may be due to the development of angiogenesis in the ischemic skeletal muscle.

Session 2.1: Cerebrovascular Diseases and Stroke

002
LARGE AND SMALL CEREBROVASCULAR DISEASE DURING HYPERTENSION
FM Faraci
Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA

Vessel disease has a major impact on human health and is particularly devastating for brain. Hypertension is a major risk factor for vascular disease and a key cause of stroke and cognitive deficits. In the cerebral circulation, hypertension produces diverse effects on structure and function. Underlying mechanisms involve interacting oxidative- and inflammatory-related processes that produce inward vascular remodeling, loss of collateral vessels, hyperperfusion, and impairment of adaptive responses that regulate cerebral blood flow (e.g., endothelium-dependent vasodilation and neurovascular coupling). The renin-angiotensin system (RAS) is a major therapeutic target in patients with essential and some other forms of hypertension. Although activation of local or tissue RAS is thought to be a key cause of hypertension, the impact of tissue RAS on the local vasculature is poorly understood. Recent work demonstrates that activation of the central RAS with deoxycorticosterone (DOCA)-salt (which simultaneously suppresses the peripheral RAS) profoundly alters the cerebrovasculature.

Endothelial function in cerebral arteries is markedly impaired by DOCA-salt whereas dilation of mesenteric arteries is normal. These vascular effects extend throughout the microcirculation and include parenchymal arterioles where NO-mediated signaling is substantially impaired. In relation to mechanisms, microvascular changes were mediated by local activation of AT1 and mineralocorticoid receptors as well as Rho kinase. Along with activation of RAS components in the cerebral cortex, DOCA-salt increased expression of RAS elements in the cerebrovasculature. Thus, in addition to direct effects of hypertension, the cerebral circulation may also be impacted by local RAS activation. Such findings may help explain why the impact of hypertension is so profound in brain.

003
THE EXERCISING BRAIN IN HEALTH AND DISEASE
WG Mayhan, DM Arrick
Department of Cellular Biology and Anatomy, and the Cardiovascular Center, Louisiana State University Health Sciences Center – Shreveport, Shreveport, Louisiana, USA

Exercise training has been shown to be beneficial for reducing the risk of premature death and disease, including cardiovascular- and cerebrovascular-related diseases. The mechanisms that account for the protective effect of exercise training appear to be related to activation/inhibition of many diverse cellular networks. Our studies have concentrated on an examination of the influence of exercise training on several aspects of cerebrovascular function during health and disease. First, we examined reactivity of cerebral arterioles in response to eNOS- and nNOS-dependent agonists in sedentary and exercise-trained animals. We found that moderate exercise training did not influence reactivity of cerebral arterioles in normal animals, but restored impaired responses of cerebral arterioles observed during disease states (diabetes and smoking). The mechanism for the protective influence of exercise training on cerebral arterioles during disease states appeared to be related to an alteration in NOS and/or oxidative stress. Second, we examined whether exercise training could alter brain injury following cerebral ischemia/reperfusion. We found that moderate exercise training did not influence infarct volume in normal animals, but lessened brain injury during disease states. Finally, we wondered whether vigorous exercise training, as compared to moderate exercise, could improve cerebrovascular function and prevent brain injury during normal physiologic conditions. We found that vigorous exercise training increased NOS-dependent reactivity of cerebral arterioles and reduced infarct volume following cerebral ischemia/reperfusion. Based upon our findings, we suggest that exercise training is a viable therapeutic approach for the prevention of cerebrovascular disease during physiologic and pathophysiologic conditions.

004
A NEW DIETARY APPROACH FOR THE CONTROL OF HYPERTENSION
GN Pierce1,2, AL Edel1,2, S Caligiuri1,2, H Aukema1,2, A Ravandi1,4, E Dibrov1,2, W Weighell1,2, R Guzman1,2, D Rodriguez-Leyva1,2, MA Li2,3
1Canadian Centre for Agri-food Research in Health and Medicine (CCARM), St Boniface Hospital; Departments of 2Physiology and Pathophysiology, 3Human Nutritional Sciences, 4Internal Medicine, 5Surgery, University of Manitoba, Winnipeg, Manitoba

Hypertension is an important silent killer and the leading global risk for burden of death in the world. Current medications used to control hypertension
are costly, can induce unwanted side-effects and they are not always effective in controlling blood pressure (BP) in all hypertensive patients. Having a food that will control BP represents an alternative strategy that is more popular amongst patients than drugs. Flaxseed is enriched in the cardioprotective omega-3 fatty acid (alpha linolenic acid (ALA)), lignans and fiber. The FlaxPAD Trial was initiated to determine if dietary supplementation with milled flaxseed in hypertensive peripheral artery disease (PAD) patients could provide beneficial actions. The clinical population was randomized into a ground flaxseed or whole wheat placebo group. Individuals were required to consume 30g of the appropriate intervention which was incorporated into different foods daily. This FlaxPAD Trial was double-blinded and involved 110 patients. Both brachial and central systolic and diastolic blood pressures were significantly reduced in the flaxseed group relative to control following the year-long intervention. Both total and LDL cholesterol levels were reduced by flaxseed by about 10-15%. The mechanisms for these effects will be discussed. We conclude that consuming ground flaxseed daily may offer a significant dietary strategy to lower both circulating cholesterol and BP.

Supported by CIHR, Flax2015, ARDI, Western Grains Research Foundation, SaskFlax and St Boniface Hospital Foundation.

Session 2.2: Inflammation, Cytokines and Cardiovascular Disease

**005 INTRACRINE ANG II FUNCTION ORIGINATES FROM NON-CANONICAL PATHWAYS IN THE HUMAN HEART**

CM Ferrario
Wake Forest University School of Medicine Winston Salem, North Carolina, USA

Increased cardiac Ang II expression and activity contributes to cardiac hypertrophic remodeling, arrhythmias, and fibrosis. Our research suggests that renin angiotensin system (RAS) inhibitors are less effective in blocking Ang II-mediated adverse cardiac remodeling because its production in cardiac myocytes follows a non-canonical pathway through the processing of the intermediate substrate angiotensin-(1-12) [Ang-(1-12)] by chymase. While in the rat angiotensin converting enzyme (ACE) hydrolyzes Ang-(1-12) into Ang II, chymase but not ACE converts Ang-(1-12) directly into Ang II in human heart tissue. The human form of cardiac α-chymase, either expressed in cardiomyocytes or incorporated into these cells from activated mast cells and fibroblasts, is the enzyme producing Ang II directly from Ang-(1-12). The importance of this non-canonical pathway comprised by the chymase/Ang-(1-12)/Ang II axis is illustrated by the demonstration of an increased expression of Ang-(1-12) and chymase in the left atrial appendage of patients undergoing open heart surgery for the treatment of ischemic heart or left valvular disease. In summary, Ang II-mediated adverse cardiac remodeling and arrhythmogenesis is a result of the intracellular activation of a chymase/Ang-(1-12)/Ang II axis that is not amenable to blockade by current RAS blockers. Furthermore, these biotransformation steps are species-specific.

**007 CASPASE-1, AN INNATE IMMUNE SENSOR IN ENDOTHELIAL CELLS**

X-F Yang
Temple University School of Medicine, Philadelphia, Pennsylvania, USA

The role of receptors for endogenous metabolic danger signals—associated molecular patterns (DAMPs) has been characterized recently as bridging innate immune sensory systems for DAMPs to initiation of inflammation. However, it remains unknown whether endothelial cells (ECs), the cell type with the largest numbers and the first vessel cell type exposed to circulating DAMPs in the blood, can sense hyperlipidemia using caspase-1/ inflammasome as innate immune sensor. We performed three interconnected projects: First, using bone marrow transplantation, and atherogenic ApoE−/−/caspase-1−/− double knockout mice, we found that early hyperlipidemia promotes EC activation before monocyte recruitment via a caspase-1–sirtn 1–activator protein-1 pathway, which provides an important insight into the development of novel therapeutics for blocking caspase-1 activation as early intervention of metabolic cardiovascular diseases, inflammations and atherosclerosis. Second, we found that caspase-1 activation inhibits vascular endothelial growth factor receptor 2 expression whereas caspase-1 inhibition improves the tube formation of proatherogenic lipid lysophosphatidylcholine-treated human ECs; and Caspase-1 depletion improves angiogenesis and blood flow in mouse hind-limb ischemic tissues. Our results have demonstrated that inhibition of proatherogenic caspase-1 activation in ECs improves angiogenesis and the prognosis of ischemic diseases including myocardial infarction (MI), peripheral arterial disease, ischemic stroke, etc. Finally, using gene knockout mice, cell therapy and MI model, we found that hyperlipidemia activates caspase-1 in Sca-1+ endothelial progenitor cells (EPC), which subsequently weakens Sca-1+ EPC repair of vascular EC injury. Our results have demonstrated the therapeutic potential of caspase-1 inhibition in improving progenitor cell therapy for MI.

**008 INFLAMMATION AS A SOURCE OF SYMPATHETIC EXCITATION IN HEART FAILURE**

RB Felder
Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA

The past decade has seen an increasing appreciation for the role of inflammation in cardiovascular disease states. In systolic heart failure, circulating levels of pro-inflammatory cytokines correlate directly with the severity of illness and portend a poor prognosis. Augmented sympathetic nervous system activity is another predictor of adverse outcomes in heart failure, promoting increased preload and afterload on the failing heart, impaired heart function, and cardiac arrhythmias. My laboratory has examined the effect of inflammation on central nervous system mechanisms driving sympathetic nervous activity in heart failure. We have found that the prototypical pro-inflammatory cytokines – tumor necrosis factor-alpha (TNF-a) and interleukin-1 beta (IL-1β) – that increase in the plasma of humans with severe heart failure, activate central neural circuits that drive sympathetic nerve activity in a rat model that mimics heart failure after myocardial infarction in humans. A small region of the brain that lacks a blood-brain barrier – the subfornical organ – plays a major role in transmitting these circulating signals of peripheral inflammation to the brain, where they act to increase sympathetic drive and to facilitate the sympathetic-excitatory influence of other circulating signals. We have also found that TNF-a and IL-1β increase early after myocardial infarction and are sustained at high levels inside the blood brain barrier in the hypothalamic paraventricular nucleus, an important cardiovascular-related nucleus that regulates sympathetic nerve activity. I will discuss the mechanisms by which these central inflammatory influences augment sympathetic nerve activity in heart failure and the potential for therapeutic interventions in the central inflammatory state.

Session 2.3: Cardiac and Vascular Regeneration

**009 CELL THERAPY FOR ISCHEMIC CARDIOMYOPATHY**

R Bolli
University of Louisville, Division of Cardiovascular Medicine, Institute of Molecular Cardiology, Louisville, Kentucky, USA

Cell-based therapies offer enormous potential for the treatment of ischemic cardiomyopathy. Among them, c-kit+ cardiac stem cells (CSCs) have emerged as extremely promising. Numerous studies from many labs have shown that CSCs improve post-infarction LV dysfunction and remodeling in animal models. Most transplanted CSCs disappear in a few days; their most likely mechanism of action is production of paracrine factors that...
beneficially affect the adjacent myocardium. We conducted SCIPIO, the first human study of CSCs. SCIPIO was a Phase I, randomized, open-label trial of c-kit+ CSCs in patients with post infarction LV dysfunction (EF <40%). In the twenty treated patients, LVEF (3D Echos) increased from 29.2±1.9% before CSCs to 37.8±2.9% at 1 year (P<0.001) and 38.1±3.6% at 2 years (P<0.004). This was associated with improved quality of life (Minnesota Living with Heart Failure Questionnaire [MLHFQ]); 45.3±4.3 vs. 22.6±5.4 and 19.5±4.2 at 1 year and 2 years, respectively (P<0.001)) and improved NYHA class (P<0.001 at 1 and 2 years). In contrast, in the thirteen controls there was no improvement. In the treated patients who underwent MRI, infarct size decreased by 43.2% at 1 year (P<0.001) and 39.4% at 2 years (P=0.008). Thus, a single infusion of CSCs was sufficient to improve ischemic cardiomyopathy for at least 2 years. These results suggest that infusion of autologous CSCs in patients with ischemic heart failure is safe and that its beneficial effects are sustained and actually increase over time.

010

GROWTH FACTOR EFFECTS ON CARDIAC STEM CELLS

AM Johnson, KG Aghila Rani1, CC Kautha
Rajiv Gandhi Center for Biotechnology and 1Sree Chitra Tirunal Institute for Medical Sciences & Technology, Trivandrum, India

Clinical utility of stem cells derived from the adult heart is hindered by lack of sufficient cell numbers. Designing strategies favoring activation and migration of resident stem cells to the site of injury are an exciting frontier of research in regenerative medicine. We have explored two avenues in this direction. We studied the effect of growth factors in inducing cardiosphere formation from cardiac stem cells (CSCs) isolated from atrial biopsies obtained from patients who underwent coronary artery bypass surgery. Among the different growth factors analyzed, EGF significantly promoted cardiosphere formation and proliferation of cardiosphere derived cells. Our findings suggest that EGF could be used for generating CDCs which could provide ample cell numbers for transplantation therapies. In a postnatal mammalian heart, cardiac stem cells exist in a quiescent state. Disrupting quiescence could induce proliferation and differentiation in these cells. We investigated the role of FoxO3a in promoting quiescence in c-kitpos cardiac stem cells. FoxO3a is highly expressed in quiescent stem cells isolated from neonatal Balb/C mice hearts. Igf-1 mRNA expression was markedly reduced in these cells. Regulation of FoxO3a by mitogens was studied in vitro using a ‘reserve cell’ model in which actively dividing cells were switched to mitogen restricted medium. This causes the cells to become either terminally differentiated or enter a quiescent phase. Our studies reveal that IGF-1 is a regulator of FoxO3a and FoxO3a regulates the transcription of Kip family proteins such as p27kip1 and p57kip2. An up-regulation of p27kip1 and p57kip2 transcripts was observed in growth factor starved CSCs which also had increased FoxO3a expression. Igf-1 stimulation significantly declined the expression of FoxO3a, p27kip1 and p57kip2 transcripts and increased the expression of Cyclin D1 mRNA. In CSCs, it may be possible that Igf-1 inactivates FoxO3a leading to down-regulation of p27kip1 and p57kip2 and promotes cell-cycle progression. Our findings add to the growing knowledge of molecular mechanisms related to quiescence and proliferation of cardiac stem cells.

The studies were funded by Department of Biotechnology, Government of India.

011

AN APPRAISAL OF BONE MARROW CELL THERAPY: METANALYSIS AND MORE

R Afzal, A Samanta, V Jeewanantham, B Dawn
Division of Cardiovascular Diseases, Cardiovascular Research Institute, Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, Kansas, USA

A number of clinical trials of bone marrow cell (BMC) therapy for heart repair have been completed over the past decade. These relatively small trials used different types of BMCs injected through various routes in highly variable numbers in patients with a wide range of clinical conditions and prognosis. The results from these studies have been therefore somewhat variable. Furthermore, the conclusions of several meta-analyses performed on dissimilar datasets from various clinical trials have also been divergent. Nonetheless, a critical review of a number of these meta-analyses suggests that BMC therapy indeed enhances left ventricular parameters compared with standard therapy in patients with ischemic heart disease. Although the magnitudes of benefits are numerically small, the favorable impact BMC therapy on clinical outcomes seems substantial. However, several important variables need to be optimized before the full potential of BMC therapy can be delivered to patients. Continued and careful analysis of data from completed and ongoing trials may provide critical insights to improve outcomes of bone marrow cell therapy in the future.

Supported in part by NIH grant R01 HL-117730.

Abstracts

Session 2.4: The Grant Pierce Young Investigator Competition in Cardiovascular Sciences

013

DIVERGENT EFFECTS OF PRO-INFLAMMATORY CYTOKINES ON VEGF-A-INDUCED DIFFERENTIATION OF MESENCHYMAL STEM CELLS INTO ENDOTHELIAL CELLS

IA Ikhapoh, CJ Pelham, DK Agrawal
Department of Medical Microbiology and Immunology and Center for Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA

Coronary artery stenting/angioplasty procedures frequently result in complications including endothelial loss and arterial thrombosis. Mesenchymal stem cells (MSCs) have therapeutic potential during cardiac interventions. We examined the effects of the pro-inflammatory cytokines, IL-6, TNFα and Ang II on VEGF-A-stimulated differentiation of Yucatan mesowsine bone marrow derived MSCs into endothelial cells (ECs). Naïve MSCs were immunonegative for classical EC markers. Low-dose VEGF-A (2ng/ml) modestly increased immunopositivity for EC markers (cells vWF+ 16±2%, PECAM-1+ 13±4%, and VE-cadherin+ 11±2%; p<0.05 vs. naïve MSCs). High-dose VEGF-A (50 ng/ml) induced greater immunopositivity for EC markers (cells vWF+ 78±1%, PECAM-1+ 61±1%, and VE-cadherin+ 65±1%; p<0.05 vs. low-dose VEGF-A). Mechanistically, high-dose VEGF-A treatment of MSCs significantly upregulated mRNA expression of S0x18 (2.0±2-fold; 24 hours), a transcription factor that programs EC differentiation. The siRNA-mediated knockdown of Sox18 greatly reduced VEGF-A-mediated induction of EC markers. Co-stimulation of MSCs with Ang II (2ng/ml) and low-dose VEGF-A caused a synergistic increase in the percentage of cells immunopositive for EC markers to similar levels as high-dose VEGF-A alone, whereas Ang II alone had no effect. In contrast, treatment of MSCs with IL-6 or TNFα induced a dose-dependent decrease in EC marker expression in the presence of high-dose VEGF-A. However, further supplementation of IL-6 or TNFα and VEGF-A with Ang II rescued the expression of EC markers. These changes in EC marker expression positively correlated with capillary tube formation and expression of Sox18 mRNA and protein. Our findings highlight the opposing effects of pro-inflammatory cytokines on EC differentiation and have important clinical implications towards cardiac interventions.

014

MITOCHONDRIAL- DEPENDENT APOPTOSIS IN ARTERIAL REMODELING: LINK TO HYPERTENSION

A Famlitsvea, A Kalani, P Chaturvedi, S Pushpakumar, N Metreveli, SC Tyagi
Department of Physiology and Biophysics, University of Louisville, Louisville, Kentucky, USA

Hyperhomocysteinemia (HHcy) has been observed to promote hypertension through endothelial dysfunction and vascular remodeling, but the mechanisms are unclear. Previously, we showed that elevated homocysteine levels facilitated excessive mitochondrial fusion with consequent endothelial cell loss and collagen deposition in the mesenteric artery. In the present study, we hypothesize that HHcy-induced excessive mitochondrial fragmentation promotes mitochondrial apoptosis through Bax activation that up-regulates
downstream apoptotic proteases (Caspase-9, Caspase-3), causing endothelial cell loss and arteriolar remodeling that predispose to hypertension. To test this hypothesis, we used 12 week old C57BL/6j mice (WT) as a control; Cystathionine-β-synthase deficient mice (CBS+/-) with generic HHCy; CH3/Het (CH3 mice, that are resistant to oxidative stress and CBS+/-/ CH3 mice. Blood pressure measurement, western blotting (Caspase-9 and Caspase-3), q-PCR (Bax, Bcl-2), immunohistochemistry (cleaved Caspase-3) and TUNEL assay were used in this study. Blood pressure values were up-regulated in CBS+/- mice (diastolic: 118.4 ± 9.8 mmHg; systolic: 153.9±12.7 mmHg; mean: 130±10 mmHg) compared to WT mice (diastolic: 101±15 mmHg; systolic: 139±10 mmHg; mean: 113±14 mmHg). q-PCR showed up-regulation of Bax mRNA expression in the mesenteric artery of CBS+/- mice compared to control. Western Blotting validated increase of Caspase-9 and Caspase-3 protein expressions in the mesenteric artery of CBS+/- mice compared to WT mice. In conclusion, our data suggested that HHCy-induced mitochondrial fission promotes Bax activation followed by mitochondrial apoptosis with activation of downstream proteases (Caspase-9, Caspase-3), leading to endothelial cell loss and arteriolar remodeling that contributes to hypertension.

015 
OVER EXPRESSION OF KV4.3 IN THE RVL M OF RATS WITH HEART FAILURE ATTENUATES SYMPATHETIC TONE

BK Becker, H-J Wang, IH Zucker
University of Nebraska Medical Center, Omaha, Nebraska, USA

Chronic heart failure (CHF) is characterized by increased sympathetic tone, which contributes to the progression of cardiovascular damage. Our laboratory has previously observed reduced Kv4.3 expression in a key brainstem area that regulates sympathetic activity, the rostral ventrolateral medulla (RVLM), in rats with CHF. Reduced expression of Kv4.3 leads to increased neuronal excitation; however, the physiological importance of Kv4.3 in the RVLM has not yet been investigated during CHF. We hypothesized that overexpression of Kv4.3 in the RVLM of rats with CHF would reduce sympathetic tone. Sprague-Dawley rats with CHF were implanted with radiotelemetry and bilaterally injected with adenoviral-associated Kv4.3 (AdKv4.3; n=6) or GFP (adGFP; n=5) into the RVLM. Telemetry recordings were collected for 14 days post injection followed by terminal/anesthetized baroreflex RSNA experiments. Conscious heart rate was lower (315.7 ± 8.88 vs. 362.8±5.81 bpm; p<0.05), and SDNN was higher (11.18±0.77 vs. 8.61±0.63 ms; p<0.05) in adKv4.3 vs. GFP. Baseline RSNA was lower (22.8±2.4 vs. 42.4±5.7 % of max; p<0.05), and the baroreflex sensitivity was higher (2.84±0.64 vs. 1.54±0.30 Gmax; p<0.05) in adKv4.3 vs. adGFP. These data support the hypothesis that overexpression of Kv4.3 in the RVLM reduces sympathetic tone during CHF.

016 
THE PROTECTIVE ROLE OF SARCOLEMMAAL MEMBRANE ASSOCIATED PROTEIN ISOFORM 3 (SLMAP3) IN CARDIAC REMODELLING POST MI

W Lefnajar, M Salih, BS Tuana
Faculty of Medicine, University of Ottawa, Ottawa, Ontario

The Sarcolemmal Membrane Associated Protein 3 (SLMAP3) is a tail-anchored membrane protein, which is ubiquitously expressed in tissues including myocardium. It is a component of subcellular membranes and the centrosome and appears to serve distinct role in cell growth and membrane biology (2). Recently, mutations in SLMAP3 isoform have been linked to Brugada syndrome which usually presents with aberrant electrical activity leading to cardiac dysfunction and death (1). Here, we have examined the effects of overexpressing SLMAP3 on postnatal heart function, pre and post myocardial infarction (MI). Transgenic (tg) mice with cardiac specific overexpression of SLMAP-3 were generated and assessed with echocardiography to measure the functional parameters, and western blotting to analyze the protein expression. The echocardiography of 8 week old tg mice showed ~55% ejection fraction (EF) and ~25% Fractional shortening (FS) which is equal to those of wild type mice (n=30, P<0.05). MI was induced by LAD ligation (9 wk old mice) and echocardiography (at 1 wk post MI) showed a greater reduction of EF and FS in the wild type mice (~37% and ~17%) compared to SLMAP3 tg mice (~45% and ~22%), respectively (n=10, P<0.05). Furthermore, Western blot analysis of apoptotic proteins such as Caspase-3 and Bax was attenuated in myocardium from tg mice compared to wild type (~ 3 in each group with MI, P<0.05). These data indicate that SLMAP3 levels may serve to limit cell death during cardiac remodeling post MI and protect the myocardium.

REFERENCES:

017 
IMPACT OF HYDROGEN SULFIDE ON THE EPIGENETICS OF DIABETIC CARDIOMYOPATHY

S Veeranki, S Kundu, SC Tyagi
Department of Physiology and Biophysics, University of Louisville, Louisville, Kentucky, USA

Although Diabetic cardiomyopathy results in enhanced risk for heart failure, epigenetic changes leading to diabetic heart failure are unclear. Hydrogen sulfide (H2S) has been implicated in the preservation of heart function owing to its anti-inflammatory and positive metabolic changes. In the current study, we investigated whether or not chronic H2S treatment (by giving NaHS) reverses diabetic cardiomyopathy using mouse model of type-1 diabetes: Akita mice. Regulators of myocardial biogenesis, calcium handling and molecules that regulate post-ischemic recovery were assayed by western blotting and Q-PCR. Further, we considered epigenetic modifications such as microRNA expression changes and DNA methylation alterations to understand the causes of diabetic heart failure with and without NaHS treatment for 30 days. Our data indicated that chronic H2S treatment significantly reduced the mitochondrial fission inducers: Drp-1 (24%) and Fis-1 (17%) in the Akita mouse hearts. Further, there was enhancement (10%) in the SRECA2a expression after NaHS treatment in the diabetic hearts. Also, there was significant decrease (16%) in TNF-1α protein expression in diabetic hearts after NaHS treatment. In addition, there was significantly increased expression of post-ischemic recovery regulators such as: Notch3 (157%), C-JUN (160%), PGC-1α (173%), HIF-2α (72%), and NRF-1 (149%) after NaHS treatment. These results suggest that the chronic NaHS treatment ameliorates diabetic cardiomyopathy through decreasing mitochondrial fission and inflammation and enhancing Ca2+ handling; as well as mitigating epigenetic changes leading to enhanced post-ischemic recovery potential. 

Acknowledgement: Part of this study was supported by the NIH grants: HL-74185, NS-84823 and HL-108621.

Session 2.5: Cellular and Molecular Aspects of Cardiovascular Diseases

012 
CARDIAC REJUVENATION: A NEW FRONTIER IN THE MANAGEMENT OF HEART FAILURE

R-K Li
Toronto General Research Institute, University Health Network, Department of Surgery, Division of Cardiovascular Surgery, University of Toronto, Toronto, Ontario

Heart failure results from cardiomyocyte necrosis after myocardial infarction. After infarction, the heart achieves limited repair through tissue resident and circulating stem cells. Resident cardiac stem cells are believed to be a legacy cardiac stem cell population that can independently direct endogenous repair. Age negatively influences the cardiac environment in transplantation recipients and reduces the cardiac tissue’s functional capacity for effective stem cell transplantation. Whereas the cardiac environment in a young recipient can recuperate aged stem cells, young stem cells perform inadequately in aged recipients. This paradox suggests that successful stem cell implantation for cardiac repair depends not only on the regenerative
capacity of the stem cells, but also on the proper myocardial milieu. We demonstrated recently that resident cardiac stem cells of hematopoietic origin govern cardiac repair. Rejuvenation of aged bone marrow increases regenerative capacity by restoring this resident cardiac stem cell niche. Cardiac resident stem cells play an important role in restoration of cardiac function and repair.

088
SCLERAXIS: A NOVEL TRANSCRIPTIONAL REGULATOR OF CARDIAC FIBROBLAST PHENOTYPE AND EXTRACELLULAR MATRIX PRODUCTION

MP Czubryt, RA Bagchi, PL Roche
Institute of Cardiovascular Sciences, St Boniface Hospital Research Centre and Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Manitoba

The cardiac extracellular matrix (ECM) is a proteinaceous structure that both contributes to the physical structure of the heart and also serves as a source of physical and growth factor signals indicative of myocardial health and integrity. Resident cardiac fibroblasts respond to these signals, and are primarily responsible for ECM synthesis in the healthy heart. Cardiac stress including infection, pressure overload and diabetes induces phenotype conversion of fibroblasts to myofibroblasts, which accelerate ECM production to cause fibrosis, in turn impairing cardiac function and rhythm. We have identified the transcription factor scleraxis as a novel regulator of cardiac fibroblast phenotype and ECM production. Scleraxis induces gene expression changes in cardiac fibroblasts indicative of activation to myofibroblasts, including increased expression of ECM proteins, direct transactivation of the α-smooth muscle actin gene resulting in increased contractility, and induction of mesenchymal marker genes. Conversely, scleraxis knockdown reverses these effects and attenuates TGFβ/Smad3 signaling, demonstrating that scleraxis is required for fibroblast-to-myofibroblast conversion. Scleraxis gene deletion in mice results in a ~50% loss of cardiac fibroblasts and ECM, likely due in part to failure of fibroblast epithelialoid precursors to undergo mesenchymal transition. Our data implicate scleraxis in the pathological events accompanying cardiac fibrosis. Supported by the Canadian Institutes of Health Research (grant MOP-136862).

089
INCREASED M2 MACROPHAGE DIFFERENTIATION REDUCES INFLAMMATION AND PLAQUE FORMATION IN APO E-/- MICE

D Singla
University of Central Florida, Department of Molecular Biology and Microbiology, Burnett School of Biomedical Sciences, College of Medicine, Orlando, Florida, USA

Inflammation plays a significant role in the inception and development of atherosclerosis (ATH). Mechanisms of inflammation include the infiltration of monocytes into the injured area and subsequent differentiation into either pro-inflammatory M1 macrophages or anti-inflammatory M2 macrophages. We have reported that bone morphogenetic protein-7 (BMP-7) enhances M2 macrophage differentiation and anti-inflammatory cytokine secretion in cell culture model. However, whether BMP-7 would inhibit plaque formation in an animal model of ATH through increased M2 macrophage differentiation remains unknown. ATH was generated in male and female Apo E-/- mice via partial left carotid artery (PLCA) ligation and mice were divided into 3 groups: Sham, PLCA, and PLCA+BMP-7 (200ug/kg; i.v.). We performed histological, biochemical and RT-PCR techniques to evaluate macrophage polarization and their impact on the released pro- and anti-inflammatory cytokines. Our data shows that there was an inhibition of monocyte infiltration in the atherosclerotic area, and a decrease is associated with reduced pro-inflammatory cytokines (MCP-1, TNF-α, and IL-6) following BMP-7 treatment. Moreover, our data suggest a significant (p<0.05) increase in M2 macrophage populations with consequential enhanced anti-inflammatory cytokine (IL-1RA, IL-10, and Arginase 1) expression following BMP-7 treatment. Formed plaque area in BMP-7 animals was significantly reduced and blood velocity functions were improved. In conclusion, we report that BMP-7 has the potential to mediate cellular plasticity and mitigate the inflammatory immune response, which results in decreased plaque formation and improved blood velocity.

Session 2.6: Diabetic Heart Failure

022
MYOCARDIAL INFARCTION ALTERS RENAL FUNCTION AND MORPHOLOGY

IL Mehta, J Lu, X Wang
University of Arkansas for Medical Sciences and VAMC, Little Rock, Arkansas, USA

It is assumed, but not proven, that acute myocardial infarction affects function of remote organs such as kidneys and brain. We examined renal function and morphology in mice subjected to left coronary artery (LCA) ligation. Wild-type (WT) mice were subjected to permanent LCA ligation resulting in extensive myocardial infarction. Soon after LCA ligation, there was a marked rise in pro-inflammatory cytokines and MDA (index of oxidative stress) levels in circulation. On Day 3, renal function had markedly declined in association with swelling of glomeruli and tubules and mild fibrosis (P<0.05). There was a significant increase in the expression of LOX-1, IL-1β and VCAM-1, TBARS in the kidney. On Day 21, renal function showed some recovery, but there was progressive fibrosis in the kidneys. To determine the role of LOX-1 (a receptor for ox-LDL) overexpression in renal dysfunction following LCA occlusion, LOX-1 knockout mice subjected to total LCA ligation; these mice showed much less increase in systemic and renal pro-inflammatory cytokines and MDA levels, and much less structural alterations and renal functional decline than the WT mice (all P<0.05). Cardiac function and survival rates were also better in the LOX-1 KO mice than in the WT mice (P<0.05). This study shows that acute myocardial ischemia results in renal dysfunction and histologic abnormalities reminiscent of acute renal injury. The morphologic changes continue to progress long after the acute myocardial ischemic event. This study also suggests that LOX-1 is a key modulator among multiple mechanisms underlying renal dysfunction following extensive myocardial infarction.

023
RELEVANCE OF PERSONALIZED MEDICINE IN THE MANAGEMENT OF HEART FAILURE

RK Goyal, S Apparsundaram
V ClionBio Labs, Sri Ramachandra University, Chennai, India; V ClionBio LLC, Newark, New Jersey, USA

Heart failure remains one of the leading causes of death worldwide and therefore, it is a main focus of research and treatment. In spite of several developments with respect to the medications, the management of heart failure is still challenging for the physician. One major concern is the report that if drugs are not accounted for inter-individual differences, they may be either ‘ineffective’ or ‘not completely effective’ in 30-60% of patients. The use of personalized medicine may allow the physician to provide a better therapy for patients in terms of efficacy, safety and treatment length, as well as to reduce the associated costs for the community. With the advent of state-of-the-art molecular profiling establishing clinical phenotype there is increasing trend to have profiling of markers to determine not only the prognosis but also for the management. There has been a remarkable growth in scientific publication on personalized medicine within the past few years in the cardiovascular field. However, application of personalized medicine into clinical treatment has been very slow. In the USA, 10% of Food and Drug Administration approved drugs include pharmacogenomic information on their labels and genetic testing is recommended or required for at least 12 FDA approved drugs. In developing countries like India as such data are scanty and there is no move for such recommendations by the drug authorities. We have undertaken studies to develop pharmacogenomics panel for the cardiac patients for the optimization of drug therapy based on genetic information for the management of heart failure.
Abstracts

024  
AMP-ACTIVATED PROTEIN KINASE AS A THERAPEUTIC TARGET FOR VASCULAR DISEASES  
M-H Zou  
Center of Molecular and Translational Medicine, Georgia State University, Atlanta, Georgia, USA  
AMP-activated protein kinase (AMPK) is widely recognized as a sensor of energy status and redox status. As a result, overwhelming evidence supports that AMPK functions as a master regulator of cellular energy metabolism and redox homeostasis. Evidence accumulating from cell culture and animal experimentation has indicated that AMPK plays a critical role in the regulation of various vascular physiology, including vascular tone, as well as pathology processes, such as endothelial dysfunction and inflammation, as well as vascular smooth muscle cells phenotypic switching, proliferation/migration and calcification. AMPK activation also regulates the function of immune cells, especially macrophage, including proliferation, differentiation, fatty acid metabolism and cholesterol efflux. Moreover, clinical and laboratory studies show that pharmacological AMPK activators markedly prevent atherosclerosis development, high blood pressure, and diabetes complications. The absence or blockade of AMPK greatly accelerates the formation of atherosclerotic lesions, neointima and hypertension in animal experiments, suggesting that AMPK as a novel therapeutic target in the treatment of vascular diseases. Therefore, my talk will summarize how AMPK regulates vascular functions and how dysfunctional AMPK results in vascular diseases.

025  
AUTONOMIC REGULATION THERAPY IN HEART FAILURE  
JE Ardell  
UCLA Neurocardiology Research Center of Excellence and UCLA Arthritis Center, Los Angeles, California, USA  
The cardiac nervous system, composed of the intracardiac ganglia, intrathoracic extracardiac ganglia, spinal cord, brainstem, and higher centers, coordinates regional cardiac function on a beat-to-beat basis. Globally, the cardiac nervous system is optimized to handle physiological stressors (e.g. orthostatic changes, exercise). However, it has not evolved a mechanism to adequately deal with catastrophic events such as myocardial infarction and the long-term evolution of congestive heart failure. Imbalances within this neural network lead to excessive and stochastic activity, and underlie the mechanisms responsible for arrhythmias and heart failure. Autonomic Regulation Therapy (ART) is a rapidly emerging therapy in the management of congestive heart failure. Modulation of the cardiac neuronal hierarchy can be achieved with biologic modulation of the spinal cord, cervical vagus, baroreceptors, or renal nerve ablation. With appropriate neuromodulation therapy, myocytes are rendered stress resistance, autonomic responsiveness for control of the heart is preserved, and the potential for fatal arrhythmias is reduced. Innovations in the field of Neurocardiology require evolving new interfaces and analytics to evaluate neural network activity and cardiac electrical and mechanical function concurrently in normal and disease states. Understanding mechanistically what is being stimulated within the autonomic nervous system by such device-based therapy and how the system reacts to such stimuli is essential for optimizing stimulation parameters and for the future development of closed-loop ART.

026  
CARDIAC SYMPATHETIC AFFERENT DENERVATION: A NEW POTENTIAL THERAPY FOR HEART FAILURE  
H Wang  
Dept of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA  
The chronic heart failure state (CHF) is characterized by neurohumoral activation and cardiac remodeling (fibrosis, dilation and hypertrophy). In the CHF state a potent cardiogenic reflex known as the “cardiac sympathetic afferent reflex” (CSAR) is activated by an increase in the activity of sympathetic afferents on or near the surface of the ventricles. This excitatory reflex, in part, drives sympathetic efferent nerve activity to the heart and the periphery. Recent data from our lab demonstrated that selective removal of these afferents using the TRPV1 receptor agonist resiniferatoxin (RTX), at the time of myocardial infarction (MI) in rats, resulted in a decrease in cardiac and renal sympathetic nerve activity and noradrenaline excretion 9-11 weeks following the MI. In addition to its classical sympatho-excitatory effect, we also found that these cardiac afferents are pro-inflammatory and can aggravate local cardiac extracellular matrix (ECM) remodeling post MI by activation of matrix metalloproteinase (MMP) activity, which can be largely prevented by RTX treatment. This intervention also decreased the remodeling process by reducing cardiac fibrosis. The resultant effect of RTX treatment was a decrease in LV end diastolic pressure and an increase in diastolic function along with an increase in the cardiac response to isoproterenol (cardiac reserve). In addition, we developed a clinically applicable delivery route (epidural T1-T4 peri-ganglion administration) targeting RTX to the afferent neuronal soma in the dorsal root ganglia. These data suggest that RTX therapy may have clinical relevance for improving cardiac and autonomic dysfunction in CHF.

027  
DEVICE-BASED NEUROMODULATION FOR HYPERTENSION THERAPY: MECHANISMS AND THERAPEUTIC IMPLICATIONS  
TE Lohmanier  
The University of Mississippi Medical Center, Jackson Mississippi, USA  
Recent technical advances have stimulated interest in device-based therapy for the treatment of resistant hypertension defined as blood pressure that remains above goal in spite of the concurrent use of ≥ 3 antihypertensive agents, with one being a diuretic and all given at optimized doses. Electrical activation of the carotid baroreflex (BA) and percutaneous renal nerve ablation provide global- and renal-specific suppression of sympathetic activity, respectively, and are currently being evaluated in clinical trials for the treatment of resistant hypertension. While clinical trials show that BA and renal denervation diminish the severity of hypertension in many with resistant hypertension, a reduction in arterial pressure does not always occur, and the conditions for a favorable response are largely unknown. A recent report indicating that renal sympathetic nerve activity (RSNA) is elevated in many patients with resistant hypertension is consistent with the hypothesis that the renal nerves likely represent the critical link between increased central sympathetic outflow and impaired renal function that sustains resistant hypertension, and that both devices may lower arterial pressure by reducing the intensity of RSNA. However, the relationship between basal RSNA and the subsequent arterial pressure response to BA and renal denervation is unclear, as are the conditions that modify a direct relationship if one were to exist. Experimental studies provide insight into the mechanisms that account for chronic lowering of arterial pressure during suppression of sympathetic activity by BA and renal denervation and may help identify the subsets of this heterogeneous hypertensive population who stand to benefit the most from device-based therapy.

028  
SYMPATHO-EXCITATORY REFLEXES IN CARDIOVASCULAR DISEASE: THE EFFICACY IN RESTRAINING THE CAROTID BODY  
HD Schultz  
Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA  
The treatment of chronic heart failure (CHF) remains an important focus for new and more effective clinical strategies. In CHF, sympathetic overactivity plays an important role in the development and progression of the cardiac and renal dysfunction (cardio-renal syndrome), and is often associated with breathing dysregulation, which in turn aggravates the autonomic imbalance. Evidence demonstrates that the elevations in sympathetic activity and breathing instability in CHF are driven, at least in part, by
maladaptive activation of the carotid body (CB) chemoreflex driven by a tonic increase in CB afferent nerve activity. Discussion will focus on mechanisms that alter CB afferent activity in CHF and its consequence on reflex control of autonomic, respiratory, renal, and cardiac function in animal models of CHF. The potential translational impact of targeting the CB in the treatment of cardio-renal syndrome in patients with CHF and its relevance to other cardio-respiratory diseases will be discussed.

Session 2.8: Dr Bruce McManus
Young Investigator Presentations

029
PTEN INHIBITOR REDUCES CARDIAC REMODELING IN DOXORUBICIN-INDUCED CARDIOMYOPATHY
TA Johnson, DK Singla
Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, USA

BACKGROUND: Doxorubicin (Doxo) is one of multiple anthracycline drugs used to effectively treat various forms of cancer. Unfortunately, Doxo treatment stimulates adverse cardiac remodeling and subsequent heart failure. We have previously demonstrated that transplanted embryonic stem (ES) cells and their conditioned medium (CM) modulate the PTEN pathway and reduce apoptosis, fibrosis and hypertrophy in a Doxo-Induced Cardiomyopathy (DIC) model. VOOhpic (VO), the most potent known PTEN inhibitor, has shown to be cardioprotective against ischemia-reperfusion injury; however VO efficacy in a DIC model has not been explored.

HYPOTHESIS: Intraperitoneal (IP) delivery of VO blunts PTEN expression and protects the heart from doxorubicin-induced cardiac remodeling.

METHODS: Animals were divided into three groups; Group 1: Control (Saline), Group 2: Doxo (12 mg/kg, Cumulative dose) and Group 3: Doxo and VO (12 mg/kg and 10µg/kg cumulative doses) via IP injection. One week post-DIC, mice were subjected to echocardiography to examine cardiac function, sacrificed and hearts were harvested for further analysis.

RESULTS: Immunohistochemistry staining revealed a significant (p<0.05) decrease in apoptotic cardiomyocytes in Doxo-VO treated hearts compared with Doxo. Furthermore, Hematoxylin and Eosin (H&E) and Mason’s Trichrome histological stains confirmed reduced hypertrophy, interstitial and vascular fibrosis in Doxo-VO treated subjects compared to Doxo group. Western Blotting confirmed the reduction in PTEN levels in Doxo-VO subjects compared to Doxo hearts. Heart function was significantly improved upon Doxo-VO treatment compared to Doxo group.

CONCLUSION: Our data suggest that VO treatment attenuates adverse cardiac remodeling and improves heart function in the DIC heart.

030
MIR-133A REGULATES CARDIAC AUTOPHAGY IN DIABETICS
SS Nandi1, PK Mishra1,2
1Department of Cellular and Integrative Physiology; 2Department of Anesthesiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

Attenuated miR-133a is associated with induced autophagy in diabetic heart failure patients. However, the underlying molecular mechanism is unclear. We hypothesized that diabetes-mediated downregulation of miR-133a induces autophagy, whereas overexpression of miR-133a in diabetic hearts would restore the basal level of autophagy. To test this hypothesis, we used four in vivo groups: C57BL/6j (WT), Ins2+/-Akita (T1D), and Akita treated with miR-133a mimic (Ak+miR) or scrambled miRNA (Ak+scm); and four in vitro treatment groups of HL1-cardiomyocytes low (0.02µM), high (0.05µM) concentrations of D-glucose, HG+miR and HG+scm. We performed transmission electron microscopy (TEM) and several molecular assays to examine autophagosome formation, degradation, and autophagic flux in the heart. Our results showed increased protein level of autophagosome formation marker LC3B (1.91±0.01) in Akita and its downregulation (0.58±0.04) in Ak+miR as fold change compared to the WT heart. Further, TEM analyses revealed an increased number of autophagosomes/total area in Akita as compared to the WT heart but it was decreased in Ak+miR. In vitro studies showed increased autophagosome formation in HG (LC3B: 1.44±0.02) and its downregulation (0.57±0.02) in HG+miR as fold change of LG. Further, LAMP2 (involved in autophagosome degradation) was upregulated in HG (1.37±0.1) and restored (1.09±0.15) in HG+miR as fold change compared to LG. The mCherry-EGFP-LC3B plasmid-based analyses elicited increased autophagic flux in HG (5.58±2.26) as fold change compared to LG, and its restoration in HG+miR (0.90±0.9). Additionally, luciferase reporter assay revealed that miR-133a targets LC3B. In conclusion, miR-133a regulates autophagosome formation, degradation and autophagic flux in diabetic hearts.

Acknowledgements: NIH grants: HL113281 and HL116205

031
IMPROVED SURVIVAL AND CARDIAC FUNCTION FOLLOWING MYOCARDIAL INFARCTION IN MOUSE MAST CELL PROTEASE-4 DEFICIENT MICE
M Hude1, M Lepea1, R Lecomte1, A Tremblay1, A Tremblay1, AG Schwartani2, P D’Orléans-Juste1
1Institute of Pharmacology, Université de Sherbrooke, Sherbrooke; 2Division of Cardiology, McGill University, Montreal, Quebec

Albeit treatment of myocardial infarction with angiotensin converting enzyme inhibitors improves prognostic, circulating angiotensin-II levels rapidly return to baseline values. Chymase, which is released from mast cells in heart failure, is an important cardiac Ang-II producing enzyme. We aimed to assess the impact of the deletion of a chymase isoform, mouse mast cell protease-4 (mMCP-4), in the progress of irreversible myocardial infarction. Anaesthetised mMCP-4 KO mice and C57BL/6j wild-type (WT) conger-ners were intubated and the left anterior descending (LAD) coronary arteries ligated. Mice were left to recover for 72 hours or 28 days before euthanasia. At 72 hours, some mice were subjected to cardiac positron emission tomography (cPET) to assess left ventricular function, after which mice were sacrificed and hearts collected for histology and biochemical measurements. Genetic deletion of mMCP-4 improved 28-day survival compared to WT mice (93.3 vs 40.0%, p<0.001). 72-hour cPET shows that infarct size and end-diastolic volume are lower, while ejection fraction is higher, in mMCP-4 KO mice when compared to WT animals (p<0.02). The deletion of mMCP-4 protects left ventricular functional integrity post-infarction, resulting in an improved survival.

This work was supported by the Canadian Institutes for Health Research (CIHR).

032
INCREASED MITOCHONDRIAL SUPEROXIDE IN THE BRAIN, BUT NOT PERIPHERY, SENSITIZES MICE TO ANGIOTENSIN II-MEDIATED HYPERTENSION
AJ Case, J Tian, MC Zimmerman
University of Nebraska Medical Center, Omaha, Nebraska, USA

Mitochondrial superoxide (O2•−) flux is sufficient to affect hemodynamics. We hypothesized that elevated levels of systemic mitochondrial O2•− exacerbates AngII-induced hypertension. However, it remains unknown if increased mitochondrial O2•− flux is essential for angiotensin II (AngII)- dependent hypertension. However, it remains unknown if increased mitochondrial O2•− flux is essential for angiotensin II (AngII)- dependent hypertension. To test this, we utilized a conditional mouse model of manganese superoxide dismutase knock-out (MnSODlox/lox). Using a systemic inducible promoter to drive cre-recombinase expression, MnSOD was knocked-down (30-98%, p<0.05) in peripheral organs, but not in the brain. Interestingly, mean arterial pressure (MAP) and heart rate were not statistically different in MnSOD knock-downs versus controls ± subcutaneous AngII (400 ng/kg/min) infusion. Due to these unexpected results, we examined AngII-dependent hypertension. However, it remains unknown if increased mitochondrial O2•− levels specifically in the subfornical organ (SFO) in the brain. After targeting cre-recombinase to this region, we observed a 60% decrease of MnSOD (p<0.05) with concomitant increase in mitochondrial O2•− in the SFO. Intriguingly, while these mice demonstrated no change in baseline MAP (92.8±2.4 mmHg vs. 93.1±0.4 mmHg - knock-down vs. control), they displayed a significant elevation in MAP upon peripheral AngII infusion (MAPmax = 137.8±2.7 mmHg vs. 108.6±3.3 mmHg - knock-down vs. control).

R of SLMAP1 is being evaluated in targeting the diabetic state. Involving fusion and size expansion of early endosomes. Enhanced expression SLMAP1 tg mice compared with wild type litter mates. Immunofluorescence up-regulation of these proteins SNAP23, (187.94% ± 60.28%, n=6, P<0.05), Syntaxin4 (133% ± 53.03%, n=5, P<0.01) in myocardium from SLMAP1 tg mice compared with wild type litter mates. Immunofluorescence analysis indicated a significant co-localization of SLMAP1 with SNAP23 and Syntaxin4 in enlarged membrane vesicles which were identified as early endosomes with the marker EEA1 in cardiomyocytes. These data indicate that SLMAP1 can specifically enhance GLUT4 protein levels by the expression of the SNARE complex in myocardium via a mechanism involving the fusion of early endosomes and their size expansion. The enlarged vessels/vacuoles noted in SLMAP1 TG myocardium [2] in part represent the early endosomes. Thus SLMAP1 can uniquely regulate GLUT4 levels, glucose uptake and metabolism through a mechanism involving fusion and size expansion of early endosomes. Enhanced expression of SLMAP1 is being evaluated in targeting the diabetic state.

REFERENCES:

Session 2.9: Eric Olson Young Faculty Competition (Biomedical Sciences)

033 THE CARDIAC SPECIFIC ISOFORM OF THE TAIL-ANCHORED MEMBRANE PROTEIN SLMAP1 ENHANCES GLUT4 LEVELS THROUGH A MECHANISM INVOLVING THE SNAP COMPLEX AND SIZE EXPANSION OF EARLY ENDOSONES T Rehmani1, A Dewan1, M Salih1, C Trigg2, H Ding2, B Tuana1
1Faculty of Medicine, University of Ottawa, Ottawa, Ontario; 2Weill Cornell Medical College, Doha, Qatar

The tail anchored Sarcomemal Membrane Associated Protein isoform 1 (SLMAP1) is structurally similar to the super family of membrane proteins involved in intracellular vesicle transport and fusion. Enhanced levels of SLMAP1 increased glucose uptake and metabolism by upregulating GLUT4 levels in cardiomyocytes [1]. A significant size expansion of early endosomes (43 fold ± 5) was evident in cardiomyocytes isolated from transgenic (tg) myocardium expressing SLMAP1. GLUT4 mRNA was unaltered by SLMAP1 expression. In order to test the hypothesis that increased GLUT4 protein levels were due to enhanced composition or fusion of early endosomes we examined the components involved in early endosome formation. In particular the expression and localization of SNARE proteins SNAP23 and Syntaxin-4 which enable fusion of early endosome membrane vesicles were examined. Western blot analysis revealed a significant up-regulation of these proteins SNAP23, (187.94% ± 60.28%, n=6, P<0.05), Syntaxin4 (133% ± 53.03%, n=5, P<0.01) in myocardium from SLMAP1 tg mice compared with wild type litter mates. Immunofluorescence analysis indicated a significant co-localization of SLMAP1 with SNAP23 and Syntaxin4 in enlarged membrane vesicles which were identified as early endosomes with the marker EEA1 in cardiomyocytes. These data indicate that SLMAP1 can specifically enhance GLUT4 protein levels by the expression of the SNARE complex in myocardium via a mechanism involving the fusion of early endosomes and their size expansion. The enlarged vessels/vacuoles noted in SLMAP1 TG myocardium [2] in part represent the early endosomes. Thus SLMAP1 can uniquely regulate GLUT4 levels, glucose uptake and metabolism through a mechanism involving fusion and size expansion of early endosomes. Enhanced expression of SLMAP1 is being evaluated in targeting the diabetic state.

Abstracts

034 UPGREGULATION OF ANGIOTENSINOGEN (AGT) IN THE PARAVENTRICULAR NUCLEUS (PVN) OF THE HYPOTHALAMUS DURING CHRONIC HEART FAILURE (CHF): ROLE OF MIR-133A NM Sharma, SS Nandi, X Liu, H Zheng, PK Mishra, KP Patel Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

Emerging evidence has demonstrated that activation of the renin-angiotensin system (RAS) is closely associated with enhanced sympathetic activation in CHF. The contribution of changes in AGT per se remains to be examined. In this study, we observed a 12-fold increase in levels of AGT gene in the PVN of CHF rats compared to sham-operated controls with a concomitant increase in Ang II type 1 receptors (AT1R). In order to elucidate the molecular mechanism of increased expression of AGT, we performed in silico analysis of 3'-UTR of AGT gene and found potential binding sites for microRNA (miR)-133A. Consistent with these observations, we found a 1.9-fold decrease in miR-133A expression in the PVN of rats with CHF. We hypothesized that decreased expression of mir-133A may be responsible for increased expression of AGT in the PVN. To test this hypothesis we used NG108 (neuroblastoma x glioma) cells, endogenously expressing RAS components, as our in vitro model. Overexpression of mir133a mimic (pEZX-MR03-miR-133a) resulted in 1.4 and 1.5-fold decrease in AGT and AT1R mRNA levels, respectively. Further, luciferase reporter assay confirmed 3.4-fold reduction in luciferase activity with miR-133a mimic. Validating our in vitro data, preliminary studies revealed, miR-133a upregulation in the PVN of rats with CHF ameliorated the increased AGT expression (0.44±0.05 CHF-0FP vs. 0.29±0.03 CHF-miR-133a). These results suggest that AGT is targeted by miR-133a, revealing a novel and unique role for miR-133a in the regulation of Ang II within the PVN, which potentially contributes to sympathoexcitation during CHF. Supported by NIH-HL62222 and AHA-14SDG1998007 grants.

035 EPIGENETIC MODIFICATION OF BRAIN (PRO)REIN RECEPTOR CONTRIBUTES TO THE DEVELOPMENT OF DOCA-SALT HYPERTENSION VIA EPITHELIAL SODIUM CHANNEL W Li, Y Feng Department of Pharmacology and Physiology & Cell Biology, University of Nevada School of Medicine, Reno, Nevada, USA

We recently reported that elevated brain (pro)rein receptor (P RR) level contributes to the development of DOCA-salt hypertension; however, the underlying mechanism remains unknown. To test our hypothesis that epigenetic mechanism is involved in the regulation of PRR during hypertension, C57BL/6j mice were treated with SHAM or DOCA-salt for 3 weeks. We found an increase (fold change) in histone 3 lysine 4 trimethylation (H3K4me3) on the PRR promoter in DOCA-salt (2.45±0.36) compared with SHAM treated mice (1.00±0.16, P<0.05). H3K4 methylation transfers (HMT) activity (OD/hour/mg protein), an enzyme complex responsible for H3K4 methylation was increased after DOCA-salt treatment (45±2, P<0.05) compared with SHAM (28±2). To examine the mechanisms of elevated HMT activity, we treated neurons with control (155mM sodium), high salt (170 mM sodium), aldosterone (100 nM), or high salt+aldosterone with or without epithelial sodium channel (ENaC) blocker (amiloride, 100 nM) for 2 hours and test the HMT activity and PRR expression levels. High salt+aldosterone increased HMT activity (41±3 vs. 24±2, P<0.05) and PRR mRNA (1.6x±0.1 vs. 1.0±0.1 fold change, P<0.05) levels compared to control. Amiloride attenuated HMT activity (25±1, P<0.05) and PRR mRNA levels (0.98±0.1, P<0.05) compared to high salt+aldosterone treatment. We conclude that ENaC may be responsible for epigenetic up-regulation of brain PRR and thus the increase in BP during DOCA-salt hypertension.

036 ANGIOTENSIN TYPE 2 RECEPTOR KNOCKOUT MICE EXHIBIT BLUNTED ARTERIAL BAROREFLEX SENSITIVITY AND OVERACTIVATED SYMPATHETIC TONE J Gao1, J Chao1, T Walther2, F Gembardt3, H Zucker1, L Gao1 1Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA; 2Centre for Cardiovascular and Metabolic Research, Hull York Medical School, University of Hull, Hull, United Kingdom

Angiotensin type 2 receptor (AT2R) knockout (KO) mice is characterized with a hypertension. The underlying mechanism(s) are not completely elucidated. Previous data from our laboratory demonstrated a sympatho-inhibition by central AT2R stimulation. In this experiment, we evaluated the potential contribution of sympathetic activity to the hypertension of this transgenic mouse. We found that, compared to wild type (WT), (1) KO mice exhibited higher blood pressure (MAP) (KO 85±3.7 vs WT 74±3.8 mmHg, p<0.05) and increased renal sympathetic nerve activity (RSNA) (KO 31.3±4.8 vs WT 18.5±0.9 % max, p<0.05); (2) Baroreflex sensitivity was significantly blunted in KO mice (Gmax for HR: KO 2.7±1.1

Curr Res Cardiol Vol 2 No 3 Autumn 2015 122
vs WT 8.4±2.7 bpm/mmHg; p<0.05; Gmax for RSNA: KO −1.2±1.7 vs WT 12.9±1.3 %/mmHg p<0.05; (3) In KO mice, icv Ang II evoked bigger pressor response and sympatho-excitation, whereas icv losartan induced a bigger fall of MAP and RSNA; (4) in the nucleus tractus solitarius (NTS) of KO mice, the supersoxide production (detected by DHE staining) and AT1R expression (measured by Western blot analysis) were significantly upregulated as compared with the WT mice. These results suggested that the increased sympathetic activity contributed to the hypertension in AT2R deficient mice. Our data also implied that the sympatho-excitation in this mouse model was due to the impaired baroreflex function and enhanced central AT1R signaling, in which the enhanced oxidative stress in the NTS was involved.

This project is supported by NIH R01HL093028 (Dr Lie Gao).

037

ABLATION OF COX-2 ATTENUATES ADIPOSE INFLAMMATION BUT IMPAIRS METABOLIC HOMEOSTASIS IN OBESITY

V Saraswathi, K Meena, C Perriotte-Olson, C Desouza, J Bowen, N Adi, R Ramalingam

Department of Internal Medicine/DEM, University of Nebraska Medical Center, and VA Nebraska Western, Iowa Health Care System, Omaha, Nebraska, USA

Obesity predisposes individuals to type 2 diabetes and cardiovascular disease (CVD). The role of cyclooxygenase-2 (COX-2), a well-known pharmaceutical target for its role in inflammation in regulating obesity and its co-morbidities, in particular, dyslipidemia, remains unclear. The objective of this study is to determine the role of COX-2 in mediating metabolic inflammation and systemic lipid homeostasis in obesity. Wild type (WT) and COX-2 knock-out (COX-2-/-) mice were fed a high fat (HF, 45% fat calories) diet for 13 wk. The expression of macrophage and inflammatory markers were reduced in visceral adipose tissue (VAT) and macrophagenchirned VAT stromal cells collected from COX-2-/- mice compared to WT mice on a HF diet. However, VAT mass was significantly increased in COX-2-/- mice. Interestingly, the protein expression of ATG7, an autophagy marker, was significantly reduced in COX-2-/- mice. Of note, autophagy is evolving as a novel mechanism regulating lipid metabolism. As with VAT, the hepatic expression of macrophage and inflammatory markers were reduced with a concomitant reduction in autophagy markers in COX-2-/- mice. This was associated with an increase in plasma total cholesterol in COX-2-/- mice. Furthermore, the genes promoting hepatic cholesterol metabolism were down-regulated in COX-2-/- mice. Not only global deletion but also COX-2 deletion in hematopoietic cells resulted in a decrease in autophagy markers and an increase in adiposity. Our data suggest that although COX-2 inhibition can be effective in reducing inflammation, it may impair lipid homeostasis likely via diminished autophagy which, in turn, can increase the risk for CVD.

This work was supported, in part, by a Scientist Development Grant from the American Heart Association.

038

CENTRAL NEURAL CONTROL OF SYMPATHETIC NERVE ACTIVITY IN HEART FAILURE FOLLOWING EXERCISE TRAINING

H Zheng, KP Patel

Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

Typical characteristics of chronic congestive heart failure (HF) are increased sympathetic drive, altered autonomic reflexes, and altered body fluid regulation. These abnormalities lead to an increased risk of mortality, particularly in the late stage of chronic HF. Recent evidence suggests that central nervous system (CNS) mechanisms may be important in these abnormalities during HF. Exercise training (ExT) has emerged as a non-pharmacological therapeutic strategy substitute with significant benefit to patients with HF. The mechanism(s) by which ExT improves the clinical status of HF patients is not fully known. Our studies have provided evidence that ExT significantly alleviates the increased sympathetic drive, altered autonomic reflexes and altered body fluid regulation in HF. The studies have revealed that ExT improves the altered inhibitory pathway utilizing nitric oxide and GABA mechanisms within the paraventricular nucleus (PVN) in HF. Exercise training alleviates elevated sympathetic outflow in HF, through normalization of excitatory glutamatergic and angiotensinergic mechanisms within the PVN. Exercise training also improves volume reflex function and thus fluid balance in HF. We conclude that improvement of the enhanced CNS-mediated increase in sympathetic outflow, specifically to the kidneys related to fluid balance, contributes to the beneficial effects of ExT in HF.

039

EXERCISE AND EXOSOME IN CARDIOVASCULAR HEALTH AND DISEASE

SC Tyagi, M Phil

Department of Physiology & Biophysics, University of Louisville School of Medicine, Louisville, Kentucky, USA

Remodeling and myocardial matrix metabolism contributes to cardiac endolymph–myocyte (perivascular fibrosis), myocyte–myocyte (interstitial fibrosis), and mitochondrion–myocyte (fusion and fission) coupling. Matrix metalloproteinases (MMPs), and tissue inhibitor of metalloproteinases (TIMPs) play differential roles in different tissues and diseases. For example, although present in the heart, MMP-3 is known as stromelysin (i.e., stromal tissue enzyme). Interestingly, TIMP-3 causes apoptosis. Exercise and nutrition are synergistic in the mitigation of diseases: exercise releases exosomes containing miRNAs. Nutrition/vitamins B6 and B12 regulate the metabolism of homocysteine (an epigenetic byproduct of DNA/RNA/protein methylation). Thus, epigenetic silencing is an important therapeutic target. The statistical analysis of cohorts may be less indicative for the treatment of a disease, particularly if the 2 twins are different in terms of responding to the medicine for the same disease, therefore, personalized medicine is the future of therapy.

006

CATIONIC PEPTIDES AND PROTEINS IN INFLAMMATION AND ATHEROSCLEROSIS: NOVEL INSIGHTS

S Parthasarathy

The University of Central Florida, Orlando, Florida, USA

BACKGROUND: Apolipoprotein A1 and apolipoprotein E mimetic peptides have attracted attention due to their ability to reduce atherosclerosis and exhibit antioxidant, anti-inflammatory, and hypolipidemic properties. We tested whether non-lipoprotein related cationic peptides and proteins would have anti-inflammatory properties both in vitro and in vivo. We also tested whether ApoB100 of low density lipoprotein (N-LDL) would have similar properties.

METHODS: 5F-mimetic peptide, LL27 derived from the anti-microbial peptide CAMP, and a human glycidol derived peptide (Gdn-P), were commercially synthesized. N-LDL was prepared and used. The ability of these peptides and protein to neutralize charges of modified lipoproteins, as well as attenuate macrophage uptake and inflammation, were analyzed. Oxidized LDL (Ox-LDL) was pretreated with increasing concentrations of peptides and N-LDL to evaluate charge neutralizing properties of the peptides as well as that of the protein (ApoB100). RAW cells were incubated with LPS or Ox-LDL pretreated with and without peptides and N-LDL. RNA was isolated from treated cells and real time PCR was performed using mouse IL-1α and IL-6 primers.

RESULTS: Cationic peptides as well as ApoB100 protein of N-LDL decomposed the peroxisome content of 13-HPODE. Incubation of Ox-LDL and Ac-LDL with the peptides as well as ApoB100 resulted in charge neutralization as noted by agrose gel electrophoresis. Pre-incubation of the peptides with modified lipoproteins reduced the uptake of the latter by macrophages and foam cell formation as detected by Oil-Red O staining.

Session 2.10: Exercise Training in Cardiovascular Disease
Reduced inflammation was observed in the presence of N-LDL as compared to LPS/Ox-LDL.

CONCLUSIONS: Based on these studies, we postulate that cationic peptides and protein might have properties that would a) affect events that are unrelated to lipid lowering, b) might play an additional role in immune competent cells, including macrophages, and c) might interact with other biologically important anionic molecules, including lipids and proteins. We also predict that lysine-rich cationic peptides and proteins could have therapeutic potential in reducing CVD/atherosclerosis-associated inflammation.

040
A RAT MODEL SYSTEM OF LOW AND HIGH SUSCEPTIBILITY TO DISEASE RISKS
SL Britton, LG Koch
Department of Anesthesiology, University of Michigan, Ann Arbor, Michigan, USA

Large-scale clinical studies show that low exercise capacity is a stronger predictor of morbidity and mortality relative to other common risk factors including hypertension, type II diabetes, or smoking. This robust association led us to formulate that variation in capacity for energy transfer is a central mechanistic determinant of the divide between complex disease and health (Energy Transfer Hypothesis). As an unbiased test of this hypothesis we reasoned that, divergent artificial selection of rats based on low and high intrinsic treadmill running capacity would yield contrasting aerobic models that also divide for disease risks.

Artificial selection for intrinsic endurance running capacity was started in 1996 using genetically heterogeneous N: NIH stock of rats as a founder population (n=168) to develop lines of low capacity runners (LCR) and high capacity runners (HCR). Selection for low and high capacity was based upon distance run to exhaustion on a motorized treadmill. By generation 35 of breeding (2014) the LCR rats exhausted on average after 205 m and the HCR exhausted after 2293 m of distance run. Studies have revealed that a surprisingly large number of clinically relevant disease risks segregated more strongly in the LCR relative to the HCR. That is, the LCR demonstrate reduced longevity, premature aging, decreases in phosphorylating respiration, and increased susceptibility for ventricular fibrillation, intra-cerebral hemorrhage, metabolic syndrome, fatty liver disease, disordered sleep, Alzheimer’s neurodegeneration, pulmonary hypertension, and vulnerability to inducible cancer. Apparently disparate conditions segregated with selection for aerobic capacity suggesting we may discover new mechanistic commonalities underlying complex diseases.

041
CLINICAL OUTCOMES AND THE CHALLENGE OF ADHERENCE TO EXERCISE IN HEART FAILURE
B Pozehl
University of Nebraska Medical Center-Lincoln Division, Lincoln, Nebraska, USA

Exercise training trials in patients with heart failure (HF) have demonstrated improvements in exercise capacity, functional disability, and clinical outcomes including quality of life. The majority of these trials have focused on patients with a diagnosis of HF with reduced ejection fraction (HFrEF) with only a few focused on patients with HF with preserved ejection fraction (HFrEF). The multi-center HF-ACTION trial demonstrated the safety of exercise training and led to the eventual approval of the US Center for Medicare Services (CMS) for cardiac rehabilitation in HFrEF. The HF-ACTION trial had only approximately 35% of patients adhering to 120 minutes of aerobic exercise per week at the end of 18 months. Adherence to exercise is reported by patients to be more difficult than any of the other required behavioral changes for HF including diet, medications, smoking cessation or keeping appointments. Patients identify lack of motivation, lack of energy, and physical symptoms as primary reasons for not adhering to exercise. They report a lack of skills for exercise and fear of exercise with a “bad heart”. System level factors also impact adherence to exercise with a significant under-referral to cardiac rehabilitation by providers and a general lack of emphasis on the benefits of exercise training as an adjunct to optimal pharmacologic therapy. Clearly there are many factors impacting adherence to exercise and as a result patients are not exercising at levels to achieve the demonstrated dose-response for benefits from exercise.

042
SIRT3 DEACETYLASE IS A GUARDIAN OF MITOCHONDRIA, WHICH PROTECTS THE HEART FROM DESCENDING TO FAILURE
MP Gupta, V Pillai, S Samant
Center of Cardiac Cell Biology, Department of Surgery, Basic Science Division, University of Chicago, Chicago, Illinois, USA

SIRT3 belongs to the sirtuin family of NAD+-dependent deacetylases. Members of this family are emerging as key regulators of many biological functions, including cell growth, apoptosis, metabolism and longevity. Mammalian genome encodes seven sirtuin isofoms (SIRT1-SIRT7). Among them SIRT3 is the only isoform whose increased expression was linked to increased lifespan of humans. SIRT3 is primarily localized in mitochondria, where it regulates activity of many metabolic enzymes involved in ROS production and ATP biosynthesis. Because bioenergetic capacity of mitochondria is also dependent upon the fusion-fission dynamics of the organelle, this study was undertaken to study the effect of SIRT3 in regulating mitochondrial dynamics. We found that OPA1, an inner mitochondrial fusion protein was hyper-acetylated in hearts under pathological stress, including hearts with pressure overload hypertrophy, doxorubicin-induced cardiac toxicity and diabetic cardiomyopathy. OPA1 was also acetylated in SIRT3KO hearts, and this modification led to reduced GTPase activity of OPA1. In cardiomyocytes, SIRT3 was capable of deacetylating and elevating GTPase activity of OPA1. Moreover, SIRT3 overexpression prevented doxorubicin-mediated mitochondrial fragmentation and myocyte cell death by activating OPA1. In vivo studies conducted with SIRT3 overexpressing transgenic mice showed that SIRT3 protects the heart from developing cardiac hypertrophy and heart failure by preserving health of mitochondrial population. In summary, our data showed that SIRT3 promotes mitochondrial function not only by regulating activity of metabolic enzymes, but also by regulating mitochondrial dynamics by targeting OPA1. Based on this and other published data SIRT3 is considered a therapeutic target for the treatment of heart failure.

043
MODELING MECHANISMS OF DILATED CARDIOMYOPATHY
BS Tuana
Department of Cellular and Molecular Medicine, University of Ottawa, Ottawa, Ontario

Dilated cardiomyopathy (DCM) is characterized by weak myocardium with inefficient pump action such that blood accumulates in the ventricles which dilate. DCM can arise due to exposure to toxic and infectious agents as well as deficits in metabolic performance of cardiac tissue. A significant portion (~30%) of DCM is associated with genetic mutations in genes encoding the cytoskeletal and contractile network as well as the nuclear lamina of cardiomyocytes. Much interest exists in modeling DCM in animals to potentially aid in clinical testing for human forms of the disease. In view of multifactorial nature of DCM and lack of knowledge for cause in a large % of cases, we have been interested in defining novel mechanisms that lead to DCM. In this regard we have generated two distinct mouse models of DCM. In the first model we sought to inhibit the E2F/Rb pathway by expressing the repressor E2F6 in postnatal myocardium. These mice presented with early onset DCM which was associated with major changes in gene expression and subcellular disorganization. In the second model we sought to alter the translation of the calcium signal by expressing a calcium/calmodulin dependent protein kinase II isoform (beta) in the postnatal heart. These mice also presented with DCM but with dysfunctional calcium handling proteins of the sarcoplasmic reticulum. The targeting of
DCM via these two unique pathways will be addressed with the potential translation to human condition. Supported by HSFC and CIHR.

044
PDE5 INHIBITION IN PROTECTION OF DOXORUBICIN-INDUCED CARDIOMYOPATHY
RC Kukreja
Pauley Heart Center, Division of Cardiology, Virginia Commonwealth University, Richmond, Virginia, USA

Doxorubicin (DOX) is one of the most effective and commonly used chemotherapeutic agents for treating cancer in both children and adults. However, its clinical utility is limited due to cumulative cardiotoxicity that can lead to heart failure. Most of the cellular events triggered by DOX contribute to cell death which is the primary mechanism by which DOX induces cardiomyopathy. Several studies have shown that phosphodiesterase-5 (PDE5) inhibitors including sildenafil, vardenafil and tadalafil induce protective effect against ischemia/reperfusion injury in the heart. We also demonstrated that treatment with sildenafil prior to DOX treatment inhibited cardiomyocyte apoptosis, preserved mitochondrial membrane potential (ΔΨm), myofibrillar integrity and prevented left ventricular (LV) dysfunction as well as ST segment prolongation. These effects were duplicated by the use of long acting PDE-5 inhibitor, Tadalafil which also prevented cardiomyocyte apoptosis in DOX-induced cardiomyopathy through mechanisms involving up-regulation of cGMP, increase in protein kinase G activity and MnSOD level. Moreover, we observed that sildenafil is a powerful sensitizer of DOX-induced killing of prostate tumors in nude mice while providing concurrent cardioprotective benefit. These studies suggest that prophylactic treatment with PDE-5 inhibitors might become a promising therapeutic intervention for managing the clinical concern of DOX-induced cardiotoxicity in patients.

Supported in part by grants HL51045, HL59469, and HL79424 from the National Institutes of Health.

045
NOVEL CARDIOPROTECTIVE ROLE OF MIR-133A
PK Mishra,1,2
1Department of Cellular and Integrative Physiology; 2Department of Anesthesiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

MicroRNA-133a (miR-133a) is the most abundant miRNA in the heart. It is a cardioprotective miRNA that plays a crucial role in heart development and prevents cardiac hypertrophy and fibrosis in the adult heart. Downregulation of miR-133a is reported in failing human hearts and rodent diabetic hearts. Recently, we demonstrated that a reduced level of miR-133a is positively correlated with induction of cardiac autophagy (a process of sequestering damaged and aged cytoplasmic components into a double membrane vesicle called autophagosome and their subsequent degradation by lysosome) in diabetic heart failure patients undergoing mechanical unloading through left ventricle assist device. However, the miR-133a→autophagy axis is unclear in the heart. Important questions that need to be investigated to understand the specific role of miR-133a in cardiac autophagy include: whether the downregulation of miR-133a is a trigger for induced autophagy in diabetic hearts? If overexpression of miR-133a is able to restore cardiac autophagy? Which specific cargo is selected for miR-133a-mediated autophagy? To address these questions, I will elucidate the underlying molecular mechanism by which miR-133a regulates autophagy in diabetic hearts. I will also provide insight on a specific cargo selected for cardiac autophagy in diabetes, which is regulated by miR-133a. Further, I will discuss that restoration of basal level of cardiac autophagy by overexpressing miR-133a has potential to become a novel therapeutic target for diabetic heart failure.

Acknowledgements: NIH grants: HL113281 and HL116205.

018
SEX DIFFERENCES IN CARDIAC TOLERANCE TO OXYGEN DEPRIVATION: DEVELOPMENTAL ASPECTS
B Ostadal
Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic

Human epidemiological studies have shown a clear association between the adverse intrauterine environments and an increased risk of ischemic heart disease in later adult life. Experimental studies have repeatedly suggested a possible link between early hypoxia and increased risk for cardiovascular disease in offspring. The question arises whether the effects of perinatal hypoxia on cardiac tolerance to ischemia differ in adult males and females. In the rat model, we have observed that the late myocardial effects of hypoxemia may be sex-dependent. Perinatal exposure to chronic hypoxia significantly increased cardiac tolerance to acute ischemia/reperfusion (I/R) injury – expressed as the lower incidence of ischemic arrhythmias – in adult female rats, while the opposite effect was observed in males. The mechanism of these late effects of perinatal hypoxia is currently unknown. The number of hypotheses includes prenatal sensitization of the apoptotic pathway, the lower expression of heat shock protein 70 in perinatal hypoxic hearts and decreased prenatal eNOS levels. Prenatal hypoxia induced sex-dependent changes in cardiac tolerance to ischemia in adults may be due to differences in fetal programming of the expression of the gene for PKCε, which plays a pivotal role in cardioprotection against I/R injury: down-regulation of PKCε function was observed in the hearts of adult male offspring only. These experimental observations would have important clinical implications because cardiac sensitivity to oxygen deprivation in adult patients may be significantly influenced by perinatal disturbances in a sex-dependent manner.

019
SEX-SPECIFIC IMMUNE MODULATION OF BLOOD PRESSURE
X Liu, H Ji, X Wu, K Sandberg
Department of Medicine and Center for the Study of Sex Differences in Health, Aging and Disease, Georgetown University, Washington, DC, USA

Male wild type mice (WT-M) exhibit higher mean arterial pressure (MAP) than female wild type mice (WT-F) after angiotensin II (Ang II) infusion; however, in recombinant activation gene-1 null mice (Rag-1-/-), which lack the ability to produce mature T cells, this sex difference in Ang II-induced hypertension was lost. After adoptive transfer of male CD3+, CD4+ or CD8+ T cells into male Rag-1-/- mice (CD3M→Rag1-/-;M; CD4M→Rag1-/-;M; CD8M→Rag1-/-;M), the MAP was similar to WT-M levels. In contrast, adoptive transfer of female CD3+ and CD4+ T cells into the male Rag-1-/- host (CD3F→Rag1-/-;M; CD4F→Rag1-/-;M) had no effect and adoptive transfer of female CD8+ T cells (CD8F→Rag1-/-;M) attenuated the magnitude of Ang II-induced hypertension. Taken together, these studies indicate that T cells modulate the development of hypertension in a sex-specific manner and that male T cells augment hypertension while female T cells do not. To determine if this sex-specific effect of T cells is due to intrinsic differences between male and female T cells or to sex differences in exposure to gonadal hormones, Rag-1-/-/M mice were exposed to 80°C (8 Gy) using a 137 Cs irradiator (Georgetown University). Seven days prior to irradiation, Baytril (0.17 mg/mL) was added to the sterile drinking water of the recipient Rag-1-/-/M mice and the mice were maintained on this antibiotic supplemented water for an additional two weeks after irradiation to prevent infections. Four to six hours after irradiation, the mice received via retro-orbital injection 5 x 107 (in 0.15 mL phosphate buffer saline) unfractionated bone marrow (BM) cells isolated from the femur and tibia from either WT-M or WT-F mice. We found a striking difference in survival after the bone marrow transplant. All of the mice receiving male BM cells died within 7 weeks of
Abstracts

020 ARGinine vasopressin in preeclampsia
JL Grobe
Department of Pharmacology & Center for Hypertension Research, University of Iowa, Iowa City, Iowa, USA
Preeclampsia is a hypertensive disorder of late pregnancy for which (despite having been recognized clinically for centuries) there remains no simple early-pregnancy diagnostic biomarker test, no simple and effective animal models of the early pathogenesis, and the only true ‘cure’ remains the (often premature) delivery of the fetus and placenta. Compared to a normal pregnancy, preeclampsia represents a low-renin subtype of hypertension, which led us to hypothesize a role for arginine vasopressin (AVP) in its pathogenesis. Copeptin, the stable / slow-clearance C-terminal portion of the AVP gene product that is released in a 1:1 molar ratio to AVP, was found to be grossly elevated in first-trimester plasma samples from women that eventually developed preeclampsia, and its levels were found to be very strongly predictive of the disorder as early as the 6th week of gestation (ROC AUC=0.90, or 0.96 for women with no history of pre-eclampsia). Chronic infusion of AVP (24 ng/hr, sc) during gestation in wildtype C57BL/6J mice resulted in pregnancy-specific hypertension, renal glomerular endotheliosis, proteinuria, intratereine growth restriction. We conclude that elevated AVP/copeptin precedes the development of preeclampsia, is strongly predictive of the disorder in very-early gestation, and is sufficient to induce symptoms of preeclampsia. Ongoing work is focused on identifying the receptor subtypes and timing of exposure which mediate AVP-induced maternal preeclampsia symptoms, the role of elevated AVP in programming of adult cardiometabolic dysfunction in offspring from pre-eclamptic pregnancies, and interactions between AVP and genetic risk factors that may synergistically precipitate the development of preeclampsia.

021 MYOCARDIAL PROTECTION ISSUES IN THE NEWBORN: SEX, STRESS AND OXYGEN
C Wittnich
Departments of Surgery & Physiology, University of Toronto, Toronto, Ontario
Newborn children undergoing congenital cardiac surgery are known to have worse outcomes than older children. This presentation will discuss our research program exploring reasons for this including that newborn hearts tolerate ischemia less well than adults, develop irreversible injury sooner and exhibit at risk metabolic profiles. For example, neonatal hearts have a greater vulnerability to acid-base disturbances during ischemia due to less buffering capacity rendering them more susceptible to injury during ischemia. Additionally, ventricular dysfunction is reported greater in the left (LV) versus right ventricle (RV) in infants following surgically induced ischemia. Our research documents significant differences in LV enzyme activities and metabolic profiles that lead to worse acidosis and lower energy levels during ischemia; offering one reason for the greater LV-dysfunction relative to the RV. Children can also be exposed to high oxygen levels (hyperoxia) for hours to days during their medical and/or surgical management. Our research shows that hyperoxia in the newborn triggers oxygen free radical-mediated membrane injury because of an inability of the newborn heart to upregulate its’ antioxidant enzyme defenses while impairing myocardial function and hemodynamics. Finally, recent reports in children with congenital heart disease, female sex has been linked to greater in-hospital mortality associated with low cardiac output, yet the reasons for this are unclear. We have identified, compared to males, the hearts of newborn females are at a metabolic disadvantage - having even lower energy levels and greater tissue lactic acidosis, both linked to an increase susceptibility to ischemic injury and impair myocardial function upon reperfusion.
role of sarcoplasmic reticulum (SR) on altered intracellular Ca\textsuperscript{2+} regulation in cardiomyocytes from MetS male rats, induced with high-sucrose drinking water during 16-week period. Basically, electrically-stimulated Ca\textsuperscript{2+} transients and L-type Ca\textsuperscript{2+}-currents (LTCC) were recorded in ventricular myocytes from MetS rats relative to myocytes from control rats. We also investigated SR-Ca\textsuperscript{2+} ATPase (SERCA) activity as well as cardiac ryanodine receptor (RyR2) family proteins’ phosphorylation levels by Western blot analysis. The Ca\textsuperscript{2+} transients exhibited significantly reduced amplitude (~30%), and prolonged time courses (2-fold) with no change in LTCC as well as depressed Ca\textsuperscript{2+} loading of SR (~55%) due to caffeine responses in cardiomyocytes from MetS rats with increased basal Ca\textsuperscript{2+} compared to aged-matched control rats. The data with caffeine responses under iNaO\textsubscript{C} also demonstrated a depressed SERCA activity in MetS cardiomyocytes which was further supported with the data on a slowed cytosolic Ca\textsuperscript{2+} removal associated with a significant decrease in SERCA2-mediated Ca\textsuperscript{2+} reuptake. Additionally, the data with tetracaine application assay was supporting a leaky-RyR2 in cardiomyocytes from MetS group. Moreover, high phosphorylation levels of both RyR2 and phospholamban are supporting a depressed SR activity which underlies Ca\textsuperscript{2+} dyshomeostasis in MetS rat model. Furthermore, we found that MetS induced cardiac dysfunction through myocardial loss, connective tissue and lipid accumulation in the myocardium. Moreover, our study showed that cardiac expressions and activities of some phosphodiesterases (PDEs) increased in MetS and, consistent with these results, the effects of PDE inhibitors on the pathways that control cardiac contraction were higher than those in the control group. In conclusion, we established that a 16-wk high sucrose feeding protocol, which induced cardiac dysfunction, leads to MetS disease model in rats. We define the components of MetS-induced cardiac dysfunction as follows: structural changes in myocardium, Ca\textsuperscript{2+} dyshomeostasis and increased PDE activity. The most striking result of this study is, in the absence of type-2 diabetes or obesity, MetS induced by a high-sucrose diet was enough to alter cardiac performance in the rats. The presence of insulin resistance or MetS should be taken into account in connection with the clinical use of some PDE inhibitors to avoid their potential side effects.

Acknowledgements: TUBITAK SBAG-1135466.

049 EVALUATION OF QT DISPERSION IN ASYMPOMATIC PATIENTS WITH GRADE I LEFT VENTRICULAR DIASTOLIC DYSFUNCTION
AO Blackman\textsuperscript{1,2}, J Sobral Neto\textsuperscript{3}, OM Gomes\textsuperscript{3}
\textsuperscript{1}Centrocard – Cardiologic Evaluation Center, Brasilia; \textsuperscript{2}Cardiovascular Foundation S Francis of Assisi – ServCor, Belo Horizonte, Brazil

INTRODUCTION: Grade 1 left ventricular diastolic dysfunction, a mechanical phenomenon related to abnormalities of ventricular relaxation, is highly prevalent in the population and leads to over heart failure. Furthermore, QT dispersion (QTD ≤ 80ms), an electrical phenomenon, is related to significantly increased risk of severe arrhythmias and sudden cardiac death.

OBJECTIVE: To analyze the influence of grade I left ventricular diastolic dysfunction on QT dispersion in asymptomatic patients estimating the circadian variation of QT dispersion and the incidence of arrhythmia in the population. Method: Consisted of assessing 26 patients with grade 1 left ventricular diastolic dysfunction and average ages between 55.7±5.8, and 65.1±9.6 ms, morning, afternoon, evening and night during sleep respectively. Nevertheless, in 32.8% of the patients it was found average heart-rate-corrected 280 ms. One patient (3.8%) presented premature ventricular complex higher than 10.

CONCLUSION: This research demonstrated the occurrence of QT interval dispersion in 30.8% of patients without cardiovascular symptoms, with grade 1 left ventricular diastolic dysfunction.
Abstracts

diabetes mellitus (T2DM) leading to accelerated development of athero-
sclerotic vascular lesions.

We analyzed the monocyte proteome for potential markers of early athero-
genesis in T2DM using 2DE/MS/MS. We identified Cyclophilin A, an
immunophilin secreted from monocytes activated by hyperglycaemia. Plasma
levels of cyclophilin A were assayed in 556 subjects including nor-
mal healthy volunteers and patients with T2DM, with or without coronary
artery disease (CAD). Plasma Cyclophilin levels were higher in diabetes
patients with or without CAD compared to normal subjects (P < 0.001).

Age, fasting blood sugar levels and HbA1C levels were positively associ-
ated with increased plasma cyclophilin. Cyclophilin levels were elevated in
patients with increased serum CRP levels (p = 0.016) and reduced in
patients using metformin (p < 0.001). There was a strong association of
high cyclophilin values with diabetes and vascular disease (p < 0.001).

Gene variants of cyclophilin did not affect the plasma protein levels.

We further studied the mechanistic role of cyclophilin in initiation of
atherogenesis in diabetes. Extracellular cyclophilin acts as a chemotrac-
tant for monocytes and promotes monocyte endothelial adhesion. Foam
cell formation, the hallmark of early atherogenesis also increases in macro-
phages cultured with Cyclophilin A. Cyclophilin A is currently being
evaluated as a marker of proinflammatory status in type 2 diabetes and
possibly a predictor of early vascular disease through a prospective study.

Acknowledgements: Indian Council for Medical Research, Government of India

053
TARGETING HOST IMMUNE RESPONSE TO ENHANCE
EFFICACY OF ALLOGENEIC MENSEMYAL STEM CELLS
FOR CARDIAC REGENERATION

S Dhingra
Regenerative Medicine Program, Institute of Cardiovascular
Sciences, St Boniface Research Centre, University of Manitoba,
Winnipeg, Manitoba

Allogeneic mesenchymal stem cells (MSCs) are immunoprivileged, there-
fore these cells can suppress host immune system and survive after transplan-
tation. However recent data from preclinical and clinical studies indicate
that allogeneic MSCs provoke immune response in the recipient and are
rejected after transplantation. We confirmed that allogeneic MSCs improved
heart function after implantation in the infarcted heart. However, late after
implantation, the cells lost their immunoprivilege, and were rejected.

Therefore we started extensive investigations to study mechanisms of rejec-
tion, our data demonstrate that immunoprivilege of MSCs was maintained
by prostaglandin E2 (PGE2) produced by these cells. We further dem-
strated that myogenic differentiation of MSCs led to PGE2 decrease and loss
of immunoprivilege. PGE2 treatment of differentiated MSCs preserved
immunoprivilege. Using an in vivo rat model, MSCs (3×106 cells/rat) with
or without a biodegradable hydrogel that slowly released PGE2 were injected
into infarct region. After 5 weeks significant number of transplanted cells
survived in hydrogel+PGE2 group compared to control group. In conclusion,
maintaining PGE2 levels in differentiated MSCs preserved immunoprivilege
and restored cardiac function after MI.

054
LOX-1 DELETION ATTENUATES BRAIN INJURY FOLLOWING
CHRONIC MYOCARDIAL ISCHEMIA

X Wang, V Manavalan, Z Ding, Y Dai, JL Mehta
Central Arkansas Veterans Healthcare System and the University of
Arkansas for Medical Sciences, Little Rock, Arkansas, USA

Ischemic heart disease is the most cause of morbidity and mortality. It is
generally thought, but not proven that myocardial ischemia affects brain
function. LOX-1, a lectin-like receptor for oxidized low density lipoprotein
(ox-LDL), is responsible for the binding and uptake of ox-LDL as well as
other ligands exhibiting oxidized phospholipids. Previous studies have dem-
onstrated that blockade or deletion of LOX-1 reduces ischemic myocardial
injury in mice. Whether myocardial ischemia per se affects brain function and
whether LOX-1 expression is involved in this process are not known.

In this study, WT C57Bl/6J mice and LOX-1 KO mice were exposed to chronic
myocardial ischemia by total ligation of left coronary artery (LCA) for 4
weeks. The sham operated WT mice and LOX-1 KO mice served as controls.
Cardiac remodeling and function were analyzed by hematoxylin and eosin
(HE) staining, Masson Trichrome (MT) staining and echocardiographic
analysis, and the brain injury was analyzed by HE staining, cresyl violet (CV)
staining and TUNEL assay. In accordance with previous studies, we observed
in this study that LOX-1 deletion reduced LCA occlusion-induced myocar-
dial damage and fibrosis, and limited deterioration of cardiac function. More
interestingly, there was a significant increase in damaged and apoptotic
neurons in the cerebral cortex of WT mice starting at 1 week after LCA
occlusion and persisting for 4 weeks. Hypoxic and apoptotic neurons were
much less in the brains of LOX-1 KO mice than in WT mice. However, the
mechanism by which myocardial ischemia induces brain injury is not known,
but it is clear that LOX-1 deletion reduces brain injury.

055
EXERCISE TRAINING ATTENUATES CHEMOREFLEX-MEDIATED
REDUCTIONS OF RENAL BLOOD FLOW IN HEART FAILURE

NJ Marcus1,2, C Pügie3, J Mediratta2, AM Schiller2, R Del Rio3,
IH Zucker2, HD Schultz2
1Department of Physiology and Pharmacology, Des Moines
University, Des Moines, Iowa; 2Department of Cellular and
Integrative Physiology, University of Nebraska Medical Center,
Omaha, Nebraska; 3Laboratory of Cardiorespiratory Control,
Universidad Autónoma de Chile, Sede Temuco, Chile

In chronic heart failure (CHF), carotid body chemoreceptor (CBC) activ-
ity is increased and contributes to increased tonic and hypoxia-evoked
elevation in renal sympathetic nerve activity (RSNA). Elevated RSNA
and reduced renal perfusion may contribute to development of the ‘cardio-
renal’ syndrome in CHF. Exercise training (EXT) has been shown to abro-
gate CBC-mediated increases in RSNA in experimental heart failure;
however the effect of EXT on CBC control of renal blood flow (RBF) is
undetermined. We hypothesized that CBCs contribute to tonic reductions
in RBF in CHF, that stimulation of the CBC with hypoxia would result in
exaggerated reductions in RBF, and that these responses would be attenu-
ated with EXT. RBF was measured in 1) CHF-sedentary (SED), 2) CHF-
EXT, 3) CHF-carotid body denervation (CBD), and CHF-renal
denervation (RDNX) groups. We measured RBF at rest and in response to
hypoxia (FiO2 10%). All animals exhibited similar reductions in ejection
fraction and fractional shortening as well as increases in ventricular systolic
and diastolic volumes. Resting RBF was lower in CHF-SED (29 ± 2 ml/
min) compared to CHF-EXT animals (46 ± 2 ml/min, p<0.05), and com-
pared to CHF-CBD animals (42 ± 6 ml/min, p<0.05). In CHF-SED, RBF
decreased during hypoxia, and this was prevented in CHF-EXT animals.
Both CBD and RDNX abolished the RBF response to hypoxia in CHF.
MAP increased in response to hypoxia in CHF-SED, but was prevented by
EXT, CBD, and RDNX. EXT is effective in attenuating chemoreflex-
mediated tonic and hypoxia-evoked reductions in RBF in CHF.

Session 3.4: New Concepts in Arrhythmogenesis

056
NEW ASPECTS OF REGULATION OF CARDIAC ACTION
POTENTIAL DURATION

PP Nánási
Department of Physiology, University of Debrecen, Hungary

In this talk three recently described features of regulation of action poten-
tial duration (APD) are discussed, each based on changes in the net mem-
brane current (Inet) during the plateau of the AP.

1. The reverse rate-dependent nature of drug effects on APD means that any
drug-induced change in APD is more pronounced at longer than at
shorter cycle lengths. Similar results are obtained when repolarization is
modified by injection of inward or outward current pulses. On the other
hand, all drug-induced or current-induced changes in APD well correlate
with the baseline value of APD in all mammalian preparations studied,

Curr Res Cardiol Vol 2 No 3 Autumn 2015
including the human heart. Since Inet is inversely proportional to APD, and consequently to cycle length, it is concluded that that reverse rate-dependency may simply reflect the inverse relationship linking Inet to APD. In summary, reverse rate-dependency is an intrinsic property of cardioactive drug actions.

2. Beat-to-beat variability (short-term variability, SV) of APD is a good predictor of cardiac arrhythmias, however, the factors influencing its magnitude are not fully clarified. In order to eliminate the direct effects of APD changes on SV, relative SV (RSV) was introduced by normalizing the observed SV-changes to concomitant APD-changes and comparing this ratio to the exponential SV-APD relationship, obtained using inward and outward current injections. RSV is decreased by ion currents playing critical role in the negative feedback regulation of APD, such as ICa, IKs and IKr, therefore blocking of these currents may carry some proarrhythmic risk. Conversely, RSV is increased by INa, in line with the known antiarrhythmic effect of late INa blockade. RSV is modulated by several further parameters, like intracellular Ca2+ concentration, tissue redox potential, stimulation rate or temperature.

3. Adrenergic activation of L-type Ca2+ and various K+ currents is a crucial mechanism of cardiac adaptation, however, it carries substantial proarrhythmic risk. It was found that the isoproterenol (ISO)-induced activation of ICaL precedes the enhancement of IKs and IKr. This since this temporal shift is different affected by selective blockade of β1 and β2 adrenoceptors, and is reduced after inhibition of phosphodiesterases, different adrenergic signal transduction pathways and compartmentalization is likely involved.

057
LQT5 TRANSGENIC RABBITS: A NEW MODEL EXHIBITING INCREASED CARDIAC REPOLARIZATION INSTABILITY AND ARRHYTHMIA SUSCEPTIBILITY
I Barczkó1, P Major2, V Juhász1, R Varga1, T Hornyik1, L Hiripi2, Z Bősze2, A Varró1,2
1Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged; 2Agricultural Biotechnology Center, Gödöllő; 3MTA-SZTE Research Group of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary

The reliable prediction of proarrhythmic risk associated with novel compounds under development remains elusive and new models with better predictive value are needed. We performed the primary characterization of a new transgenic LQT5 rabbit model, recently generated by our group, based on selective cardiac overexpression of a mutant human KCNE1 gene. This missense mutation was first described in a Chinese LQT syndrome family. Arrhythmias were provoked by i.v. administration of the IKr blocker dofetilide in LQT5 transgenic (TG) rabbits and wild type(WT) littermates. The ECG was continuously registered, and arrhythmia development was monitored. Conventional ECG parameters characterizing repolarization duration, the QT and frequency corrected R-SV (RSV) was introduced by normalizing the observed SV-changes to concomitant APD-changes and comparing this ratio to the exponential SV-APD relationship, obtained using inward and outward current injections. RSV is decreased by ion currents playing critical role in the negative feedback regulation of APD, such as ICa, IKs and IKr, therefore blocking of these currents may carry some proarrhythmic risk. Conversely, RSV is increased by INa, in line with the known antiarrhythmic effect of late INa blockade. RSV is modulated by several further parameters, like intracellular Ca2+ concentration, tissue redox potential, stimulation rate or temperature.

Abstracts

058
ANTIAARRHYTHMIC AND CARDIAC ELECTROPHYSIOLOGIC EFFECT OF DESETHYLMIODARONE
A Varró
University of Szeged, Department of Pharmacology and Pharmacotherapy, Szeged, Hungary

Desethylamiodarone (DEA) is the major metabolite of amiodarone (AMIO), which is considered as one of the most effective drugs for the treatment of various types of cardiac arrhythmias including atrial fibrillation (AF). The therapeutic value of AMIO, however, is greatly limited by its non-cardiac adverse effects. Previous reports indicated that DEA had more binding affinity for the cardiac thyroid receptor than its parent compound AMIO. Therefore, the aim of our study was to compare the possible antiarrhythmic effect of DEA in comparison with AMIO in different experimental arrhythmia models. In a conscious rat model of coronary artery ligation-induced ventricular arrhythmias, per os 50 mg/kg/day (3 weeks) DEA administration exerted similar antiarrhythmic effects to 100 mg/kg/day (3 days) AMIO pre-treatment increasing survival from 23 % (n=39) to 80% and 75%, respectively. In the atrial tachypaced dog atrial fibrillation model, per os 50 mg/kg/day (4 weeks) AMIO treatment decreased the duration of AF episodes to a similar extent to per os 25 mg/ kg/day (4 weeks) DEA treatment. In the cellular level chronic DEA treatment - similarly to that of AMIO - increased cardiac ventricular action potential duration and frequency dependently decreased the maximal rate of depolarization (Vmax). On the surface ECG significant QTc lengthening was observed also after both AMIO and DEA treatments. After chronic treatment with AMIO and DEA the corresponding tissue (lung, liver and brain) drug levels measurements yielded smaller drug levels with DEA compared to that of AMIO. Based on these results it can be expected that using DEA instead of AMIO would result in similar therapeutic effects with possibly reduced drug toxicity.

059
FIBROSIS: A STRUCTURAL MODULATOR OF ATRIAL PHYSIOLOGY AND ARRHYTHMIAS IN THE HUMAN HEART
V Fedorov, BJ Hansen, TA Cepe
Department of Physiology & Cell Biology and Davis Heart & Lung Research Institute, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA

Atrial fibrillation (AF) is the most common sustained arrhythmia and is associated with increased cardiovascular morbidity and mortality. Despite several decades of extensive research, gaps in understanding the mechanisms of AF still exist, making successful treatment particularly challenging. Electrophysiological and structural (fibrosis) abnormalities have been shown to underlie AF development. However, the contribution of the three dimensional (3D) atrial microstructure, including heterogeneous fibrosis distribution, to both the development and persistence of AF in the diseased human atria has not been clearly elucidated. Importantly, the 3D microstructural substrates of AF in diseased human hearts cannot be directly reproduced in any animal model and currently cannot be studied in vivo. For this purpose, we developed a novel approach to simultaneously map sub-endocardial (sub-Endo) and sub-epicardial (sub-Epi) activation patterns and integrate these data with ex vivo 3D gadolinium-enhanced MRI images of the atrial microanatomic architecture, including fibrosis, in order to elucidate possible mechanisms of AF in diseased human hearts. Our pilot data show that the primary mechanism of AF maintenance in human hearts is a limited number of patient-specific AF drivers (intramural reentries) anchored to microanatomic substrates with predictable structural features, such as enhanced interstitial fibrosis, atrial bundle thickness, and high Sub-endo vs Sub-epicardial myocardial angle differences. We suggest that the use of explanted human hearts combined with our novel integrative 3D functional/structural approach will uncover the localized pathologic microanatomy of the human heart that is responsible for AF and other arrhythmias, ultimately leading to new treatment strategies of these heart rhythm disorders.
Dilated cardiomyopathy (DCM) is an important cause of heart failure (HF). Myocardin, a cardiac-specific transcription factor, has been shown to be involved in DCM associated cardiac remodeling and identified miRNA-33a as a regulator of Myocardin expression. We propose that Myocardin is involved in DCM associated cardiac remodeling and identified miRNA-33a as a regulator of Myocardin using a homing peptide in RAL model of cardiomyopathy.

β-MHC), fibrotic markers (Col1a, Col3a, Col4a, CTGF, TGF-β), resulted in decreased cardiac expression of hypertrophy markers (ANP and BNP) in DCM patients and in RAL model of cardiomyopathy. In vitro silencing of Myocardin by siRNA resulted in decreased expression of sarcomeric genes (troponin I, troponin T and cardiac actin), hypertrophy marker, ANP and fibrotic genes (Col1a, Col3a, Col4a, CTGF, TGF-β and FGF-β) in myocytes and cardiac fibroblasts respectively. Cardiac specific Inhibition of Myocardin using a homing peptide in RAL model of cardiomyopathy resulted in decreased cardiac expression of hypertrophy markers (ANP and β-MHC), fibrotic markers (Col1a, Col3a, Col4a, CTGF, TGF-β and FGF-β) and attenuated cardiac hypertrophy and fibrosis. We investigated the upstream regulatory mechanisms controlling the expression of Myocardin and identified miRNA-33a as a regulator of Myocardin expression. We propose that Myocardin is involved in DCM associated cardiac remodeling and Myocardin gene targeting offers a novel therapeutic target in DCM.

Abstracts

**Session 3.5: George Jackowski Symposium – Prevention of Heart Disease**

**060 CANDIDATE GENE TARGETING REVEALS THE FUNCTIONAL ROLE OF MYOCARDIN IN DILATED CARDIOMYOPATHY**

M Khullar, A Mittal, S Rana, R Sharma, A Kumar, SK Raut, V Arige, S Sharma, R Prasad, UN Saikia, S Sarkar, NR Mahapatra, A Bahl

1Department of Cardiology; 2Department of Experimental Medicine and Biotechnology; 3Department of Histopathology; 4Department of Internal Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India; 5Department of Zoology, University of Calcutta, India; 6Department of Biotechnology, Indian Institute of Technology, Madras, India.

Dilated cardiomyopathy (DCM) is an important cause of heart failure (HF) and sudden cardiac death and a leading indication for cardiac transplantation. To combat the very poor outcome of HF in general and DCM in particular, it is critical to better understand the pathophysiology of DCM. Myocardin, a cardiac-specific transcription factor, has been shown to be increased in end stage HF, and in DCM patients. We examined role of Myocardin in DCM and in Renal artery ligation (RAL) model of cardiomyopathy. We found increased cardiac Myocardin expression in DCM patients and in RAL model of cardiomyopathy. In vitro silencing of Myocardin by siRNA resulted in decreased expression of sarcomeric genes (troponin I, troponin T and cardiac actin), hypertrophy marker, ANP and fibrotic genes (Col1a, Col3a, Col4a, CTGF, TGF-β and FGF-β) in myocytes and cardiac fibroblasts respectively. Cardiac specific Inhibition of Myocardin using a homing peptide in RAL model of cardiomyopathy resulted in decreased cardiac expression of hypertrophy markers (ANP and β-MHC), fibrotic markers (Col1a, Col3a, Col4a, CTGF, TGF-β and FGF-β) and attenuated cardiac hypertrophy and fibrosis. We investigated the upstream regulatory mechanisms controlling the expression of Myocardin and identified miRNA-33a as a regulator of Myocardin expression. We propose that Myocardin is involved in DCM associated cardiac remodeling and Myocardin gene targeting offers a novel therapeutic target in DCM.

**061 UPDATE ON INFECTIVE ENDOCARDITIS**

E Castañeda Saldaña

Cayetano Heredia Peruvian University, Lima, Peru

Infective endocarditis (IE), a microbial infection of the endocardial surface of the heart, has been classified as acute or subacute–chronic. The epidemiologic features of infective endocarditis are changing as a result of increasing longevity, new predisposing factors, and an increase in nosocomial cases. Mitral-valve prolapse is now the most common cardiovascular diagnosis predisposing patients to infective endocarditis. Other conditions associated with an increased incidence of infective endocarditis include poor dental hygiene, long-term hemodialysis, diabetes mellitus and infection with the human immunodeficiency virus (HIV). The modified Duke criteria provide the basis for the diagnosis of infectious endocarditis; also include recommendations for choosing between transthoracic echocardiography (TTE) and transesophageal echocardiography (TEE). TEE is more sensitive than TTE for defining perivalvular extension of infective endocarditis and the presence of a myocardial abscess and valve perforations. Congestive heart failure and neurologic events have the greatest influence on the prognosis of infective endocarditis. It has not been demonstrated benefits of anticoagulant therapy. Combined medical and surgical therapy for infective endocarditis can decrease mortality among patients who have congestive heart failure, perivalvular invasive disease, or uncontrolled infection despite maximal antimicrobial therapy; congestive heart failure is the strongest indication for surgery in infective endocarditis. A recent neurologic complication of infective endocarditis has been considered a relative contraindication to valve-replacement surgery. Early surgery for native valve endocarditis is associated with an in-hospital mortality benefit compared with medical therapy alone.

**062 MOLECULAR SIGNATURES AS TOOLS FOR MANAGEMENT OF ORGAN FAILURE**

B McManus

PROOF Centre of Excellence, Vancouver, British Columbia

Heart, lung and kidney diseases together constitute a massive and growing burden that amounts to over $3 trillion of health care spending worldwide. Through non-targeted identification of omics biomarker signatures (transcripts, proteins, metabolites) and development of relevant signatures into actionable blood tests, the Prevention of Organ Failure (PROOF) Centre of Excellence aims to produce a new generation of patient-specific laboratory tests to better guide patient care and to identify those at risk of organ failure. In our lead program, Biomarkers in Transplantation (BiT), we are now implementing a discriminative blood test that determines which heart transplant patients are not undergoing acute rejection and thus need not receive biopsies. The biopsy is the “gold standard” for detecting rejection, but is an expensive, highly invasive procedure that may produce inconclusive results. Our previous BiT1 and BiT2 studies used Affymetrix microarrays to measure whole blood mRNA levels in heart transplant patients, and identified a promising 40-mRNA signature for excluding acute rejection with high negative predictive value (NPV). In BiT3, these signatures were developed on two clinically amenable gene-expression platforms: HTG EDGE-Seq and NanoString nCounter. Using a discovery cohort of 38 patient samples, we have initially replicated biomarker panels that exclude acute rejection virtually 100% of the time on both HTG and NanoString assay platforms. A 6-mRNA panel on the NanoString assay was successfully validated on another set of unique, banked bio-samples from 126 patients, with 98% NPV, 4% PPV, 91% sensitivity, and 15% specificity. Heart transplant patients are biopsied as often as every week during the first 3 months post-transplant. Acute rejection, the most important cause of early morbidity and graft injury, occurs in 20-30% of patients during this timeframe. The BiT blood test has the potential to dramatically reduce the need for biopsies and aid clinicians in moderating immunosuppressive treatment according to individual patient needs.

**063 CARDIAC ENERGY METABOLIC PERTURBATIONS IN HEART FAILURE ASSOCIATED WITH OBESITY**

GD Lopaschuk, S Sankaralingam, O Aho Alrob, CS Wagg, VB Patel, RS Padwal, DE Johnstone, AM Sharma, GY Oudit

Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta

Dramatic alterations in cardiac energy metabolism occur in obesity and heart failure, including the development of cardiac insulin-resistance that can contribute to cardiac dysfunction. We therefore investigated what effect lowering body weight in obese mice with heart failure (by inducing caloric restriction, CR) had on cardiac function, and insulin-resistance. Obesity was induced in C57Bl/6 mice by feeding a high fat diet (HFD, 60% kcal from fat) and heart failure was induced by a transverse aortic constriction (TAC). At 6 wk post-TAC, mice were then either continued on a HFD for a further 8 wk period, or subjected to CR (40% decrease in calories). Control mice were fed a low fat diet (LFD, 12% kcal from fat) or HFD and underwent a sham surgery. An increase in body weight was seen in HFD Sham mice (45.2±2.1 g) and HFD TAC mice (42.1±1.3 g) compared to LFD sham mice (31.1±1.1 g), as well as an impaired whole body glucose tolerance. CR of HFD TAC mice decreased body weight (23.1±1.0 g) and lowered body weight in obese mice with heart failure (by inducing caloric restriction, CR) had on cardiac function, and insulin-resistance. Obesity was induced in C57Bl/6 mice by feeding a high fat diet (HFD, 60% kcal from fat) and heart failure was induced by a transverse aortic constriction (TAC). At 6 wk post-TAC, mice were then either continued on a HFD for a further 8 wk period, or subjected to CR (40% decrease in calories). Control mice were fed a low fat diet (LFD, 12% kcal from fat) or HFD and underwent a sham surgery. An increase in body weight was seen in HFD Sham mice (45.2±2.1 g) and HFD TAC mice (42.1±1.3 g) compared to LFD sham mice (31.1±1.1 g), as well as an impaired whole body glucose tolerance. CR of HFD TAC mice decreased body weight (23.1±1.0 g) and greatly improved whole body glucose tolerance. Heart transplant patients are biopsied as often as every week during the first 3 months post-transplant. Acute rejection, the most important cause of early morbidity and graft injury, occurs in 20-30% of patients during this timeframe. The BiT blood test has the potential to dramatically reduce the need for biopsies and aid clinicians in moderating immunosuppressive treatment according to individual patient needs.
isolated working heart perfused at the end of the study. CR improved insulin-stimulated glucose oxidation compared to HFD TAC mice (67±59 vs 210±40 nmol/joule, respectively P<0.05). This was associated with increased phosphorylation of Akt and decreased acetylation of pynurate dehydrogenase (PDH activation). CR also decreased the high palmitate oxidation rates observed in the HFD TAC hearts (206±25 vs 677±125 nmol/joule, respectively P<0.05), which was accompanied by a decrease in CD36 expression and a decreased acetylation of long chain acyl CoA dehydroge- nase (LCAD inactivation). We conclude that weight loss in obese mice with heart failure improves cardiac insulin sensitivity, increases glucose oxida- tion, and improves cardiac function.

064
ENERGY SUBSTRATE METABOLISM IN NORMAL AND FAILING HEARTS
FA Recchia
Cardiovascular Research Center, Temple University School of Medicine, Philadelphia, Pennsylvania; Institute of Life Sciences, Scuola Superiore Sant’Anna, Piazza Martiri della Libertà, Pisa, Italy

Under physiological conditions and at rest, the cardiac muscle generates most of its energy from the oxidation of long chain free fatty acids and, to a lesser extent, of lactic acid and glucose. Direct and indirect quantifications of cardiac substrate consumption have revealed profound alterations in fatty acids and carbohydrate utilization in pathological conditions such as ischemia, hypertrophy and failure. A characteristic metabolic change observed in severe heart failure is the reduced cardiac fatty acid oxidation associated with a marked increase in glucose oxidation. Whether this is an adaptive or a maladaptive mechanism remains an open question. We have tested the hypothesis that, in the failing heart, an abnormally high fraction of glucose is directed into the oxidative pentose phosphate pathway (oxPPP). While this pathway regenerates cytosolic NADPH necessary for the cellular anti-oxidant system, in the failing heart the excess NADPH, due to oxPPP upregulation, can also feed the superoxide-generating enzymes NADPH oxidase and uncoupled nitric oxide synthase. We pro- vided indirect evidence, ex vivo, that the inhibition of oxPPP blunts superoxide production in homogenates of cardiac tissue harvested from failing hearts. Consistently, the acute administration of an oxPPP inhibitor in dogs with pacing-induced heart failure normalizes the high cardiac free radical production occurring in response to glycemic peaks. Although more evidence is needed to draw definitive conclusions, our findings suggest that pharmacological modulators of energy substrate metabolism might attenuate oxidative stress in the failing heart and prove therapeutically effica- cious for the treatment of this syndrome.

065
MYOCARDIAL CELL MEMBRANE BIOKINETICS AND STRESS IONIC DISKINESY DISEASE CONTROL FOR CARDIOVASCULAR MORTALITY PREVENTION
O Gomes
ServCor-St Francis of Assisi Truth is Jesus Cardiovascular Foundation, South America Section International Academy Cardiovascular Sciences

In the myocardium the cell biokinetics is responsible for the EKG generation, being the Na ion flow the main responsible for the generation of the R wave. The ST segment is highly dependent of the transmembrane velocity of the Calcium flow and of its intracellular concentration. In patients with Stress Ionic Diskinesy Disease, more com- monly during Stress Test, there is calcium transmembrane improved flow, responsible by the ST depression (STD) generally diagnosed as myocardium ischemia. This Exercise Induced Silent ST Segment Depression is a disease already proved to be related with high risk for Stroke and Cardiovascular Disease during life. Based on experimental study demonstrating the biokinetics specificity of myocardial cell membrane in EKG generation and the calcium-dependent variation of ST, 40 patients with STD, after a normal coronary circulation proven by tomographic myocardial perfusion during stress and rest, were treated with calcium inhibitor diltiazem (90 mg 8/8 hours) associated (20 cases) with a daily oral intake dose of 130 mg of Mg chelate for 20 days. The repeated exercise stress test showed normal STD with improved physical and psychological fitness to stress supporting the involvement of the myocardium cell membrane bio- kinetics disease with calcium dependent myocardial ionic diskinesy in the genesis of silent ST segment depression.

066
VAGAL STIMULATION IN HF: READY FOR PRIME TIME?
ME Dunlap
Director, HF Section, Heart and Vascular Center, MetroHealth Medical Center; Professor of Medicine, Physiology, & Biophysics, Case Western Reserve University, Cleveland, Ohio, USA

Activation of the renin-angiotensin-aldosterone and sympathetic nervous systems are hallmarks of heart failure (HF), and continued activation of these systems portends a worse prognosis. Current effective HF therapy is aimed largely at blocking activation of these systems, including ACE inhibitors, beta blockers, and mineralocorticoid blockade. Parasympathetic influences are blunted markedly in HF, and decreased parasympathetic control portends a worse prognosis. In animal models of HF, enhancement of parasympathetic influences protects against ventricular arrhythmias and promotes beneficial LV anti-remodeling. Promising emerging technologies to enhance vagal influences on the heart chronically include baroreflex activation and vagal stimulation. This talk will explore mechanisms of abnormal parasympathetic control in HF along with data supporting vagal stimulation for HF, including recent and ongoing clinical trials in humans.

067
CARDIAC NEUROTRANSMISSION: SCIENTIFIC RATIONALE FOR TREATING VENTRICULAR TACHYCARDIA AND FIBRILLATION
K Shikumar
Cardiac Arrhythmia Center, UCLA Health System, Los Angeles, California, USA

Cardiac neurotransmission (afferent and efferent) modulates key physiological functions of the heart (chronotropy, dromotropy, lusitropy and inotropy). Cardiac afferent information is relayed to four major destinations: (i) intrinsic cardiac nervous system, (ii) extracardiac-intrathoracic ganglia (e.g. stel- late ganglion), (iii) spinal cord and (iv) to the brain stem (via the vagus). This information is processed and results in efferent cardiomotor control (via the sympathetic and parasympathetic nerves). This system ensures fine- tuned regulation of sympathetic-parasympathetic balance in the heart under normal and disease states. This system has also been shown to remodel (neu- ronal structure changes and trans-differentiation) in response to disease, and plays a major role in the pathophysiology and progression of heart disease (heart failure and arrhythmias leading to sudden cardiac death). Improved knowledge of the cellular and molecular processes governing cardiac inner- vation and the functional control of the myocardium in health and disease has resulted in a logical mechanistic framework for developing neuraxial therapies for preventing SCD and other arrhythmias.

068
REGENERATIVE CELL THERAPY FOR HEART FAILURE
MB Kutryk
Division of Cardiology, Keenan Research Center for Biomedical Science at the Li Ka Shing Knowledge Institute, St Michael’s Hospital, University of Toronto, Toronto, Ontario

While improvements in medical and interventional therapies for ischemic heart disease have reduced early mortality, they have resulted in a higher incidence of chronic heart failure among survivors. Recurrent hospitaliza- tions and premature death, prevalent in this growing patient population, have imposed a major unmet need associated with the inability of current, largely palliative, therapies to address tissue destruction post-infarction.
Stem cell-based regenerative treatment has been proposed as a promising approach for the treatment of both ischemic and non-ischemic cardiomyopathies based on numerous animal studies. A variety of potential stem cell types, including skeletal myoblasts and bone marrow and circulating stromal progenitor cells, have been investigated in clinical trials for cardiac repair and regeneration, and have demonstrated their ability to improve cardiac function, infarct size, and cardiac remodeling. Based on these exciting but tentative results, other stem cell types are being explored for their particular advantages as a source of adult stem cells. The results of the clinical trials of cell therapy for heart failure will be reviewed and the proposed mechanisms of benefit discussed. The design and promise of ongoing trials will be described.

069 ROLE OF BONE MARROW AND NEUROINFLAMMATION IN HYPERTENSION

MM Santisteban¹, N Ahmari², JM Carvajal¹, MB Zinger¹, Y Qi³, S Kim¹, J Joseph¹, F Garcia-Pereira², RD Johnson², V Shenoy⁴, MK Raizada¹, J Zubecvic²
¹Department of Physiology and Functional Genomics, College of Medicine; ²Department of Physiological Sciences, College of Veterinary Medicine; ³Division of Cardiovascular Medicine, Department of Medicine; ⁴Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Florida, USA

Microglial activation and dysfunctional autonomic nervous system (ANS) activity are associated with hypertension (HTN). Despite evidence that impaired sympathetic nerve activity supplying the bone marrow (BM) increases inflammatory cells and decreases angiogenic cells, little is known about the reciprocal impact of BM-derived inflammatory cells on neuroinflammation and HTN. The overall objective of this study was to investigate the hypothesis that the BM cells from hypertensive animals are proinflammatory, contribute to neuroinflammation and thus important in sustained HTN. Chimeric SHRs were generated by reconstitution with the BM from the WKY rats. The resultant chimeric SHR displayed significant reduction in mean arterial pressure (MAP; SHR-WKY 138±11 mmHg vs SHR-SHR 188±6 mmHg) associated with attenuation of both central and peripheral inflammation compared with SHR-SHR. In contrast, an elevated MAP (WKY-SHR 147±16 mmHg vs WKY-WKY 114±12 mmHg) along with increased central and peripheral inflammation was observed in chimeric WKY rats reconstituted with SHR BM. Microcyline, an inhibitor of microglia activation, attenuated HTN in both SHR and chronic angiotensin II (Ang II)-infused rats. This was accompanied by decreased sympathetic drive and peripheral inflammation. Furthermore, in chronic Ang II-infused rats, microcyline reduced the number of BM-derived cells in the PVN. Therefore, the BM contributes to HTN by increasing peripheral inflammatory cells and their extravasation into the brain. Microcyline effectively modified peripheral and neurogenic components of HTN. Taken together, these observations support the hypothesis that dysfunctional brain-BM activity is important in HTN, and targeting this axis may be an innovative strategy for neurogenic resistant HTN therapy.

070 ATRIAL FIBRILLATION DRIVEN BY MICRO-ANATOMIC INTRAMURAL RE-ENTRY REVEALED BY SIMULTANEOUS SUB-ENDOCARDIAL AND SUB-EPICARDIAL OPTICAL MAPPING IN EXPLANTED HUMAN HEARTS

Bj Hansen¹, J Zhao², TA Cespe³, BT Moore⁴, N Li⁵, IA Jayne⁶, A Kalyanasundaram⁷, P Lim⁸, A Bratasz⁹, KA Powell⁹, O Simonetti²,³,⁴, RSD Higgins³,⁵, A Klici³,⁵, PJ Mohler¹,³,⁴, PML Janssen¹,³,⁴, R Weiss¹,³, JG Hummel¹,³,⁴, VV Fedorov¹,³
¹Department of Physiology and Cell Biology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA; ²Auckland Bioengineering Institute, The University of Auckland, Auckland, New Zealand; ³Davis Heart and Lung Research Institute; ⁴Department of Internal Medicine; ⁵Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA

AIMS: The complex architecture of the human atria may create physical substrates for sustained reentry to drive atrial fibrillation (AF). The existence of sustained, anatomically-defined AF drivers in humans has been challenged partly due to the lack of simultaneous endocardial/epicardial (Endo/Epi) mapping coupled with high-resolution 3D structural imaging.

METHODS AND RESULTS: Coronary-perfused human right atria from explanted diseased hearts (n=8, 43-72 y.o.) were optically mapped simultaneously by three high-resolution CMOS cameras (two aligned Endo/Epi views (330µm² resolution) and one panoramic view). 3D Gadolinium-enhanced MRI (GE-MRI, 80µm³ resolution) revealed the atrial wall structure varied in thickness (1.0±0.7mm 6.8±2.4mm), transmural fiber angle differences, and interstitial fibrosis causing transmural activation delay from 23±11ms to 43±22ms at increased pacing rates. Dual-sided sub-Endo/sub-Epi optical mapping revealed that AF was driven by spatially and temporally stable intramural reentry with 107±50ms cycle length and transmural activation delay of up to 67±31ms. Intramural reentrant drivers were captured primarily by sub-Endo mapping, while sub-Epi mapping visualized reentry or "breakthrough" patterns. Reentrant drivers were anchored on 3D microanatomic tracks (15.4±2.7x6.0±2.3mm², 2.9±0.9mm depth) formed by atrial musculature characterized by increased transmural fiber angle differences and interstitial fibrosis. Subsequent targeted radiofrequency ablation of the tracks terminated 8/8 AF drivers leaving AF undinucilable.

CONCLUSIONS: Integrated 3D structural-functional mapping of the diseased human heart revealed that the complex atrial microstructure caused significant differences between Endo vs Epi activation during pacing and sustained AF driven by intramural reentry anchored to fibrosis-insulted atrial bundles. Radiofrequency ablation of microanatomic reentry tracks represents a promising treatment of AF.

071 TLR-4 DEPENDENT COLLAGEN LOSS IN HUMAN CAROTID PLAQUE SMOOTH MUSCLE CELLS

VRai¹, VH Rao², S Stoupas³, DK Agrawal¹,²
¹Center for Clinical and Translational Science; ²Department of Biomedical Sciences, Creighton University, Omaha, Nebraska, USA

Atherosclerosis is a multifactorial chronic inflammatory disease resulting in development of atheroma and plaque. Thromboembolism may result from rupture of thin fibrous cap and subsequent ischemic stroke. The precise mechanism of plaque rupture remains to be defined. Triggering receptor expressed on myeloid cells-1 (TREM-1) expressed on immune cells amplify inflammation. Toll-like receptors (TLRs) induced by stimulation of pattern recognition receptors are involved in the pathogenesis of various cardiovascular diseases. However the role of TLR-4 in the destabilization of carotid plaques in atherosclerosis remains unknown. The mRNA expression of TREM-1 and TLR-4 by qPCR were increased significantly in symptomatic (S) compared to asymptomatic (AS) patients with carotid stenosis in both tissue extracts and isolated vascular smooth muscle cells (VSMCs). The TLR-1 and TLR-4 immunofluorescence was greater in tissue sections of S compared to AS plaques which confirmed our results of qPCR. Increased MMP-1 and –9 and decreased collagen I and III mRNA transcripts were observed in VSMCs from S compared to AS patients with
RESULTS AND CONCLUSION: Compared with Control, TAD-treated animals had lower blood glucose level (198±30 vs 365±44 mg/dL, p<0.05). Reduced blood glucose level was also seen in HCQ and TAD+HCQ groups. Increased plasma insulin level was observed in both HCQ and TAD+HCQ groups with more synergistic increase following the combination treatment (HCQ 40±54 and TAD+HCQ 52±73 vs. Control 23±30 mU/L, p<0.05). Increased IGF-1 and decreased triglycerides levels were found only in TAD+HCQ group. Cardiac SIRT3 protein expression was upregulated in both HCQ and TAD+HCQ groups. These results suggest that TAD+HCQ treatment causes improvement in overall metabolic profile in Type 2 diabetic mice. Furthermore, increased Sirt3 expression may protect cardiac mitochondria through suppression of oxidative stress. The data suggest that TAD+HCQ could be a novel combination therapy for reducing cardiovascular risk factors in Type 2 diabetes.

Acknowledgment: This study is supported by National Institutes of Health (1RO1HL118808).
075 WHAT PREVENTIVE STRATEGIES CAN WE USE TO CURB THE ESCALATING MORTALITY AND MORBIDITY ASSOCIATED WITH CARDIOVASCULAR DISEASES?
HS Buttar
Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario
The burdens of premature mortality and morbidity due to non-communicable diseases such as cardiovascular diseases (CVDs), obesity, diabetes mellitus, cancers, musculoskeletal disorders, anemia, and depression are escalating worldwide. Though these diseases generally manifest in middle age and beyond, it is now recognised that roots of these diseases lie in childhood and adolescence. The conventional risk factors of CVD consist of hypertension, hyperlipidemia, atherosclerosis, and hyperglycemia. Lifestyle factors including tobacco use, lack of exercise, unhealthy dietary habits, and low socioeconomic status contribute heavily to the development of obesity, diabetes and CVD in children and adults. Sugar-loaded beverages and excessively salted foods are also potential risk factors. Diets rich in whole grains, fruits and vegetables, olive oil, fish, low-fat dairy products, and moderate wine consumption are recommended for improving cardiovascular health and quality of life. Ingestion of phytosterol-enriched foods, vitamins, minerals, and amino acids assist to improve overall health beyond basic nutritional functions. Emerging evidence suggests that dietary supplements containing flavonoids and antioxidants modulate gene and protein expression and thereby modify endogenous metabolic pathways and homeostasis, and consequently reduce the risk of CVD and chronic diseases multifactorial in origin. Given the scope and prevalence of CVDs, a cost effective population health strategy - 'prevention is better than cure' - would be the most appropriate model to adopt to deal with CVD-related mortality and morbidity.

076 LYCOSPHATIDIC ACID, GROWTH FACTORS, AND MATRICELLLULAR PROTEINS IN VASCULAR SMOOTH MUSCLE CELL MIGRATION
F Zhang, D Wu, F Hao, X Xu, M-Z Cui
University of Tennessee College of Veterinary Medicine, Knoxville, Tennessee, USA
Vascular smooth muscle cell (SMC) migration from the intima media to the intima is a key component of neointimal formation following vascular injury and atherosclerotic lesion formation. Lysophosphatidic acid (LPA), a potent bioactive lipid found in atherosclerotic lesions and produced by activated platelets, has been shown to markedly induce SMC migration. Platelet-derived growth factor (PDGF) is a major growth factor involved in SMC migration. We have recently identified matricellular protein Cyr61 (CCN1) to be a key extracellular mediator in LPA- and PDGF-induced SMC migration. LPA and PDGF induced temporal and spatial expression of Cyr61, which promptly accumulated in the cellular Golgi apparatus and then translocated to the extracellular matrix. Cyr61 antibody blockade and siRNA inhibition both diminished LPA- or PDGF-induced SMC migration, indicating a novel regulatory role of Cyr61. SMCs derived from LPA receptor 1 (LPA1) knockout mice lack the ability of Cyr61 induction and cell migration, supporting the concept that LPA1 is required for Cyr61 expression and migration. Our data show that the newly synthesized Cyr61 physically interacted with the SMC plasma membrane integrins a6b1 and a2b3. Further, we demonstrated that Cyr61 and integrins are integral and important components of the LPA and PDGF signaling pathways via an "outside-in" signaling route to activate intracellular focal adhesion kinase (FAK), leading to cell migration. Therefore, extracellular Cyr61 convergence with lipid/growth factor signaling and integrin/FAK signaling is a new concept of lipid/growth factor-induced SMC migration. These data provide new insights into mechanisms underlying SMC migration-related disorders, including atherosclerosis and restenosis.

077 BENEFICIAL ROLE OF OMEGA-3 FATTY ACIDS IN CVD: WHY ARE THERE CONTROVERSIES IN CLINICAL TRIALS’ OUTCOME?
NA Shaikh
University of Toronto and Pivotal Therapeutics Inc, Toronto, Ontario
The role of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) for the prevention of cardiovascular disease (CVD) has been known for many decades. Although some clinical trials support the epidemiological lines of evidence that omega-3 PUFAs protect against coronary heart disease, all cause or cardiac mortality, many others have drawn no such conclusions. This presentation provides a prospective that could explain some of the inconsistencies in trial outcomes. This viewpoint is not meant to address all the differences or cover all studies that could contribute to the variability in the findings, but to point out some of the factors that could affect trial results and meta-analyses outcomes. Meta-analysis of the RCTs are more prone to be affected adversely by the inclusion of studies with heterogeneous patients with mixed end points than those conducted with homogeneous group. Other factors that could contribute to the variability of the outcome are the use of different omega-3 PUFAs formulations and doses, choice of placebo, lack of pre- and post omega-3 PUFAs measurements as well as differential uptake of omega-3 PUFAs in study subjects. Consideration of these factors may play an important role in subsequent trial designs for the consolidation of outcome measures and efficacy of omega-3 PUFAs in primary and secondary prevention of CVD.
function. Genetic deletion of Drf1 limited myocardial I/R injury and improved heart function. These effects were recapitulated in the hypoxia/reperfused H9C2 rat cardiomyocytes. Notably, we show that the reduction in injury can be attributed to improved calcium handling and actin-related transcriptional changes involving early growth response-1 and serum response factor. Our work demonstrates a novel formin driven mechanism mediating myocardial I/R injury and identifies new therapeutic target for acute myocardial infarction.

Session 3.11: Echocardiography and Other Novel Modalities

080
DIABETES INDUCED CARDIOMYOPATHY (DCM)

GE Nagib El-kilany
Consultant of Cardiology, United Arab Emirates

Diabetic cardiomyopathy is a distinctly primary disease process, independent of coronary artery disease, which leads to heart failure in diabetic patients. The link between heart failure (HF) and diabetes is well documented, but the existence of diabetic cardiomyopathy as a distinct clinical entity continues to be the subject of debate. Rubler et al. coined the term "diabetic cardiomyopathy" after performing post mortem studies in diabetic patients with cardiac failure having excluded alcohol, hypertension, coronary and structural heart disease as possible etiologies. In diabetes induced cardiomyopathy, identification of high-risk patients in the presymptomatic phase and those prone to sudden cardiac death has become the "holy grail" for physicians and efforts have evolved for risk profiling of such patients population. Currently detailed novel echocardiographic examination and measurements of NT-pro BNP levels provide sensitive methods that identify the early signs of myocardial dysfunction among diabetic patients. Emerging novel diagnostic techniques such as tissue Doppler imaging (TDI) and deformation imaging - to identify patients earlier, together with the development of more targeted therapeutic strategies, may lead to improved outcome in patients with DCM.

081
COMPUTED TOMOGRAPHY CORONARY ANGIOGRAPHY: DIAGNOSTIC AND PROGNOSTIC VALUE

FB Sozzi
Cardiology Unit, Policlinico Hospital, Milan, Italy

Coronary computed tomography (CCT) is increasingly being used as a tool for non-invasive visualization of the coronary arteries. The technique provides information about atherosclerotic plaque burden and plaque composition. The diagnostic and prognostic value of CCT is high. Its accuracy needs to be assessed in management outcome studies, in which diagnostic and therapeutic strategies are decided based on CCT alone, without reference to coronary angiography results. A main point is that plaque composition represents a long-term predictor of cardiac events. In a follow-up study on the predictive value of CCT, Sozzi et al. (1) demonstrated that non-calcified and mixed plaques carried a worse prognosis compared to calcified plaques. Referring to plaque vulnerability concept, Mann et al. (2) found that lipid core size and minimal cup thickness, two major determinants of plaques vulnerability, were not related to the absolute plaque size or degree of stenosis, in patients who died suddenly of coronary artery disease. Accordingly, atherosclerotic plaque growth and destabilization are highly variable. Many angiographic studies have demonstrated that most of the acute myocardial infarction are characterized by the occlusion of coronary arteries without previous significant stenosis. Thus, plaque progression and clinical outcome are not always closely related. Both factors are not easily predictable on exclusively clinical and angiographic grounds.

REFERENCES:

082
THE ROLE OF ECHOCARDIOGRAPHY IN DIAGNOSING EARLY CHANGES FOLLOWING CHEMOTHERAPY IN BREAST CANCER DISEASES

K Hristova
University National Heart Hospital, Sofia, Bulgaria

The literature exploring the utility of advanced echocardiographic techniques (such as deformation imaging) in the diagnosis and prognostication of patients receiving potentially cardiotoxic cancer therapy has involved relatively small trials in the research setting. In this systematic review of the current literature, we describe echocardiographic myocardial deformation parameters in 2500 patients during or after cancer chemotherapy for 3 clinically-relevant scenarios. All studies of early myocardial changes with chemotherapy demonstrate that alterations of myocardial deformation precede significant change in left ventricular ejection fraction (LVEF). Using tissue Doppler-based strain imaging, peak systolic longitudinal strain rate has most consistently detected early myocardial changes during therapy, whereas with speckle tracking echocardiography (STE), peak systolic global longitudinal strain (GLS) appears to be the best measure. A 10% to 15% early reduction in GLS by STE during therapy appears to be the most useful parameter for the prediction of cardiotoxicity, defined as a drop in LVEF or heart failure. In late survivors of cancer, measures of global radial and circumferential strain are consistently abnormal, even in the context of normal LVEF, but their clinical value in predicting subsequent ventricular dysfunction or heart failure has not been explored. Thus, this systematic review confirms the value of echocardiographic myocardial deformation parameters for the early detection of myocardial changes and prediction of cardiotoxicity in patients receiving cancer therapy.

083
NON-INVASIVE IMAGING FOR THE ASSESSMENT OF RIGHT VENTRICULAR STRUCTURE AND PERFORMANCE

S Kutty
Department of Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

The right ventricle plays an important role in various forms of heart disease. The assessment of right ventricular structure and function is an often-encountered clinical challenge due to the chamber's complex geometry. Right ventricular assessment has assumed a lot of focus recently because it is an independent prognostic indicator of morbidity and mortality in heart failure and pulmonary hypertension. Echocardiography is the primary modality used for right heart imaging, and cardiovascular magnetic resonance is the current reference standard. Non-invasive imaging has shed light on the right ventricle's adaptation to pressure and volume overload states. The goal of this presentation is to review non-invasive imaging in the assessment of the right heart, focusing on newer two and three-dimensional echocardiography techniques, cardiovascular magnetic resonance, and deformation imaging. Improvements in non-invasive imaging will lead to a better understanding of the pathophysiology of right heart failure, and enhanced ability to follow responses to treatment.
Abstracts

Session 3.12: Jawahar Mehta Young Faculty Orations

084
A NEW METHOD FOR MEASURING THE FUNCTIONAL CARDIOMYOCYTES CONTRACTILITY AND DRUGS EVALUATION
I Rajasingh1, R Rajasingh1, A Czirók2, S Samanta1, DG Isai2, E Kosa2, B Dawn1
1Cardiovascular Research Institute, Division of Cardiovascular Diseases, Department of Internal Medicine; 2Department of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, Kansas, USA
INTRODUCTION: Current methods of assessing the functional property of cardiomyocytes (CMCs), such as patch clamping or dye-based confocal calcium imaging, are labor-intensive, invasive, which can affect the cells' contractility. No optimal method is currently available to assess functional CMCs.

HYPOTHESIS: We hypothesized that a novel particle image velocimetry (PIV) method would provide accurate assessment of CMC contractility, maturity and drug effects.

METHODS: Recently, we have reported an efficient animal-free and viral-free method of generating iPSC from human somatic cells. These iPSCs were further differentiated into functional CMCs with defined culture conditions.

RESULTS: To analyze the contractility of iPSC-derived CMCs (iCMCs), we recorded the same areas of culture plate at different time-points using high frame-rate video microscopy. Our novel image analysis technique provided beat patterns time-series data of cell displacement, measured relative to a resting reference state. As beat patterns of recordings in video microscopic images revealed, the contractility of early CMC nodes was asynchronous in space and irregular in time. During subsequent days after the onset of beating, however, the spatially distinct contractile centers became synchronous and gradual increase in beating frequency. Our PIV method in agreement with calcium imaging showed that the CMCs treated with verapamil or isoproterenol changes both the amplitude and beating frequency.

CONCLUSIONS: This PIV image analysis is a novel method that enables assessment of contractility multiplicity times, if necessary, without jeopardizing the biology of cells. This method may also prove beneficial for drug screening and detection of cardiotoxicity in iPSC-derived CMCs.

085
EFFEROCYTOSIS HEALS THE HEART: NEW INFLAMMATORY TARGETS FOR MYOCARDIAL REPAIR
E Thorp
Department of Pathology and Feinberg Cardiovascular Research Institute, Northwestern University Medical School, Chicago, Illinois, USA
Heart failure after myocardial inflammation or myocardial infarction (MI) is a significant cause of morbidity and mortality. Though pharmacological advances have significantly reduced mortality, the residual risk of post MI-induced heart failure is increasing. This necessitates development of new approaches to preserve heart function. Post infarction, we have discovered that efficient phagocytic removal of dying cardiomyocytes by efferocytosis is critical to initiating resolution inflammation and cardiac repair. Myocardial efferocytosis is in part driven by the apoptotic cell receptor and tyrosine kinase MERTK. Our findings in humans suggest MERTK is inactivated during MI by proteolysis, implicating natural inefficiencies in cardiac repair. Collaborative efforts to reconstitutally inhibit the susceptibility of MERTK to proteolytic inactivation in vivo reveal enhanced cardiac repair in preliminary data. Current studies also show that suppression of anti-phagocytic ligands on the surface of cardiomyocytes, such as CD47, enhance engulfment by phagocytes. These data implicate cross talk between macrophages and cardiomyocytes as a potential therapeutic target for cardiac healing. Several ongoing lines of investigation include (I) the degree to which MERTK-dependent efferocytosis and proteolysis drives the extent of post MI repair in the setting of risk factors such as hyperlipidemia and clinically-relevant reperfusion, (II) MERTK-dependent and independent mechanisms of efferocytosis and inflammation resolution during hypoxia, and (III) novel cardiomyocyte interactions with macrophages.

086
REGULATION OF CARDIAC GENE EXPRESSION BY MED1
K Spiteri, DD Hall, CE Grutter
University of Iowa, Iowa City, Iowa, USA
Despite significant advances in cardiovascular research, the complex regulatory mechanisms that control cardiac gene expression in response to developmental and environmental stimuli are not well defined. Thus, there is a major need for new insights into the mechanisms that govern transcriptional regulation of developmental processes in the heart as a prelude to the design of therapeutic strategies to normalize cardiac function during disease. Common developmental pathologies in the heart leading to decreased cardiac function include mitochondrial dysfunction and disrupted cardiac energetics. Med1, a key component of the Mediator complex, functions as a transcriptional cofactor involved in regulating mitochondrial gene expression and metabolism. Multiple studies have demonstrated that systemic deletion of Med1 is embryonic lethal due to cardiac defects. However, the mechanism by which Med1 functions to regulate cardiac development and disease has not been examined. To test the hypothesis that Med1 governs a gene network that is critical for the heart to respond to developmental and pathological signaling events, we generated a mouse model with a cardiac specific knockout of Med1 (cMed1KO). Postnatal deletion of Med1 in cardiomyocytes is lethal by 3-6 weeks of age due to heart failure. We performed RNA-seq analysis and identified multiple key pathways were augmented including down regulation of metabolic and cation transport pathways and up regulation of developmental and cell cycle processes. Further studies are underway to identify the molecular targets of Med1 that are necessary for normal cardiac response to developmental and environmental signals regulating transcriptional remodeling in the heart.

ACKNOWLEDGEMENT: The authors acknowledge JK Reddy for the MEDI ββ/β mouse.

087
VITAMIN D REGULATES GLUCOSE METABOLISM THROUGH TARGETING FOXO1 GENE IN SKELETAL MUSCLE
S Chen, DK Agrawal
Center for Clinical & Translational Science and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska, USA
Skeletal muscle insulin resistance has been shown to be a primary defect in the majority of patients with type 2 diabetes mellitus (DM2) and overexpression of forkhead box O1 (FOXO1), a key insulin signaling negative regulator, plays a critical role in skeletal muscle insulin resistance. Recent prospective studies have consistently shown that vitamin D deficiency is closely associated with the incidence of DM2. However, the mechanism underlying vitamin D signaling induced skeletal muscle insulin resistance and the progression of DM2 remains unknown. We generated skeletal muscle-specific VDR-null (SMVDR-/-) mice that were confirmed by almost complete deletion of VDR in genomic DNA, mRNA, and protein levels in skeletal muscle. We discovered that these mice developed insulin resistance and glucose intolerance accompanied by increased muscle FOXO1 expression, nuclear translocation, and its target gene expression. Importantly, we also found persistent FOXO1 activation in skeletal muscle of global VDR-null mice. Treatment of C2C12 muscle cells with 1,25-dihydroxyvitamin D increased VDR levels and reduced FOXO1 expression and nuclear translocation, indicating that activated VDR signaling negatively regulates FOXO1 activity. The results suggest that persistent FOXO1 activation-induced insulin resistance in skeletal muscle may be responsible for impaired glucose metabolism in SMVDR-/- mice and provide evidence for the utility of vitamin D supplementation for intervention of DM2.
Combined Poster Session & Competition

090
IMPLICATION OF THE SODIUM-HYDROGEN EXCHANGER TYPE 1 NHE1 IN THE DEVELOPMENT OF HYPOTENSION IN HEREDITARY CARDIOMYOPATHY
A K Johny, J Danielle, B Ghassan
Department of Anatomy and Cell Biology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec
Cardiomyopathy in general is defined as a disease of the heart muscle. The purpose of this study is to test the hypothesis that hereditary cardiomyopathy (HCM) is also a vascular disease to which NHE1 may contribute. Our results show a decrease in mean arterial pressure during the development of HCM. The change in blood pressure was accompanied by an increase in NHE-1 density as well as in cytosolic and nuclear sodium levels. The cytosolic and nuclear Na+ overloads were modulated by ET-1 and were surprisingly upregulated only in VSMCs from HCMs. Treatment with the NHE1 inhibitor EMD87580 partially prevented the decrease in blood pressure and early death. To conclude, our results suggest that the vascular abnormality taking place during the development of HCM is at the level of both VECs and VSMCs. In addition, the changes in NHE-1 sensitivity to ET-1 in VSMCs could be compensatory mechanisms to overcome a vascular failure. Supported by a CIHR grant.

091
ENDOTHELIAL CELL DIFFERENTIATION OF PORCINE ADIPOSE-DERIVED MESENCHYAL STEM CELLS IS REGULATED BY THE EXPRESSION OF MMP2 AND MMP14
SG Almalki2, Y Lamass1,2, DK Agrawal1,2,3
1Department of Biomedical Sciences; 2Department of Medical Microbiology and Immunology; 3Department of Clinical and Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA
RATIONAL: Adipose-derived mesenchymal stem cells (AMSCs) represent promising tools in various clinical applications. The molecular mechanisms that control the ability of AMSCs to remodel extracellular matrix (ECM) barriers during differentiation are not clearly understood. In this study, we investigated the expression of matrix metalloproteinases (MMPs) during the differentiation of AMSCs to endothelial cells (ECs). Methods: AMSCs were characterized by positive staining for MSC markers, CD44, CD90, CD105, and negative staining for CD14, and CD45. The plasticity of MSC was detected by multi-lineage differentiation. The mRNA transcripts for different MMPs and TIMPs were analyzed by RT-PCR. The enzyme activity and protein expression were also analyzed by gelatin zymography, ELISA, and Western blot.
RESULTS: The differentiation of AMSCs to ECs was confirmed by the mRNA expression of EC markers. The mRNA transcripts of MMP2 and MMP14 were significantly increased during the differentiation. Western blot and ELISA showed an elevated MMP14 and MMP-2 expression. The enzyme activity of MMP2 was also observed. MMP2 and MMP14 silencing showed significant increase in the expression of EC markers, formation of tubes, and acetylated-LDL uptake. Conclusion: We demonstrated that porcine AMSCs have the ability to differentiate into ECs. The data presented herein, for the first time, demonstrate that the up-regulation of MMP2 and MMP14 has an inhibitory effect on the differentiation of AMSCs to ECs, and silencing them increases the differentiation of AMSCs to ECs. These results could provide novel insights aimed at therapeutic strategies for re-endothelialization of coronary arteries or regulation of angiogenesis.

092
CARNOSINE LOADING IN CARDIAC TISSUE ATTENUATES MYOCARDIAL ISCHEMIA REPERFUSION INJURY
SP Baha, D Zhang, D Hoetker, Y Guo, D Conklin, A Bhatnagar
Department of Medicine, University of Louisville, Louisville, Kentucky, USA
Myocardial ischemia/reperfusion (I/R) remains the leading cause of death, however there is still no effective therapy to prevent I/R injury. I/R injury increases the generation of reactive aldehydes that are metabolized by enzymes such as aldose reductase, aldehyde dehydrogenase and also seques-tered by endogenous dipeptide carnosine. Although the role of these detoxifying enzymes is known however the role of carnosine in I/R injury has not been elucidated. Carnosine is a histidyl dipeptide of b-alanine and histidine that is synthesized by the enzyme carnosine synthase (ATPGD1). Carnosine has the abilities to buffer intracellular pH, bind metals and form conjugates with reactive aldehydes. Our previous studies had shown that carnosine protects isolated mice hearts from I/R injury. To completely understand the role of carnosine in cardio-protection we generated cardio-specific ATPGD1 transgenic (TG) mice. Levels of carnosine and anserine were increased 100 fold in the cardiac tissue. Echocardiographic analysis showed that the ATPGD1 overexpression did not affect cardiac function. When subjected to 30 mins of ischemia and 24h of reperfusion the infarct size of ATPGD1TG was significantly decreased compared to the WT mice heart. To establish the clinical role of this dipeptide mice were fed with carnosine (10µg/ml) for 7 day and subjected to 30mins of ischemia and 24h of reperfusion. The infarct size was significantly decreased in carnosine treated compared to the non-treated mice. These finding indicate the cardioprotective role of carnosine and suggest that this dipeptide can be used as a potential therapy for attenuating myocardial I/R injury.

093
TNF-α ENHANCES IGF-1 INDUCED DNMT3A EXPRESSION IN HUMAN CORONARY ARTERY SMOOTH MUSCLE CELLS
CS Boosani, DK Agrawal
Center for Clinical & Translational Science and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska, USA
INTRODUCTION: We previously reported increased expression and activity of TNF-α and IGF-1 with significant reduction in SOCS3 expression in atherosclerotic and restenotic lesions in coronary arteries. Also, we found that TNF-α and IGF-1 treatment epigenetically restores DNMT1 expression and inhibits SOCS3 in human coronary artery smooth muscle cells (hCASMcs). In this study, we report a novel role of IGF-1 to independently induce the expression of DNMT3a, and when treated in combination with TNF-α, it can enhance the expression of DNMT3a.
RESULTS: In hCASMcs, IGF-1 treatment alone induced the expression of DNMT3a. However, when treated with both TNF-α and IGF-1 together, DNMT3a expression was significantly up-regulated with concomitant decrease in SOCS3. The increase in DNMT3a expression was independent of DNMT1 expression, although the expression of both DNMT1 and DNMT3a was induced by the combined treatment of hCASMcs with TNF-α and IGF-1.
CONCLUSION: Since intimal hyperplasia following balloon angioplasty or intravascular stenting is enhanced in the presence of both IGF-1 and TNF-α, and increase in SOCS3 would be beneficial in controlling intimal hyperplasia. The present findings suggest a novel mechanism underlying pro-hyperplasia effects of IGF-1, and identifies DNMT3a as a novel target to develop better therapeutic approaches to prevent intimal hyperplasia and restenosis following coronary intervention.
Abstracts

094
PLASMA OXYLIPINS INCREASE THE ODDS OF HIGH CENTRAL AORTIC BLOOD PRESSURE, CEREBROVASCULAR ACCIDENTS, AND MYOCARDIAL INFARCTIONS AND ARE BENEFICIALLY INFLUENCED BY DIETARY FLAXSEED
S Caligiuri1,2,3, H Aukema4, D Rodriguez-Leyva1,2, A Ravandi5,6,7, R Guzman5, G Pierce1,2,3
1CCARM; 2IC5, St Boniface Hospital Research Centre; 3The Departments of Physiology; 4Human Nutritional Sciences; 5Internal Medicine; 6Surgery, University of Manitoba, Winnipeg, Manitoba
INTRODUCTION: Uncontrolled hypertension leads to cardiac and cerebrovascular events. A novel therapeutic target may be a class of highly bioactive molecules called oxylipins. Dietary flaxseed may modulate oxylipins by altering the oxylipin substrate profile.
METHODS: The FlaxPAD trial assessed the impact of dietary flaxseed on central blood pressure (BP)(n=81), the relationship between central BP and plasma oxylipins, and the relationship of oxylipins to cardiac and cerebrovascular events. Oxylipins at baseline and on flaxseed were measured at baseline and 6 months with pulse wave analysis, HPLC-MS/MS, and patient file assessment, respectively.
RESULTS: Central BP was lower in the flaxseed group by (systolic/diastolic) 8 mmHg/4 mmHg versus placebo at 6 months (p<0.05). Significant associations were observed between 17 of the 43 detected oxylipins and central BP. Flaxseed induced a significant decrease in 7 pro-inflammatory/vasoconstrictive oxylipins. The prevalence of transient ischemic attacks, angina, and myocardial infarctions was 16%, 10%, 16%, & 24%, respectively. Eight plasma oxylipins influenced the odds of these events. 16-hydroxyeicosatetraenoic acid increased the odds of high central BP, angina, and cerebrovascular accidents (p<0.05).
CONCLUSION: Oxylipins may be a novel target or diagnostic/risk marker for central BP, cerebrovascular/cardiovascular events. Flaxseed decreased the concentration of vasoconstrictive plasma oxylipins.
SUPPORTED BY: CIHR, Heart & Stroke Foundation, Flax 2015, ARDI, Western Grains Research Foundation & SBH Foundation

095
ANGIOTENSIN II RECEPTOR DISTRIBUTION, INTERNALIZATION AND MODULATION OF INTRACELLULAR CALCIUM: DIFFERENCES BETWEEN HUMAN RIGHT AND LEFT VENTRICULAR ENDOTHELIAL CELLS
M Chamoun, N Abdel-Karim Abdel-Malak, C Provost, Y Simon, C Bkaily, D Jacques
Department of Anatomy and Cell Biology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec
We previously reported that Ang II and AT1R and AT2R are present but differently distributed in right ventricular endocardial endothelial cells (EECRLs) and that AT1R mediates the effects of Ang II on intracellular Ca2+ ([Ca2+]i). In the present study, we determined if similar to EECRLs, left ventricular endocardial endothelial cells (EECLs) possess Ang II and its receptors and if they have the same distribution and regulation of [Ca2+]i. We also studied the internalization of AT1R and AT2R by Ang II in both cell types. Our results demonstrated that Ang II and its receptors are also present in EECRLs with a similar distribution as compared to EECRLs. However, their densities are higher in EECLs versus EECRLs. Our results also showed that Ang II induced a concentration-dependant increased in [Ca2+]i that is mediated by the AT1R and AT2R. Finally, pretreatment of EECRLs and EECLs with Ang II induced de novo synthesis of AT1R in EECRLs and degradation in EECLs whereas it induced de novo synthesis of AT2R in both cell types. In conclusion, the present study is the first to show that differences exist between EECRLs and EECLs regarding the Ang II system. FUNDING: Supported by the HSPC.

096
HOMOCYSTEINE INCREASES MACROPHAGE-DERIVED PARAOXONASE EXPRESSION INDEPENDENT OF CD68
I Chernyavskyi1, I Winchester1, S Veeranki1, SC Tyagi1
1University of Louisville School of Medicine Department of Physiology and Biophysics, Louisville, Kentucky, USA
BACKGROUND: Although atherosclerotic plaque rupture is the leading cause of myocardial infarction, the mechanisms are unclear. Macrophages burdened with oxidized LDL (oxLDL) become foam cells and are hallmarks of plaque instability. One of the main macrophage-specific receptors for oxLDL is CD68. Paraoxonase (PON) is a family of high-density lipoprotein (HDL)-associated lactonases capable of retarding/inhibiting LDL oxidation. Homocysteine (Hcy), an amino acid homologue and independent cardiovascular risk factor, is metabolized by PON.
HYPOTHESIS: Given the connections between oxLDL, PON, Hcy, and macrophages to atherosclerosis, we hypothesized that PON expression is increased by Hcy via CD68.
METHODS: Murine J774.1 macrophages were treated with LDL, oxLDL, Hcy, or oxLDL+Hcy. Also, separate treatment groups included macrophages that had CD68 silence. Cell lysates were analyzed via Western blotting.
RESULTS: PON1 is present in macrophages. Hcy along with oxLDL significantly increases PON (51%, 1.51 vs 0.97) expression compared to controls than oxLDL alone. PON expression is significantly decreased (33%, 0.67 vs 1) with silencing of CD68. PON expression is significantly decreased more with oxLDL+Hcy (24% 1.24 vs 1). CD68 expression tends to increase more with oxLDL+Hcy than oxLDL alone when compared to control and the tendency follows with silencing of CD68. Our results conclude that Hcy increases macrophage-derived PON expression independent of CD68.

097
EFFECTS OF ACUTE AND CHRONIC HYPERGLYCEMIA ON LUNG CAPILLARY PERMEABILITY
L Clemmer, L Xiang, S Lu, P Mittwedle, R Hester
Department of Physiology, University of Mississippi Medical Center, Jackson, Mississippi, USA
Hyperglycemia is correlated with increased vascular oxidative stress and endothelial dysfunction including increased vascular permeability. The role of chronic hyperglycemia in affecting lung permeability is unclear in a type 2 diabetes setting. Lung capillary coefficient (Kf) was measured in the isolated lung of lean Zucker (LZ) and obese Zucker rats (OZ). We hypothesized obesity increases lung permeability through chronic hyperglycemia. OZ had impaired glucose and insulin tolerance which was associated with elevated lung Kf (19.4±3 ml/mmHg/min) as compared to LZ.
(11.4±2 ml/mmHg/g/min). In a separate experiment, OZ were subject to 4 weeks of Metformin treatment (300 mg/kg/day orally) to improve insulin resistance and glycemic control. Metformin treatment significantly improved oral glucose tolerance, insulin sensitivity, and vascular oxidative stress and this was associated with improved baseline lung Kf (15.2±1 ml/min/mmHg/g/min) as compared to OZ control animals. To examine the role of acute hyperglycemia in lung permeability regulation, lungs from LZ and OZ were subject to acute hyperglycemia (550 mg/dL). Thirty minutes of hyperglycemia increased lung Kf in LZ but not in OZ. Acute apocynin treatment (3mM) added in the isolated lung perfusion solution significantly ameliorated the increased Kf in the acute hyperglycemic-treated LZ. These data suggests that the chronic hyperglycemia in obesity can exacerbate lung Kf and that acute hyperglycemia can acutely increase leakage control through increases in oxidant stress. This warrants further investigation into using antioxidants in the treatment of diabetic and acute hyperglycemic-induced lung permeability.

Supported by AHA-14PRE2038069, AHA-12SDG1205025, AHA-12POST1206126, NIH P20GM104357, HL-51971, HL-89581 and T32 HL-105324.

098

EFFECT OF COLCHICINE ON RAT CARDIAC FUNCTION AFTER ACUTE MYOCARDIAL INFARCTION

El Couture, B Tricot, MP Ricapito, L Tremblay, A Carpentier, M Nguyen, M Auger-Messier, P Farand
Department of Medicine, Université de Sherbrooke, Sherbrooke, Quebec

INTRODUCTION: Use of non-steroidal anti-inflammatory drugs after acute myocardial infarction (AMI) deteriorates cardiac function. Colchicine inhibits mitosis and neutrophil activity. Colchicine is indicated in post-AMI pericarditis but its safety in regards to cardiac function is unknown.

METHODS: Under general anesthesia, AMI was induced in 27 rats by permanent ligation of the left anterior descending coronary artery. Then, rats were randomly assigned to placebo (N=15) or colchicine 30 µg/kg daily by intra-peritoneal injection (N=12). At day 7, cardiovascular magnetic resonance imaging with 7T scanner was performed in 20 randomly assigned rats. Left ventricular ejection fraction (LVEF), end-systolic volume (EDV), and end-diastolic volume (ESV) were measured. At day 8, all hearts were harvested for protein analysis with TTC staining for evaluation of scar extent.

RESULTS: Death before day 7 occurred in 2 rats in colchicine group and 4 in placebo group. No statistically significant differences between colchicine and placebo were observed: EDV (631 vs 574 uL, p=0.26), ESV (252 vs 176 uL, p=0.20) and LVEF (60% vs 69%, p=0.16). Scar amount as measured by LGE showed good qualitative correlation with pathologic assessment.

CONCLUSIONS: In this model, colchicine does not deteriorate cardiac function after AMI. A trend toward negative left ventricular remodeling was observed. These results warrant more studies to evaluate colchicine safety after AMI.

099

ELASTIN-DERIVED PEPTIDES INFLUENCE MACROPHAGE PHENOTYPES IN ABDOMINAL AORTIC ANEURYSM

M Dale, W Xiong, JS Carson, MK Ruhlman, BT Baxter
Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska, USA

OBJECTIVE: Abdominal aortic aneurysm (AAA) is a disease characterized by inflammatory cell infiltration and extracellular matrix (ECM) degradation. Damage to the ECM results in release of elastin-derived peptides (EDPs). EDPs recruit inflammatory cells and promote the differentiation of macrophages to pro-inflammatory M1 phenotype. BA4, a monoclonal antibody that specifically recognizes six peptide sequences in EDPs, blocks the EDP-mediated effect on macrophages. Our hypothesis is that introducing anti-inflammatory M2 macrophages or blocking the EDP-mediated M1 differentiation of macrophages in AAA will prevent aneurysm formation.

METHODS: Bone marrow-derived macrophages (BMMs) were isolated and treated with various doses of EDPs and their gene expression profiles were analyzed by qPCR. Additionally, BMMs were treated with IFN-γ to induce a pro-inflammatory M1 phenotype or IL-4 to induce an anti-inflammatory M2 phenotype. M1 or M2 BMMs were administered into mice, which then underwent aneurysm induction via the calcium chloride (CaCl2) induced murine model. A third group of mice was given weekly intraperitoneal injections of BA4 (10 mg/kg). Aortic tissue was then removed and subjected to Western blot, gelatin zymography, and histological analysis six weeks after aneurysm induction.

RESULTS: EDP treatment induced a response similar to IFN-γ induced M1 activation via expression of M1 associated markers such as TNF-α and IL-1β. Additionally, administration of M1 polarized BMMs to CaCl2-treated mice significantly increased aortic dilation compared to administration of M2 polarized BMMs. BA4 treatment reduced aortic dilation similar to the administration of M2 polarized BMMs. BA4 treatment was also able to reduce ECM degradation and macrophage infiltration.

CONCLUSIONS: EDP’s cause a pro-inflammatory M1 polarization of BMMs. Reducing the M1 response in AAA by administration of M2 polarized BMMs or inhibition of EDP-mediated signaling may provide potential therapeutic targets for AAA.

100

6MWT SCORES CAN BE A VAILABLE TOOL IN PREDICTING VO2 MAX SCORES IN PATIENTS WITH HEART FAILURE

P Dekel1, BJ Pozez1, D Pathak2
1University of Nebraska Medical Center, Omaha; 2University of Nebraska at Lincoln, Lincoln, Nebraska

BACKGROUND: A cardio-pulmonary exercise (CPX) test is the gold standard in evaluating VO2 max scores. The test is expensive, requires specific equipment that may limit enrollment of subjects and does involve some risk to patients with cardiac problems.

PURPOSE: The purpose of this study was to evaluate the predictive validity of equations provided by Burr et al. (2011) and Ross et al. (2010) in predicting VO2 max scores from 6 min walk test (6MWT) scores in patients with heart failure (HF).

METHODS: HF patients (n=107) with NYHA class II-IV performed a VO2 max CPX test and the 6MWT. Correlation between the CPX VO2 max score and the calculated VO2 max scores using the two equations and the 6MWT was analyzed.

RESULTS: Participants were 62.5±11.5 years old with a mean of 16.5±3.5 m/minute VO2 max score from CPX testing and mean 6MWT distance of 420.7±90.8 meters. The Burr et al. (2011) predicted VO2 max was 22.9±8.7 and the Ross et al. (2010) predicted VO2 max was 14.6±2.1 m/minute. Pearson correlation between the actual VO2 max score from CPX testing and the equation provided by Burr et al. (2011) was .498 while the equation provided by Ross et al. (2010) was .752.

CONCLUSION: The equation provided by Ross et al. (2010) is simpler and has stronger correlation with the actual VO2 max score from CPX testing. The use of this equation to predict VO2 max score in patients with HF may be a viable alternative to a CPX VO2 max exercise test.

ACKNOWLEDGEMENT: Research reported in this study was supported by NHLBI of the National Institutes of Health under award number R01HL112979. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

101

CALCIOTRIOL INHIBITS THE DIFFERENTIATION OF ADIPOSE-DERIVED MESENCHYMAL STEM CELLS INTO ADIPOCYTES

KP Djissou, P Kokouvi, DK Agrawal
Center for Clinical & Translational Science and Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska, USA

BACKGROUND: The global obesity pandemic requires action to stem the tide of obesity-related disorders, including cardiovascular diseases and type-2 diabetes. The Third National Health and Nutrition Examination Survey revealed that much of the American population has low vitamin D levels and 33% are obese. Generation of new adipocytes from multi-potent...
mesenchymal stem cells (MSCs) plays a key role in the development of obesity. Most knowledge of adipocyte differentiation and adipogenesis comes from in vitro studies of fibroblast and pre-adipocytes. There has not yet been a carefully study to evaluate the effect of vitamin D on adipogenesis using adipose-derived MSCs and their role in obesity. Here, we investigated the mechanism by which adipocyte differentiation of MSCs is regulated by in vitro stimulation with calcitriol.

METHODS AND RESULTS: MSCs were isolated from porcine abdominal adipose tissue and characterized by positive staining for MSCs' markers, CD44, CD73, CD90; negative staining for CD34, and CD45; and tri-lineage differentiation into adipocytes, chondrocytes, and osteocytes. MSCs from porcine adipose tissue were stimulated with adipose differentiation medium (ADM). No toxicity was observed when MSCs were stimulated with calcitriol at concentrations 0.1-10nM. Cells were then analyzed for adipogenic markers and expression of vitamin D metabolizing enzymes, CYP24A1 and CYP27B1, and VDR by Western Blotting, real-time PCR and flow cytometry. Stimulation of the cells with ADM only significantly increased the expression of adiponectin, leptin, lipoprotein lipase, fatty acid synthetase, PPAR-γ, and C/EBPα. In the presence of calcitriol there was significant decrease in PPAR-γ, C/EBPα and adipogenic markers. The VDR and CYP27B1 expression peaked at 3h and CYP24A1 at 24h after stimulation with calcitriol.

CONCLUSION: MSCs possess the machinery for vitamin metabolism, and stimulation with calcitriol can inhibit the differentiation of adipose MSCs, thus helping to curb obesity.

102 ROLE OF BRANCHED-CHAIN AMINO ACID OXIDATION IN CARDIAC INSULIN RESISTANCE
N Fillmore1, L Zhang1, A Fukushima1, SC Wagg1, GD Lopaschuk1
1Cardiovascular Research Centre, Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta

In addition to skeletal muscle insulin resistance (IR), obesity is also associated with cardiac IR. Recent studies have proposed that elevated branched-chain amino acids (BCAA) may induce IR due to BCAA oxidation inhibition of fatty acid metabolism. However, in obesity-associated IR, cardiac fatty acid oxidation is actually elevated. In order to examine the role of BCAA oxidation in cardiac IR, mice were fed a high fat diet (HFD) for 10 weeks to induce IR and glycolysis. BCAA oxidation, glucose oxidation, and palmitate oxidation were measured in isolated working hearts. Perfusate contained 5 mM glucose, 0.8 mM palmitate, 0.15 mM leucine, 0.15 mM isoleucine, and 0.2 mM valine. HFD significantly reduced cardiac BCAA oxidation (30.8±3.9 vs 55.3±7.1 nmol/min/g dry wt) decreasing its already low relative contribution to TCA cycle CoA production from 1.3% to 0.9%. This decline in BCAA oxidation was accompanied by a rise in circulating BCAA. The expression of branched-chain α-keto acid dehydrogenase (BCKDH) was significantly reduced in HFD hearts, potentially contributing to this decline in BCAA oxidation. Together these results suggest that cardiac IR is not due to increased BCAA oxidation and inhibition of fatty acid oxidation. We hypothesized that reduced BCAA oxidation contributes to IR by leading to increased BCAA levels which stimulate mTOR, decreasing insulin signaling.

103 ROLE OF HYDROGEN SULFIDE IN THE REGULATION OF DNA METHYL TRANSFERASES IN CARDIOMYOCYTES
BT Hackfort, P Prathipati, PK Mishra
University of Nebraska Medical Center, Omaha, Nebraska, USA

DNA methyl transferases (DNMTs) induce cardiac hypertrophy and are upregulated in diabetic hearts. Hydrogen sulfide (H2S) mitigates hypertrophy and ameliorates diabetic heart failure. However, the role of H2S in the regulation of DNMTs in diabetic hearts is unclear. We hypothesized that H2S mitigates the high glucose-mediated induction of DNMT-1, DNMT-3a, and DNMT-3b in cardiomyocytes. To test this hypothesis, HL-1 cardiomyocytes were treated with a physiological dose of glucose (LG, 5 mM), high glucose (HG, 25 mM), HG+SiG1002 (hydrogen sulfide donor, 20 μM), or HG+DMSO (SiG1002 control) for 24 hours. Cells were collected for protein and RNA analysis. Our results showed high glucose treatment tended to induce DNMT-1 (1.21±0.12), DNMT-3a (1.19 ±0.11), and DNMT-3b (1.10±0.10) protein levels as fold change compared to LG (N=3), however it was not significant. SiG1002 had no effect on DNMT-1 (1.14±0.09) but tended to further increase DNMT-3a (1.28±0.04, P =0.03) and DNMT-3b (1.23±0.16) protein levels compared to LG treatment (N=3). Interestingly, qPCR analyses demonstrated downregulation of DNMT-1 (0.48±0.11, P=0.015, N=4) and DNMT-3b (0.27±0.07, P=0.003, N=5) mRNA in HG compared to LG, which was mitigated in HG+SiG (0.79±0.17 and 0.67±0.18, respectively, N=4). These results elicit a role of H2S in regulation of DNMTs in hyperglycemic cardiomyocytes. The increases in protein levels and decreases in the mRNA levels suggest increased protein stability and/or shorter mRNA half-life of DNMTs by H2S treatment. Further analyses with DNMT inhibitor treatment and using a diabetic animal model are required to conclude the specific role of SiG1002 on DNMTs in diabetic cardiomyocytes.

104 PRIMARY CARDIOVASCULAR PREVENTION: A KINESIOLOGY-BASED INTERVENTION IN THE WORKPLACE
NC Hamm1,2, A Edye-Mazowitz3, AN Stammers1,2, DS Kehler1,2, DE Kimber1,2, ME Norman1, AJ Johnson1, AE Ready1, DR Bouchard1, SM Strachan1, J McGavock1, TA Duhame1,2
1Health, Leisure & Human Performance Research Institute, Faculty of Kinesiology & Recreation Management, University of Manitoba; 2Institute of Cardiovascular Sciences, St Boniface Hospital Research Centre, Winnipeg, Manitoba

The majority of Canadians do not participate in enough physical activity to receive health benefits. Physical inactivity is a major contributor to cardiovascular and heart disease risks, whereas greater amounts of physical activity is known to reduce risk. There is a growing recognition that workplaces have the capacity to deliver health promotion initiatives that successfully reduce the prevalence of chronic disease risk factors among employees. This project will determine if the ENCOURAGE physical activity promotion model can be adapted to support workplace wellness programs. A 1-year, quasi-experimental intervention was developed, where participants met with a kinesiologist on at least four separate occasions to learn the skills needed to adopt and maintain a more physically active lifestyle. The primary outcome is a change in physical activity measured with accelerometers.

Baseline data shows participants are only engaging in 43.5±37.5 (Mean±SD) and 30.1±41.0 minutes per week of total and moderate to vigorous physical activity (MVPA). MVPASporadic for those who have completed their 2-month time point (n=8); however, there was a significant increase in Total Sporadic physical activity levels at 1574±509 minutes per week.

Results suggest a kinesiology based physical activity program in the workplace can increase TotalSporadic physical activity levels among employees, thus decreasing cardiovascular disease risk. Data collection is scheduled until July, 2016.

ACKNOWLEDGEMENTS: This project is funded by a Heart and Stroke Foundation Primary Prevention Challenge grant.

105 FEASIBILITY OF ARTIFICIAL CARBON DIOXIDE BALENEOTHERAPY IN HEMODIALYSIS PATIENTS WITH HEART FAILURE
H Hayashi1, Y Moriyama2, T Yamada2, H Kasuga2, D Kamo1, H Kawahara2
1Seijo University; 2Nagoya Kyoritsu Hospital, Nagoya, Japan

BACKGROUND: Artificial carbon dioxide balneotherapy (CDB) has been shown to have positive effects on the cardiovascular system via peripheral
vasodilatation, but its efficacy in the treatment of hemodialysis (HD) patients with heart failure and preserved ejection fraction (HFpEF) has not been clarified. Therefore, we assessed the feasibility of CDB in HD patients with HFpEF.

METHOD: Two hundred sixteen patients were screened to exclude those with an E/e’ of <8 and NYHA class III/IV. Seven eligible patients (mean age: 71±11 years) received CDB daily for 2 weeks. CDB efficacy was evaluated based on the peak oxygen uptake/heart rate ratio (VO2/HRR), minute ventilation versus carbon dioxide production (VE vs. VCO2) slope, brain natriuretic peptide (BNP) level, high-sensitivity cardiac troponin I (hs-cTnl) level, and ejection fraction.

RESULT: In 4 patients with an E/e’ of >13, the hs-cTnl level (0.62±0.02 to 0.45±0.02 mg/ml, p=0.03) and VE vs. VCO2 slope (34.8±1.87 to 30.93±2.09, p=0.05) decreased and the VO2/HRR improved (5.43±0.69 to 4.16±0.55 ml/kg/min), although this change was not statistically significant. The 3 patients with an E/e’ ≤13 showed no significant change in the evaluated parameters.

CONCLUSION: CDB could be feasible in HD patients with HFpEF, with an E/e’ >13.

106

PTEN INHIBITOR REDUCES CARDIAC REMODELING IN DOXORUBICIN-INDUCED CARDIOMYOPATHY

TA Johnson, DK Singla

Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, Orlando, Florida, USA

BACKGROUND: Doxorubicin (Doxo) is one of multiple anthracycline drugs used to effectively treat various forms of cancer. Unfortunately, Doxo treatment stimulates adverse cardiac remodeling and subsequent heart failure. We have previously demonstrated that transplanted embryonic stem (ES) cells and their conditioned medium (CM) modulate the PTEN pathway and reduce apoptosis, fibrosis and hypertrophy in a Doxo-Induced Cardiomyopathy (DICC) model. VOHHPic (VO), the most potent known inhibitor of PTEN, has shown to increase survival in a Doxo-induced cardiomyopathy model.

HYPOTHESIS: Intraperitoneal (IP) delivery of VO attenuates PTEN expression and protects the heart from doxorubicin-induced cardiac remodeling.

METHODS: Animals were divided into three groups; Group 1: Control (Saline), Group 2: Doxo (12 mg/kg, Cumulative dose) and Group 3: Doxo and VO (12 mg/kg and 100 µg/kg cumulative doses) via IP injection. One week post-DIC, mice were subjected to echocardiography to examine cardiac function, sacrificed and hearts were harvested for further analysis.

RESULTS: Immunohistochemistry staining revealed a significant (p<0.05) decrease in apoptotic cardiomyocytes in Doxo-VO treated hearts compared with Doxo. Furthermore, Hematoxylin and Eosin (H&E) and Masson’s Trichrome histological stains confirmed reduced hypertrophy, interstitial and vascular fibrosis in Doxo-VO treated subjects compared to Doxo group. Western Blotting confirmed the reduction in PTEN levels in Doxo-VO subjects compared to Doxo hearts. Heart function was significantly improved upon Doxo-VO treatment compared to Doxo group.

CONCLUSION: Our data suggest that VO treatment attenuates adverse cardiac remodeling and improves heart function in the DICC heart.

107

DOWNREGULATION OF THE UNFOLDED PROTEIN RESPONSE IN TAURINE DEFICIENT HEARTS

JC Ju1, W Takashi1, S Stephen1

1University of South Alabama, Department of Pharmacology, College of Medicine, Mobile, Alabama; 2Hyogo University of Health Sciences, School of Pharmacy, Kobe, Japan

The unfolded protein response is a cellular quality control process that regulates the proper function of proteins in the endoplasmic reticulum. Accumulation of unfolded and misfolded proteins in the endoplasmic reticulum leads to the activation of a process known as the unfolded protein response. An ER chaperone, GRP78, regulates the unfolded protein response by interacting with three transmembrane sensor proteins (PERK, IRE-1, ATF6), which upon initiation activate downstream pro-survival or pro-death pathways. In pathologies, such as aging and degenerative diseases, downregulation of the unfolded protein response is associated with oxidative modification of GRP78. However, the unfolded protein response in the taurine deficient heart, which is associated with development of a cardiomyopathy, remains to be clarified. Taurine is a sulfur-containing amino acid and has cytoprotective actions, including antioxidant activity. Indeed, taurine-deficient hearts are oxidatively stressed as shown by decreased aconitate activity, decreased glutathione redox ratio and increased levels of carbonylated proteins. Enhanced oxidative stress in taurine deficient hearts is associated with the downregulation of the unfolded protein response, as evidenced by reduced levels of GRP78 and suppressed activation of the PERK- and IRE-1-mediated pathways. However, these reductions were abolished when oxidative stress in taurine deficient hearts was prevented by mitoTEMPO, a mitochondrial-specific antioxidant. In conclusion, the present study demonstrates that taurine depletion induces oxidative stress, which interferes with protein folding and the unfolded protein response, events that likely contribute to the development of a cardiomyopathy.

Acknowledgements: This work was supported in part by American Heart Association funding.

108

PHOSPHORYLATION OF IRS-1 BY NOVEL PROTEIN KINASES INDUCES NAFLD THROUGH IR IN SWINE DEPENDENTLY OF THEIR VITAMIN D STATUS

T Kounou1, DK Agrawal

Center for Clinical & Translational Science, Creighton University School of Medicine, Omaha, Nebraska, USA

Non-alcoholic fatty liver disease (NAFLD) results in a spectrum of liver pathology ranging from benign steatosis to non-alcoholic steatohepatitis (NASH), and carries a significant potential to progress to liver cirrhosis and hepatocellular carcinoma. Diacetylglycerol (DAG) is a potent activator of novel protein kinases (nPKCs) that inhibit insulin receptor substrate-1 (IRS-1) to induce insulin resistance (IR), and IR dominates the pathogenesis of NAFLD. Here, we investigated the effect of high cholesterol high fructose (HCHF) diet with/without vitamin D deficiency on liver pathology and examined the role of nPKCs in the development of NAFLD. Yucatan microswine were fed HCHF diet either deficient or supplemented with vitamin D-deficient and vitamin D-supplemented diet. The liver histology was examined and correlated with the expression of nPKCs and effects on IRS-1 signaling.

RESULTS: There was significant accumulation of fat in the liver of vitamin D-deficient and HCHF-fed compared to vitamin D-sufficient and −supplemented swine. Steatosis was more severe in the form of microvesicular fat in the nucleus of the centrum. HCHF-fed developed more fibrosis (METAVIS score=2) than vitamin D-deficient (METAVIS score=0), while vitamin D-sufficiency and -supplementation protected the liver from fibrosis (METAVIS score=0). There was consistently high expression of PKC-δ in the liver of HCHF and vitamin D-deficient swine with a strong co-localization with phosphorylated IRS-1. Significant variability was observed in the expression of PKC-ε and PKC-θ in the liver.

CONCLUSION: These data suggest that swine fed HCHF and vitamin D-deficient diet are more susceptible to develop NAFLD, which can progress to NASH while vitamin D has a protective role. Insulin resistance through IRS-1 phosphorylation by PKC-δ might play a key role in inducing NAFLD.

109

RESUSCITATION OF A DEAD CARDIOMYOCYTE “MITOCHONDRIAL INTERVENTION AND CALPAINs”

GH Kunkel, P Chaturvedi, SC Tyagi

Department of Physiology and Biophysics, University of Louisville, Kentucky, USA

Regulation of mitochondrial dynamics is essential for cardiovascular disease (CVD) related issues like heart failure (HF). Up regulation of proteolytic activity such as calpains and matrix metallo-proteinases (MMPs) are found within the HF model. Although calpains have been known to

Abstracts
Abstracts

underline the degradative mechanisms leading to cell death, the molecular mechanisms are unclear. Additionally, the mitochondrial roles behind myocyte death need much to be determined. We propose that activation of calpains leads to PCP4 degradation, suggesting that PCP4 is a modulator of calmodulin kinase II and calmodulin. Mitochondrial Transcription factor A (TFAM) plays a major role in proteolytic activation contributing to myocyte death. Our preliminary data of live versus dead cardiomyocytes suggests involvement of calpain-1, MMP9, mitochondrial transcription factor A (TFAM) and ion protease. We found upregulated expression of calpain 1 in dead myocytes along with decreased PCP4. The upregulated levels of calmodulin kinase and subsequently calmodulin suggested that these events harbor more calcium into the myocyte and lead to myocyte death. The downregulated levels of TFAM in dead myocytes suggest increased ROS production. In view of the above observations we project that regulating the levels of TFAM in dead myocytes suggest increased ROS production and increased mitochondrial transcription.

METHODS AND RESULTS: MSCs were CD11b-CD34-CD44+CD73+CD90+ and showed characteristics of MSCs. MSCs were stimulated and differentiated into ECs with endothelial growth media (EGM+50ng/ml of VEGF) and EGM media containing 10nM of calcitriol (EGM+50ng/ml of VEGF+10nM calcitriol) for 10 days. Calcitriol enhanced EGM+VEGF-induced differentiation of MSCs into ECs, as revealed by 3-fold increase in mRNA and 4-fold increase in protein expression of EC markers. Angiogenesis assay and acetylated low density lipoprotein (LDL) uptake assay were used to assess endothelial functionality that showed significant increase in capillary tube sprouting, and increased LDL uptake by differentiated cells in response to EGM+VEGF+calcitriol. Findings from Wnt pathway array revealed a 3-fold decrease in β-catenin and 4-fold increase in KREMEN1 protein in the cells treated with EGM+VEGF+calcitriol. β-catenin silencing showed significant increase in the expression of EC markers, formation of capillary tubes, and LDL uptake.

CONCLUSION: The downregulation of β-catenin and upregulation of KREMEN1 significantly enhanced the differentiation of MSCs into endothelial cells. These results provide novel insight into therapeutic strategies for patients undergoing coronary intervention to limit thrombosis and intimal hyperplasia.

110 CHRONIC NICOTINE EXPOSURE EXACERBATES TRANSIENT FOCAL CEREBRAL ISCHEMIA-INDUCED BRAIN INJURY

C Li, H Sun, WG Mayhan
Center for Cardiovascular Diseases and Sciences, Louisiana State University Health-Shreveport

Tobacco smoking is a risk factor contributing to the development and progression of ischemic stroke. Among many chemicals in tobacco, nicotine may be the key contributor. We hypothesized that nicotine alters the balance between oxidant and antioxidant networks leading to an increase in brain injury following transient focal cerebral ischemia. Male Sprague-Dawley were treated with nicotine for 4 weeks via implanted subcutaneous osmotic minipump and subjected to a 2-hour middle cerebral artery occlusion (MCAO). Infant size and neurological deficits were evaluated at 24 hours of reperfusion. Expression of oxidant and antioxidant proteins was measured using Western blot analysis. Superoxide production was determined by lucigenin-enhanced chemiluminescence. We found that chronic nicotine exposure significantly increased infarct size and worsened neurological deficits. Interestingly, infarct size and neurological deficits were not further increased in 4 mg/kg/day nicotine group compared to 2 mg/kg/day nicotine group. In addition, chronic nicotine exposure didn’t alter protein expression of SOD-1 and NADPH oxidase, but significantly down-regulated SOD-2 in cerebral cortex and arteries. Furthermore, nicotine significantly elevated superoxide production of cerebral cortex under basal conditions. Cerebral ischemia/reperfusion produced an increase in superoxide production of cerebral cortex in control group. However, no further increase in superoxide production of cerebral cortex was found in nicotine group. Our findings suggested that nicotine induced excitation in brain damage following transient focal cerebral ischemia may be related to an increase in oxidative stress via down-regulation of SOD-2.

111 WNT/β-CATENIN PATHWAY PROMOTES THE DIFFERENTIATION OF ADIPOSE-DERIVED MESENCHYAL STEM CELLS STIMULATED WITH 1,25-DIHYDROXYVITAMIN D AND VEGF-CELLS TOWARD THE ENDOTHELIAL PHENOTYPE

Y Llamas1, S Almalki2, DK Agrawal1,2
1Center for Clinical and Translational Science, 2Department of Biomedical Sciences, Creighton University School of Medicine, Omaha, Nebraska, USA

BACKGROUND: Cell-based therapy using adipose-derived mesenchymal stem cells (AMSCs) is an attractive option for re-endothelialization post-acute coronary artery bypass procedures. Wnt/β-catenin pathway in AMSC may regulate AMSC-based re-endothelialization of injured arteries. The role of Wnt/β-catenin pathway in the differentiation of adipose-derived AMSCs into endothelial cells (ECs) is unknown. In this study, we investigated the effect of Wnt/β-catenin pathway on AMSC treated with vitamin D and VEGF in the differentiation of MSCs into ECs.

METHODS AND RESULTS: MSCs were CD11b-CD34-CD44+CD73+CD90+ and showed characteristics of MSCs. MSCs were stimulated and differentiated into ECs with endothelial growth media (EGM+50ng/ml of VEGF) and EGM media containing 10nM of calcitriol (EGM+50ng/ml of VEGF+10nM calcitriol) for 10 days. Calcitriol enhanced EGM+VEGF-induced differentiation of MSCs into ECs, as revealed by 3-fold increase in mRNA and 4-fold increase in protein expression of EC markers. Angiogenesis assay and acetylated low density lipoprotein (LDL) uptake assay were used to assess endothelial functionality that showed significant increase in capillary tube sprouting, and increased LDL uptake by differentiated cells in response to EGM+VEGF+calcitriol. Findings from Wnt pathway array revealed a 3-fold decrease in β-catenin and 4-fold increase in KREMEN1 protein in the cells treated with EGM+VEGF+calcitriol. β-catenin silencing showed significant increase in the expression of EC markers, formation of capillary tubes, and LDL uptake.

CONCLUSION: The downregulation of β-catenin and upregulation of KREMEN1 significantly enhanced the differentiation of MSCs into endothelial cells. These results provide novel insight into therapeutic strategies for patients undergoing coronary intervention to limit thrombosis and intimal hyperplasia.
113

MIRNA-33A AS A NOVEL THERAPEUTIC TARGET IN DILATED CARDIOMYOPATHY
A Mittal1, S Rana, R Sharma, S Arigei2, S Khanna2, N Mahapatra2, S Sarkar4, A Bahl, SK Goswami2, M Khullar2
1Department of Cardiology; 2Department of Experimental Medicine and Biotechnology; 3Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh; 4Department of Zoology, University of Calcutta; Department of Biotechnology, Indian Institute of Technology, Madras; 5School of Life Sciences, Jawaharlal Nehru University, New Delhi, India

OBJECTIVE: Dilated cardiomyopathy (DCM) accounts for approximately 1/3rd of total cases of heart failure (HF) and is a leading indication for cardiac transplantation. Myocardin (MYOCD), a potent transcriptional co-activator of smooth muscle (SM) and cardiac genes, is upregulated in failing myocardium in animal models and human end-stage heart failure (HF). microRNAs (miRNAs) are 20-22 nucleotide long non-coding RNAs found to regulate gene expression. However, the role of miRNAs regulating MYOCD expression in heart failure remains unknown. The goal of this study was to identify the miRNAs regulating the cardiac specific MYOCD and to study the molecular and functional consequences of cardiac specific modulation of MYOCD specific miRNA in an animal model of DCM.

APPROACH AND RESULTS: Our study design included identification and validation of miRNA targeting MYOCD using bioinformatics tools and to study its cardiac expression in idiopathic DCM (IDCM) endomyocardial biopsies, renal artery ligation rat model of DCM (RAL). We identified and validated miRNA-33a as a putative regulator of MYOCD expression in cardiomyocytes. Cardiac miRNA-33a expression was significantly decreased in IDCM and in RAL. We investigated if cardiac specific augmentation of miRNA-33a expression using a homing peptide conjugated siRNA could potentially modulate the cardiac remodelling and outcome in RAL. We observed that targeted modulation of miRNA-33a attenuated cardiac hypertrophy and fibrosis, decreased expression of hypertrophy and fibrotic genes and ameliorated the impaired diastolic dysfunction in RAL model of cardiomyopathy.

CONCLUSION/SIGNIFICANCE: This data provide the first evidence that miRNA-33a is involved in regulating cardiac MYOCD expression and cardiac specific augmentation of miRNA-33a offers a putative therapeutic target in DCM.

114

LOWER DIABETES PREVALENCE ABOVE 3,000 M OF ALTITUDE IN PERU CAN BE EXPLAINED BY WEALTH INDEX, AGE AND SEX DISTRIBUTION: ANALYSIS OF THE PERUVIAN DEMOGRAPHIC AND HEALTH SURVEY
LM Morí-Hontop1, SN Selcén-Santisteban1, ME Rosas1, AJ Arias2
1Universidad Peruana Cayetano Heredia (UPCH), Lima, Peru; 2Instituto Nacional de Estadística e Informática (INEI), Lima, Peru

We used the Peruvian Demographic and Health Survey (DHS) 2014 database to ascertain if self-reported diabetes prevalence was different above and below 3,000 m of altitude, and tried to explain any difference by controlling for confounder variables age, sex, education years, latitude, wealth index, hypertension, tobacco and alcohol use, overweight and obesity status. The final database included 29,806 people from rural and urban settings across the country. Both populations had rather similar age by sex distribution; however, highland population was markedly less wealthy, had lower education level, less obesity, arterial hypertension, alcohol and smoking rates, and lived predominantly at rural settings, compared with the lowland counterpart.

Diabetes prevalence (percent [95% CI]) above and below 3,000 m of altitude was 2.4% (1.8-3.3) and 4.6% (4.1-5.2), respectively (OR=0.51% [0.36-0.72]). After adjusting for the before mentioned characteristics, however, the OR became non-significant (OR=0.91 [0.64-1.3]). Diabetes diagnoses were strongly associated with wealth index, followed by female status, hypertension diagnoses and older age. We conclude that the observed difference, in our country, can be explained in part by poverty rates associated with lower nutritional resources. The role of the low availability of health services in such deprived and underserved areas, which would explain the lower diabetes diagnoses rate, is discussed.

115

TRANSCRIPTIONAL REGULATION OF MMP-2 BY SCLERAXIS
RS Nagalingam, BA Bagchi, PL Roche, HA Safi, MP Czubryt
Institute of Cardiovascular Sciences, St Boniface Hospital Research Centre and Department of Physiology and Pathophysiology, University of Manitoba, Winnipeg, Manitoba
Extracellular matrix (ECM) homeostasis is altered during cardiac fibrosis. ECM synthesis is increased, as is the expression of matrix remodeling enzymes such as Matrix Metalloproteinases (MMPs). Scleraxis is a transcriptional regulator found in cardiac fibroblasts and myofibroblasts that we previously demonstrated plays a vital role in the production of ECM proteins including collagen Iα2 by binding to E-box consensus sequences located in the target gene promoter. MMP-2 (Type IV collagenase-Gelatinase-A) maintains the homeostasis of extracellular matrix by controlling the degradation of matrix protein. Our present proof-of-concept study reveals that the MMP-2 gene is transactivated by scleraxis. Over-expression of scleraxis or 48 hours in NIH-3T3 cells induced MMP-2 expression at the mRNA and protein levels. Using in silico analysis, we identified putative E-box sites in the MMP-2 gene promoter to which scleraxis may bind, and found that scleraxis was capable of directly transactivating this promoter using luciferase reporter assay. Our data suggests that scleraxis may govern the expression of both ECM components such as collagen, as well as ECM remodeling enzymes such as MMP-2. This finding is consistent with a potential role for scleraxis in cardiac fibrosis where MMP-2 and fibrillar collagen gene expression is elevated concurrently with scleraxis.

Supported by the Canadian Institutes of Health Research (grant MOP-136862).

116

INHIBITION AND ACTIVATION OF THE CARDIAC NA+/-CA++ EXCHANGER – TWO ASPECTS OF TRANSPORT MODULATION
N Nag1, Z Kohajda1, K Acsai1, A Kormos2, A Tóth2, K Oravecz2, P Pollesello2, J Levijoki1, L Virág2, N Jost2, J G Yapp2, A Varró1,2
1IMTA-SZTE Research Group of Cardiovascular Pharmacology, Hungarian Academy of Sciences, Szeged, Hungary; 2Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary; 3Orion Pharma, Espoo, Finland

The important role of NCX in several types of arrhythmias is well established. Therefore, its inhibition is proposed as a promising novel antiarrhythmic strategy. Furthermore, a possible positive inotropic effect can be also expected. Also activation of NCX could be advantageous by supporting Ca++-extrusion during Ca++-overload. However, the exact evaluation of the putative antiarrhythmic role and inotropic action of NCX modulation was hampered by the lack of selective inhibitors. Our aim was to characterize the novel selective NCX-inhibitors, ORM10103, ORM10962, and a putative NCX-activator ORM10792.

Under close to physiological conditions, NCX-inhibition had little influence on CaT magnitude. NCX-inhibition decreased the Ca2+-overload-induced CaT and CS. However, activating this promoter using luciferase reporter assay. Our data suggests that scleraxis may govern the expression of both ECM components such as collagen, as well as ECM remodeling enzymes such as MMP-2. This finding is consistent with a potential role for scleraxis in cardiac fibrosis where MMP-2 and fibrillar collagen gene expression is elevated concurrently with scleraxis.

Supported by the Canadian Institutes of Health Research (grant MOP-136862).

Acknowledgement: This work was supported by the Postdoctoral Program of the Hungarian Academy of Sciences (for N.N.)
117
CENTRAL ANGIOTENSIN-II RAISES BLOOD PRESSURE AND SYMPTOMATIC OUTFLOW VIA THE RHOA/RHO KINASE PATHWAY IN CONSCIOUS RABBITS
PR Pellegrino, AM Schiller, KK Haackh, IH Zucker
Cellular & Integrative Physiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

INTRODUCTION: Elevated sympathetic tone and activation of the renin-angiotensin system are pathophysiologic hallmarks of diseases like chronic heart failure, hypertension, chronic kidney disease, and obstructive sleep apnea, all of which have compelling burdens and therapeutic needs. The RhoA/Rho kinase pathway is an important mediator of the effects of Angiotensin-II (AngII) in the periphery, but the functional role of this pathway in the brain in AngII-induced sympathetic-excitation is not well-characterized.

HYPOTHESIS: We hypothesized that central inhibition of the RhoA/Rho kinase pathway prevents AngII-mediated autonomic dysfunction in rabbits.

METHODS: Each rabbit received all four of the following intracerebroventricular infusion treatments for two weeks in random order: AngII, the Rho kinase inhibitor Fasudil (Fas), AngII and Fas, and vehicle infusion via osmotic minipump. After two weeks, the treatment was washed out with vehicle infusion for 7-14 days. Baseline recordings of mean arterial pressure (MAP) and heart rate (HR) were acquired throughout treatment. After ten days of infusion, cardiac sympathetic tone and sympathetic vasomotor tone were assessed by the change in HR after metoprolol and change in MAP after hexamethonium, respectively.

RESULTS: AngII treatment resulted in a pressor effect that was blocked with Fas co-infusion. Both cardiac sympathetic tone and sympathetic vasomotor tone were increased with AngII infusion; this sympathetic excitation was abrogated by co-infusion of Fas. Each of these measures showed a significant interaction between AngII and Fas, indicating that the pressor and sympathetic-excitatory responses of central AngII are mediated by the RhoA/Rho kinase pathway.

CONCLUSIONS: These data indicate that inhibition of the Rho kinase pathway centrally could act as a therapeutic brake on the positive feedback between central renin-angiotensin system activation and sympathetic outflow in many diseases.

118
ABLAITION OF MMP9 ALLEViateS MITophagy AND MITIGates CARDiac DYSFUNCTION IN DIABETICS
P Prathipati1, BT Hackfort1, SS Nandi1, HR Shashshahan1, PK Mishra1, 2
1Department of Cellular and Integrative Physiology; 2Department of Anesthesiology, University of Nebraska Medical Center, Omaha, Nebraska, USA

Mitochondrial abnormalities and induced matrix metalloproteinase-9 (MMP9) contribute to diabetic heart failure. However, the specific role of MMP9 in mitochondrial autophagy (mitophagy) is unclear. We hypothesized that deletion of MMP9 gene alleviates excessive mitophagy and mitigates cardiac dysfunction in diabetes.

To test this hypothesis, we created Ins2+/−/MMP9−/− mice by ablating MMP9 gene from Ins2+/− Akita (type 1 diabetic) mice. To investigate the specific role of MMP9 in diabetes-induced mitophagy, we used C57BL/6j (WT), Ins2+/− Akita, Ins2+/−/MMP9−/− and MMP9−/− mice, and measured the level of mitophagy markers: PINK1, Parkin and LC3B in the heart by qPCR, Western blotting and immunohistochemistry.

To determine the role of MMP9 on cardiac dysfunction in diabetes, we performed M-mode echocardiography and measured percentage ejection fraction (%EF) and fractional shortening (%FS) in the above four groups. Our results showed elevated mRNA levels of PINK1 (1.25±0.42), Parkin (1.95±0.48) and LC3B (1.89±0.54) in Akita as fold change compared to the WT heart suggesting upregulated mitophagy in Akita. However, their levels were downregulated in Ins2+/−/MMP9−/− (PINK1: 0.06±0.02, Parkin: 0.76±0.18 and LC3B: 0.27±0.02), which was comparable to MMP9−/− hearts demonstrating downregulation of mitophagy. The protein levels of PINK1, Parkin and LC3B were similar in pattern as mRNA levels. Echocardiography results showed cardiac dysfunction in Akita (%EF: 56.9±4.77, %FS: 29.3±3.21), and its alleviation in Ins2+/−/MMP9−/− (%EF: 62.68±1.77, %FS: 33.44±1.34) without significant difference in cardiac function between WT and MMP9−/−. In conclusion, abrogation of MMP9 downregulates mitophagy and ameliorates cardiac dysfunction in diabetic hearts.

Acknowledgements: NIH grants: HL12381 and HL116205

119
REMODELING OF PULMONARY VASCULAR ENDOTHELIUM IN LEFT HEART FAILURE
SS Binl Rai1, GS Ajithkumaran1, G Sanjay2, CC Kartha1
1Cardiovascular Disease Biology Division, Rajiv Gandhi Centre for Biotechnology; 2Department of Cardiology, SCTIMST, Thiruvananthapuram, India

Pulmonary hypertension associated with left heart disease (PH-LHD) represents the most common form of PH and is characterized by lung endothelial dysfunction and vascular remodeling. LHD results in passive backward transmission of elevated left atrial pressure and partial obstruction to pulmonary venous drainage. This hemodynamic disturbance in circulation causes increased shear stress and turbulent (disturbed) flow in pulmonary circulation. We hypothesize that pulmonary vascular endothelial cells (PVECs) are exposed to disturbed flow in LHD leading to PVEC dysfunction, pulmonary vascular remodeling and PH. We studied the expression pattern of different shear sensitive factors such as HuA and its downstream targets such as Klf2, eNOS and BMP4 in PVECs exposed to parallel and disturbed flow in vitro and in lungs of rats with LHD developed after constriction of ascending aorta. Our study reveals the activation of HuA and downregulation of Klf2 and upregulation of BMP4 and CTGF. We also found that endothelial character are lost in PVECs when exposed to disturbed flow and the cells display a smooth muscle like phenotype. On analyzing the lung tissues of rats with LHD we could find that the markers of En-MT were upregulated. Results of our study suggest that the disturbed flow could change the PVECs into a pro-inflammatory and proliferative phenotype leading to pulmonary vascular remodeling. PVEC dysfunction developed due to chronic exposure to disturbed flow in pulmonary circulation may be a reason for pulmonary vascular wall remodeling and PH in LHD.

120
NUCLEAR MEMBRANES ETB RECEPTORS MEDIATE ET-1-INDUCED INCREASE OF NUCLEAR CALCIUM IN HUMAN ENDOCARDIAL ENDOTHELIAL CELLS
R Keita, F Jules, Al Khoury, G Bkaily, D Jacques
Department of Anatomy and Cell Biology, Faculty of Medicine, Université de Sherbrooke, Sherbrooke, Quebec

In human left ventricular endocardial endothelial cells (ECECs), plasma membrane (PM) ET-1-IRs were reported to mediate ET-1-induced increase of intracellular calcium ([Ca]i). However, in right EECs (EEECs), this effect was mediated by ETAR. In the present study we determined if, as for the PM, nuclear membranes (NMs) ET-1-IRs activation in ECECs and EECRs induce an increase of nuclear calcium ([Ca]n) and we verified whether this effect is mediated via the same type of receptor as in PM. Using the PM-perforated technique and real 3D confocal microscopy, our results show that, as in PM intact cells, addition of cytosolic ET-1 to nuclei of both cell types induced a concentration-dependent sustained increase of [Ca]n. The ETAR antagonist prevented the effect of ET-1 on [Ca]n only in EECRs. However, the effect of cytosolic ET-1 on [Ca]n was prevented by the ETBR antagonist in both EECs and ECECs. In conclusion, NMs' ETAR and ETBR mediated the effect of cytosolic ET-1 on [Ca]n in EECs whereas only NMs' ETBR activation mediated the effect of cytosolic ET-1 in ECECs. Thus, the type of NMs' receptors mediating the effect of ET-1 on [Ca]n are different from those of the PM mediating the increase in [Ca]n. Supported by an NSERC grant.
In recent years there has been an increase in the number of antibiotic resistant microorganisms, particularly Pseudomonas aeruginosa and Acinetobacter baumannii. High rates of infection caused by these microorganisms are responsible for high morbidity and mortality, failure of drug therapy, increased hospital stay and consequently the financial impact on the health system. However, while the occurrence of these bacteria to configure a public health problem, numerous studies show there is scarce information about the resistance genes present in multidrug-resistant bacteria. This reality associated with the negative impact on the society, justifies the importance of identifying the expressed resistance genes in Acinetobacter baumannii and Pseudomonas aeruginosa resistant to carbapenems isolated from patients at a public hospital in northeastern Brazil. It was an experimental ecological study, prospective and quantitative. The demographic and clinical data of patients were being conducted through a specifically designed form. Multiplex PCR technique was performed for identification of resistance genes of Acinetobacter baumannii (imp bla, bla came, yes bla, bla Oxa-51, bla Oxa-58, bla bla Oxa-23 and Oxa-24) and Pseudomonas aeruginosa (. spm bla, bla bla came and imp). Descriptive analysis was performed using position and measures of variability for continuous variables and simple frequency for categorical variables. For the analysis of gene extraction amplification of resistance markers, we used GraphPad Prism version 5.0. The sample consisted of 17 patients, most men (11- 64.8%), median 40 years. Eleven (64.8%) were from the response men (11- 64.8%), median 40 years. Eleven (64.8%) were from the response.
Abstracts

125 Eearly Post-Ischemic Blood-Brain Barrier (BBB) Disruption in Obesity
H Sun, C Li, Z Jiang
Cellular Biology & Anatomy, Louisiana State University Health Sciences Center, Shreveport, Louisiana, USA
We determined the effect of high fat diet (HFD)-induced obesity on early BBB disruption following transient focal cerebral ischemia. Male C57BL/6J mice were fed a HFD or standard chow for 16 weeks. A cranial window was prepared over the left frontal, parietal and temporal cortex. Transient focal cerebral ischemia was induced by directly ligating the middle cerebral artery (MCA) for two hours. Early BBB disruption was assessed by measuring Evans Blue and sodium fluorescein extravasation at 3 hours of reperfusion. The body weight was significantly increased in obesity group (49.2 ± 0.4g) compared to control group (31.9 ± 0.6g). There was no significant difference in conscious blood pressure and fasting blood glucose between control and obesity groups. Transient focal cerebral ischemia produced an early BBB disruption in both control and obesity groups. However, the magnitude of early BBB disruption was significantly greater in obesity group compared to control group. Topical treatment with L-NPA, 7-NI (neuronal nitric oxide synthase inhibitors) or L-NAME (a nonspecific nitric oxide synthase inhibitor) completely abolished the BBB disruption in control group, but only partially suppressed the BBB disruption in obesity group. Interestingly, matrix metalloproteinase (MMP)-9 activity of cerebral cortex was reduced in obesity group either under basal conditions or following ischemic stroke. Our findings suggest that obesity exacerbates early post-ischemic BBB disruption via a mechanism that appears to be unrelated to MMP-9 or NOS.

126 PDGF-BB induces Phosphorylation of Polo-Like Kinase-1 to Potentiate Proliferation of Smooth Muscle Cells in Human Saphenous Vein: Potential Implication in Vein-Graft Disease
S Su, S Chen, JT Sugimoto, DK Agrawal
Creighton University School of Medicine, Omaha, Nebraska, USA
Coronary artery bypass grafting (CABG) is the choice of procedure in patients with multi-vessel or left main coronary artery disease. Patency of saphenous vein graft (SVG) significantly declines following surgery compared to internal mammary artery (IMA). Intimal hyperplasia is the key event in SVG failure. PDGF-BB is a major growth factor released at the site of graft injury. Here, we examined, for the first time, the expression of PLK1 and pPLK1 in isolated human SV and IMA conduits that were freshly collected, SMCs isolated and cultured. In cultured SMCs, effect of PDGF-BB was examined on total PLK1, pPLK1, CDC2 and pCDC2 by Western blot analysis. Cell proliferation was measured using cell count and cell proliferation assay. PDGF-BB was examined on total PLK1, pPLK1, CDC2 and pCDC2 by Western blot analysis. PDGF-BB was examined on total PLK1, pPLK1, CDC2 and pCDC2 by Western blot analysis. Cell proliferation was measured using cell count and cell proliferation assay. We found significantly higher expression of pPLK1, total PLK1, CDC2 and pCDC2 in PDGF-stimulated SV SMCs than IMA. These data suggest a greater and sustained sensitivity of SV SMCs to PDGF-BB-induced PLK1 activity than in IMA. A PLK1 inhibitor attenuated PDGF-induced proliferation in both IMA and SV SMCs. This could explain the development of intimal hyperplasia in SV conduits compared to IMA following CABG. Thus, inhibition of PLK1 could be a target in developing better therapeutic approach to prevent vein-graft disease.

Supported by NIH R01HL09580 grant

127 The Propensity of Vitamin D Supplementation to Reduce Characteristics of Inflammation and Proliferation Caused by Coronary Artery Interventional Procedures
VL Swier Mosher, L Tang, MM Radwan, DK Agrawal
Center for Clinical and Translational Science, Creighton University, Omaha, Nebraska, USA
Neointimal formation and cell proliferation resulting into in-stent restenosis is a major pathophysiological event following interventional coronary artery procedures. In this study, we examined the inflammatory profile and smooth muscle cell proliferation of microswine fed a high cholesterol diet. Swine were placed into one of three groups: a vitamin D-supplemental diet (3000 IU/4000 IU), a vitamin D sufficient diet (1000 to 2000 IU), or a vitamin D deficient diet. After six months of the high cholesterol diet, PTCA was performed in the LCX and bare mental stent implantation in the LAD for each swine. After a year of the diet, swine were euthanized and coronary arteries were embedded in methyl methacrylate or paraffin; and sections were stained with H&E, trichrome, and Movat’s pentachrome. The expression of Ki67 (proliferation marker), HMGB1 (inflammation and necrosis marker), TLR2 (monocyte and T-cell marker), and TLR4 (leukocyte marker) was evaluated by immunohistochemistry. We continue to find a greater inflammation profile and a greater number of proliferating cells in the Vitamin D Deficient swine based on histological staining and immunoreactivity to HMGB1, TLR2, TLR4, and Ki67 in both PTCA LCX arteries and stented LAD arteries. This inflammation and proliferating profile decreases with increasing levels of Vitamin D, we find an even distribution of smooth muscle cells based on histological staining and only a few cells were immunopositive to HMGB1 and Ki67 in the Vitamin D Supplemental LCX and only cells surrounding the stent struts were immunopositive to TLR2 and Ki67 in the stented LAD arteries.

128 CARBOTHERA IN THE TREATMENT OF ISCHEMIC FOOT ULCERS: CASE STUDIES
H Hasebe, H Kumamoto, T MacInnis, J T Gregor, PS Tappia, GN Pierce
Mitsubishi Rayon Cleansui, Tokyo, Japan; and 1Asper Clinical Research Institute, 1St Boniface Hospital Research, Winnipeg, Manitoba
Foot ulceration usually precedes more serious foot complications such as infection, gangrene or amputation. The therapeutic potential of CO2-enriched water on treating foot ulcers is being evaluated. In the two case studies, a 57-year old male and a 72-year old female with diabetes, peripheral arterial disease and undergoing hemodialysis for end-stage renal disease presented with one non-infected ischemic arterial foot ulcer. Foot bathing in CO2-enriched water (1000-1200 ppm) at 37±0.5°C 3 times for 15 min for 3 months resulted in a significant healing of the wound that was associated with an increase in pH; saturation levels of the wound area, improved blood flow as evidenced by increases in ankle-brachial index, reduction in fasting blood glucose levels, and a small decrease in HbA1c. CO2 foot bathing could help to accelerate the wound healing process.

129 Generation of Human Induced Pluripotent Stem Cells Without Integration and Transgene Under Feeder-Free Conditions
Y-T Xuan, O-L Wang, Y Zhu, B Dawn
Division of Cardiovascular Diseases, Cardiovascular Research Institute, Midwest Stem Cell Therapy Center, University of Kansas Medical Center, Kansas City, Kansas, USA
Human induced pluripotent stem cells (hiPSCs) have immense potential for cardiac repair. However, for translational purposes, it is critical to generate clinical-grade hiPSCs under viral integration-free feeder-free conditions. We examined the efficacy of hiPSC generation from human skin fibroblasts using an episomal reprogramming method. Human fibroblasts were transfected with episomal vectors expressing transcription factors Oct4, Sox2, Nanog, Lin28, Klf4, and L-Myc (Combination 1) or Oct4, Sox2, Nanog, Lin28, Klf4 (Combination 2) via electroporation. Because the protocarcinogenic product c-Myc markedly increases tumor formation in iPSC-derived chimeric mice, c-Myc was replaced with L-Myc (less tumorigenic) in Combination 1 and was omitted in Combination 2 to limit the incidence of tumor formation. Transfected fibroblasts were then plated to vitronectin-coated 6-wells in fibroblast culture medium and 24 h later the medium was changed to chemically defined N2B27 medium containing inhibitors of GSK3β, MEK, TGF-β receptor, and ROCH and human leukemia inhibitory factor. Emerged iPSC colonies were readily picked between days 21 and 24 after transfection in Combination 1 and
much earlier between days 17-21 in Combination 2. These cells highly expressed pluripotent cell surface antigens (SSEA-4, TRA-1-60, and TRA-1-81) and endogenous transcription factors (Oct4 and Sox2) and were able to differentiate into three germ layers in vitro. Taken together, these data demonstrate that these are pluripotent cells.

In summary, hiPSCs can be successfully generated from human skin fibroblasts using a non-integrating and non-viral episomal reprogramming method under feeder-free conditions. These hiPSCs are also completely free of vector and transgene. This method can be easily adapted to the production of clinical-grade human iPS cells for cardiac cell therapy.

Author Index

A
Abdel-Karim Abdel-Malak N ............. 095
Abo Alrob O ..................... 063
Acsai K ....................... 116
Ahi N ....................... 037
Aifs R ....................... 211
Aghila Rani KG .............. 010
Agrawal SS ................... 074
Ahmarami L .................. 123
Ahmari N .................... 069
Ajithkumar GS ............... 019,118
Aliami M ...................... 004
Al-Khouy J ................... 120
Almalki S ..................... 111
Almalki SG .................... 091
Apparansundaram S ........... 023
Arick JL ....................... 025
Arias Aj ....................... 114
Arige V ....................... 060,113
Arrick DM ..................... 003
Auger-Messier M .............. 098
Aukema H ..................... 004,094

B
Bafa K ....................... 095
Baclo I ....................... 092
Bagchi RA .................... 088,115
Bahl A ....................... 060,113
Baxter BT ..................... 099,124
Becker BK ..................... 015
Bhatnagar A .................. 092
Binul Raj SS .................. 119
Biakly G ...................... 095,120,123
Blackman AO ................ 049
Boli R ....................... 009
Boosami CS ................... 093
Böse Z ....................... 057
Bouchard DR .................. 014
Bowen J ...................... 037
Bratasz A ..................... 070
Britton SL ................... 040
Buttar HS ..................... 075

C
Caligiuri S ................... 004,094
Carpentier A .................. 098
Carson J ..................... 124
Carson JS .................... 099
Carvajal JM ................... 069
Case AJ ...................... 032
Castañeda Saldaña E ........ 061
Chacko G ..................... 072
Chamoun M .................. 095
Chao J ....................... 036
Chaturvedi P ................. 014,109
Chaudhary R .................. 112
Chen S ....................... 087,126
Chernyavskyi I .................. 096
Clemmer J .................. 097
Conklin D ................... 092
Couture EL ................... 098
Ceepe TA ..................... 099,070
Cut M-Z ..................... 076
Czirk A ....................... 084
Czubryt MP .................. 088,115

D
D’Orléans-Juste P .................. 031,078
Dai Y ....................... 054
Dale M ....................... 099,124
Danielle J ................... 090
Daw B ....................... 011,084,129
Deka PK ..................... 100
Del Rio R .................... 055
Desbiens L ................... 078
Desouza C .................... 037
Dewar A ...................... 033
Dhalla NS ................... 001
Dhingra S ................... 053
Dibrov E ...................... 004
Ding H ....................... 033
Ding Z ....................... 054
Djoussou KP ................. 101
Duhamel TA .................. 104
Dunlap ME ................... 066

E
Edel AL ...................... 004
Edye-Mazowita A .............. 104

F
Familiova A ................... 014
Faraci FM .................... 002
Farand P ...................... 098
Fedorov VV .................. 059,070
Felder RB .................... 008
Feng Y ....................... 035
Ferrario CM ................ 005
Fillmore N ................... 102
Fukushima A .................. 102

G
Ganguly R .................... 112
Gao J ....................... 036
Gao L ....................... 036
Garcia-Pereira F ............ 069
Gembardt F .................. 036
Ghassan B ................... 090
Gomes O ..................... 065
Gomes OM ................... 049
Gowanski SK .................. 113
Goyal RK ...................... 023
Gregor T .................... 128
Grohe JL ..................... 020
Grueter CE .................. 086
Guo Y ....................... 092

H
Haack KK ...................... 117
Hackett BT ................... 103,118
Hall DD ...................... 086
Hamm NC ..................... 104
Hansen Bj .................... 059,070
Hao F ....................... 076
Hanzal T ..................... 112
Hasee H ..................... 046,128
Hawksins D ................... 046
Hayashi H ................... 105
Hester R ..................... 097
Higgins RSD ................ 070
Hiripi L ...................... 057
Hoeftier D .................... 092
Hong B ....................... 050
Hornyk T ..................... 057
Houve M ..................... 031,078
Hristova K ................... 082
Hummel JD ................... 070

I
Ikhahop IA ................... 013
Isi DG ....................... 084

J
Jacques D ..................... 095,120,123
Jansen FIL ..................... 070
Jayne LA ..................... 016
Jayyamenanth V ............. 011
Ji H ....................... 019
Jiang Z ....................... 125
Johnson AJ ................... 104
Johnson AM ................... 010
Johnson RD ................... 069
Johnson TA .................. 029,106
Johnstone DE .................. 063
Johny A-K ................... 090
Joseph J ..................... 069
Jost N ....................... 116
Ju JC ....................... 107
Juhrville-Leblanc C ........ 123
Julie V ....................... 057
Jules F ....................... 120

K
Kalani A ...................... 014
Kalyanasundaram A ........... 070
Kamoi D ..................... 105
Karthaa CC .................. 010,052,119
Kausa H ..................... 105
Kawahara H ................... 105
Kehler DS ................... 104
Keita R ....................... 120
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wang X</td>
<td>022, 054</td>
</tr>
<tr>
<td>Weighell W</td>
<td>004</td>
</tr>
<tr>
<td>Weiss R.</td>
<td>070</td>
</tr>
<tr>
<td>Winchester L</td>
<td>096</td>
</tr>
<tr>
<td>Wittnich C.</td>
<td>021</td>
</tr>
<tr>
<td>Wu D.</td>
<td>076</td>
</tr>
<tr>
<td>Wu X</td>
<td>019</td>
</tr>
<tr>
<td>Xi L</td>
<td>073</td>
</tr>
<tr>
<td>Xiang L.</td>
<td>097</td>
</tr>
<tr>
<td>Xiong W.</td>
<td>099, 124</td>
</tr>
<tr>
<td>Xu X.</td>
<td>076</td>
</tr>
<tr>
<td>Xuan Y-T</td>
<td>129</td>
</tr>
<tr>
<td>Yamada T.</td>
<td>105</td>
</tr>
<tr>
<td>Yang X-F.</td>
<td>007</td>
</tr>
<tr>
<td>Zhang D.</td>
<td>092</td>
</tr>
<tr>
<td>Zhang F.</td>
<td>076</td>
</tr>
<tr>
<td>Zhao J.</td>
<td>070</td>
</tr>
<tr>
<td>Zhong H.</td>
<td>034, 038</td>
</tr>
<tr>
<td>Zhu Y.</td>
<td>129</td>
</tr>
<tr>
<td>Zimmerman MC</td>
<td>032</td>
</tr>
<tr>
<td>Zingler MB</td>
<td>069</td>
</tr>
<tr>
<td>Zou M-H</td>
<td>024</td>
</tr>
<tr>
<td>Zubcevic J.</td>
<td>069</td>
</tr>
<tr>
<td>Zucker IH.</td>
<td>015, 036, 055, 117, 122</td>
</tr>
</tbody>
</table>